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Soon We will show them our signs 
in the horizons and in their own souls, 
until it becomes manifest to them that this the truth. 
Is it not enough that your Lord does witness all things?
Qur’an
(Chapter 41, Verse 53)
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Abstract
In recent years there has been growing interest in the self-emulsified lipid technology 
as an approach for the oral delivery of hydrophobic compounds. The use of 
combinatorial chemistry in synthesizing active molecules has produced wide range of 
drugs with high molecular weight and poor water solubility. The rout for tablet 
formulation restricts the bioavailability of these compounds due to their low intrinsic 
water solubility and hence slow dissolution rate which' is a key step in the absorption 
of these compounds. Therefore, if a rapid onset action is required the choice for tablet 
formulation is not an efficient approach. Various formulation methods have been 
attempted to improve the bioavailability of lipophilic compounds of which, self- 
emulsifying drug delivery systems (SEDDS) exhibit the most successful approach. 
Dissolution and disintegration steps are not necessary for drugs formulated in SEDDS 
as they are presented to the GIT in a soluble form dissolved within the lipid matrix, 
and. ready for absorption after the emulsification process takes place. In order to 
facilitate dealing with these lipid systems, they were classified into type I, n, IIIA and 
EUB based on various physicochemical factors. In the design for a successful lipid 
formulation, various key elements in the composition have to be optimized to obtain 
dispersions with minimum emulsion droplet size, less sensitive to the presence of 
electrolytes in the emulsification media and are able to maintain the drug in solution 
after the dispersion of the formulation. These elements include; type of oil, the use of 
cosurfactant (mixed mono/di-glycerides), oil-cosurfactant ratio, type of surfactant and 
the inclusion of cosolvents. In this study a self-emulsifying type II formulation was 
developed composed of Miglyol 812 (medium chain triglycerides), Imwitor 988 
(medium chain mono/di-glycerides) and the non-ionic surfactant Tagat TO. The 
constituents of this system are considered to be water insoluble materials which make 
the formulation highly unlikely to loose its solvent capacity after dispersion. Very fine 
dispersions of droplet size between 50 and 60nm which are arbitrary called o/w 
microemulsions were obtained at Miglyol 812/Imwitor ratios of 70/30 or 60/40 and at 
Tagat TO concentration of 30% w/w. Phase behaviour studies of these systems have 
shown regions of no liquid crystalline material (LC) yet, extended areas of water 
solubilization (L2) was observed. This indicates that ‘Diffusion and Stranding’ theory 
is the putative mechanism for the emulsification process in these systems. These 
systems appear to be prone to the effect of electrolytes present in the emulsification 
media. Furthermore, Physical characterization of resultant dispersions of type IE self- 
micro-emulsified lipid system composed of Miglyol 812/Imwitor 988-Cremophor 
RH40 was carried out. Optimum dispersions of ~30nm were obtained using oil blends 
of Miglyol 812/Imwitor 988 at ratios of 1:1 and Cremophor RH40 at concentration of 
30% w/w. In order to find alternatives to Cremophor RH40 because of its waxy nature 
at ambient temperature, various hydrophilic surfactants were screened for 
microemulsion systems. Self-micro-emulsifying systems were obtained using blends 
of Miglyol 812/Imwitor 988 at ratios of 1:1 in the case Cremophor EL, and at ratio of 
2:3 in the case of Crillet 4 or Tagat 02. The inclusion of water-soluble cosolvents in 
SEDDS formulations was found to accelerate precipitation of drug after dispersion 
depending on the emulsification media. Oil-cosurfactant ratio, type of surfactant and 
the amount of included water-miscible cosolvents can influence the solubilization 
behaviour of the drug after dispersion. Finally, Solid self-micro-emulsified lipid 
systems (SMELS) were developed from eutectic mixtures of various solid carrier 
systems and oil mixtures. These new vehicles have the potential of presenting the 
dmg to the GIT in the amorphous state with no susceptibility to the aging processes.
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Origin and Scope of this Study
The use of Self-emulsifying drug delivery systems (SEDDS), as an approach to 
improve the bioavailability of poorly water-soluble drugs, was first initiated by the 
work of Pouton in 1982 on various mixtures of oils and surfactants. Self- 
emulsifying formulations are considered to be mixtures of oils and surfactants which 
upon gentle agitation in water to simulate physiological conditions in the stomach 
spontaneously emulsify forming dispersions of droplet size of <5 pm. Pouton in his 
work identified a self-emulsifying system composed of Miglyol 812 (medium chain 
triglyceride) and Tween 85 (polyoxythelene-(25)-sorbitan trioleate). Later, Wakerly 
working under the supervision of Pouton identified a system which satisfied the 
parameters of self-emulsifying lipid systems composed of Miglyol 812 and Tagat TO 
(polyoxythelene-(25)-glycerol trioleate). Thorough studies on those two systems have 
revealed the formation of liquid crystalline material which is involved in the 
mechanistics of emulsification in these formulations. Since then, SEDDS have 
attracted the attention of many researchers and recently, culminated in the 
development of Sandimmune™ (cyclosporine A) as Neoral™ which is a vivid 
example of the advances in this technology. Neoral™ is considered a stereotypical 
type ID self-micro-emulsifying drug delivery system (SMEDS) according to the 
classification suggested by Pouton tlll]. Self-emulsifying systems have the potential 
advantage of presenting the active compound already dissolved in the lipid matrix 
ready for absorption. These systems skip the disintegration and dissolution processes 
which are rate-limiting steps in the absorption of traditional tablet formulations.
One of the major breakthroughs in this technology is the use of mixed mono and di­
glycerides (such as, Imwitors and Capmuls) in the oil blend as co-surfactants to aid in 
the emulsification process, and also the use of surfactants of high solubilizing 
capacity like Cremophors (polyoxyethylene caster oil derivatives).
The core theme of this project is divided into two parts which are presented 
respectively in chapter 3 and 4: Firstly; identifying and physical characterization of 
systems which are potential self-micro-emulsifying drug delivery systems (SMEDS) 
composed of oil blends of Miglyol 812/Imwotor 988 and various surfactant systems, 
investigating mechanistic processes involved in emulsification and exploring the fate
x
of dissolved drug after the dispersion of the formulation, and secondly; preparing self­
micro-emulsified lipid systems as a solid dosage form in order to replace costly and 




1.1 The Concept of Self-emulsifying Drug Delivery Systems 
(SEDDS): Formulation Perspective.
It is important to distinguish between self-emulsifying systems and conventional 
emulsion systems which will be finely dispersed only after exposure to strong 
shearing forces. A self-emulsifying system is a mixture of oil and surfactant which 
emulsifies in water under conditions of gentle agitation. Such mixtures may be 
spontaneously emulsified if the entropy change favoring dispersion is larger than the 
energy required to increase the surface area of dispersion [1]. Self-emulsifying 
formulations have been used by the herbicide and pesticide industries for several 
years ^  3]. Recently, self-emulsifying systems have been formulated using medium- 
chain triglyceride oils and nonionic surfactants, which being acceptable for oral 
ingestion, could form the basis of self-emulsifying drug delivery systems [4'10]. These 
mixtures can be formulated into soft gelatin capsules to produce precise and 
convenient unit dose forms which, after oral administration, will emulsify within the 
gastric contents Lipid-based formulation can reduce the inherent limitation of 
slow and incomplete dissolution of poorly- water soluble drugs, and facilitate the 
formation of solubilised phases from which absorption may occur [12^ . In theory the 
use of SEDDS for oral administration of hydrophobic drugs would appear 
advantageous however few exist. A significant limitation to their use is the effort 
involved in optimization of a SEDDS. An ideal SEDDS should disperse into an 
emulsion consisting of droplets <5 pm in diameter with a uniform size distribution, to 
reduce the diffusion path of the drug from the droplet[4,13,14]. Such a formulation will 
present a lipophilic drug in oily solution with a large interfacial area across which 
diffusion can take place. The mechanisms, rate and extent of drug absorption from the 
resulting emulsion will be strongly dependent on the oils and surfactants used in each 
formulation. For example, absorption will be influenced by whether or not the oil is 
digestible and by the partitioning of drug between the oil and water [15]. Therefore, the
1
Introduction
absorption profiles of a drug from a series of self-emulsifying formulations are likely 
to be different but it is hoped that the absorption from an individual formulation will 
be comparatively reproducible, leading to improved control of the bioavailability of 
lipophilic drugs from GIT. One advantage that self-emulsifying formulations have 
over solid dosage formulations is the avoidance of slow drug dissolution, In addition, 
distribution of the emulsion within the GIT may help to avoid the irritancy which can 
be caused by contact between bulk solids and the gut wall. Obviously, the excipients 
used for formulation would need to be non-irritant and free from other acute or 
chronic toxicity problems. Choice of oils is likely to be restricted to silicones, liquid 
paraffin or vegetable oils and other derivatives. These could be used in combination 
with non-ionic surfactants which are generally less toxic than ionic surfactants fl6]. 
The efficiency of SEDDS depends on three main factors; particle size of oil droplets 
on exposure to aqueous media, rate of emulsification and the polarity of the 
resulting oil droplets ^  which promotes partitioning of the drug into the aqueous 
phase. The polarity of the oil droplets is governed by the hydrophilic-lipophilic 
balance (HLB), the chain length and degree of un-saturation of the fatty acid, 
molecular weight of the hydrophilic portion and the concentration of the emulsifier.
The pharmaceutical application of self-emulsification requires the identification of 
surfactant-oil mixtures which might be pharmaceutically acceptable, be capable of 
good self-emulsification and be feasible of encapsulation in a soft gelatin capsule. 
Pouton ^  has identified a vegetable oil - nonionic surfactant mixture composed of 
Miglyol 812 or Miglyol 840, a medium chain triglyceride oil of vegetable origin, and 
Tween 85 (polyoxythelene-(25)-sorbitan trioleate) which satisfied these parameters. 
However, the self-emulsifying behavior of this system was found to be extremely 
sensitive to dissolved solutes in both the SEDDS and the aqueous test media. Within a 
range of more efficiently emulsifying mixtures (20-60 % w/w Tween 85), the shortest 
emulsification times occurred between 30 and 45% w/w Tween 85. A minimum in 
particle size of approximately 300nm for self-emulsified systems was produced by 
compositions of oil and surfactant containing 25-35% w/w Tween 85.
Wakerly et al. screened a range of non-ionic surfactants and oils for self- 
emulsifying behavior. It was determined that unsaturated ester- based surfactants were 
more efficient at forming self-emulsifying systems than the corresponding saturated 
surfactants with either a medium chain triglyceride lipid or Archis oil. They studied
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binary mixtures of Tagat TO and Miglyol 812 in very great detail, efficient self- 
emulsification was produced from mixtures containing 35 to 52.5% Tagat TO. 
Minimum particle size of 100-200 nm was achieved using approximately 50% 
surfactant concentration. Charman et al. [13J formulated and evaluated a self- 
emulsifying formulation, based on the system developed by Wakerly et a\ [7], for the 
delivery of an investigational lipophilic anti-viral compound (WIN 54954). Their 
observations demonstrated that substantial proportions of WIN 54954 could be 
successfully incorporated into a self-emulsifying mixture with substantial 
improvement in bioavailability.
Many factors should be considered and optimized when formulating with lipid 
systems which will be discussed in more details in sections to come. This includes:
1. Emulsification rate and resultant particle size
2. Surfactant type and concentration
3. Electrolyte
4. Temperature
5. Inclusion of drug
1.2. Emulsions and Microemulsions
1.2.1. Definition of Emulsions
Over the last few decades, the production of emulsions has gained the interest of 
many scientists due to the wide range of technological products and processes 
involved. Stable emulsion systems are used in a large area of industry, such as the 
food industry, pharmacy, cosmetics and coatings. An emulsion may be defined as an 
opaque, heterogeneous system of two immiscible liquid phases (oil and water) where 
one of the phases is dispersed in the other as drops of microscopic or colloidal size, 
normally in the range 250nm-25pm [17]. There are two kinds of simple emulsions 
depending on which phase comprises the drops; if oil is dispersed in-water (O/W), 
water is called the continuous phase and oil is the dispersed phase; if water is 
dispersed in oil (W/O), oil is the continuous phase. Emulsions made by agitation of 
the pure immiscible liquids are very unstable as mixing increases the interfacial area 
resulting in an increase in the interfacial free energy, thus producing a
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thermodynamically unstable system. Such emulsions can be stabilized by the addition 
of surface-active material which protects the newly formed drops from re­
coalescence. An emulsifier is a surfactant which facilitates emulsion formation by 
reducing the system's interfacial tension and aids in stabilization through a 
combination of surface activity and possible structure formation at the interface. 
Surfactants are available in many forms:
• Ionic surfactants: Cationic & Anionic
Quaternary ammonium alkyl salts form one of the best classes of cationic
surfactants; amongst the most well known examples are:
* Cetyltrimethylammonium Bromide (CTAB) and
* Didodecyldimethylammonium Bromide (DDAB)
One of the most commonly used anionic surfactant which is twin-tailed, and is
particularly effective stabilizer in w/o microemulsions is:
* Sodium bis(2-ethylhexyl)-sulfocucinate (AOT)
• Zwitterionic surfactants
A particular important class of this type is the naturally occurring
Phosphoglycerides, which include Phosphatidylethanolamine (PE) and
Phosphatidylcholine (PC).
• Nonionic surfactants
Examples of nonionic surfactants include
* Polyoxyethylenated fatty alcohol (Brij sereies)
* Sorbitan esters (Span series)
* Polyoxyethylene glycerol fatty acid esters (Tagat series)
* Hydrogenated caster oil ethoxylates (Cremophor series)
* Polyoxyethelene sorbitan esters (Tween series)
The safest surfactants to be used orally are the nonionic types and the most widely 
used are probably the ethoxylated esters of fatty acids such as Tweens and Spans. 
Nonionic surfactant molecules contain a polar hydrophilic group (polyoxyethylene 
chain) and a non-polar (lipophilic) chain. This amphilicity results in a double affinity 
which can only be satisfied at a polar-non-polar interface. Nonionic surfactant-oil- 
water systems (nSOW) are usually ‘pseudo ternary’ i.e. the surfactant may be a 
mixture of surfactants, the aqueous phase may be a salt solution and the oil phase may 
be a mixture of oils or contain dissolved polymers.
4
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1.2.2. Definition of Microemulsions
It is possible to mix polar liquids such as water, glycerol or dimethylformamide [18] 
with non-polar hydrocarbons such as w-alkanes to form single-phase 
thermodynamically stable dispersions by the addition of a suitable surfactant or 
amphiphile. This phenomenon was reported to have been explained as early as 1943 
by Hoar and Schulman [19] who proposed an “oleopathic hydro-micelle” model. 
Nonetheless, the term ‘microemulsion’ has been defined by Danielsson and Lindmann 
[20J as ‘a system usually consisting of oils, surfactants, cosolvent, and water which is a 
single phase, optically isotropic and thermodynamically-stable liquid solution” . The 
difference between a microemulsion and an ordinary emulsion is shown by the 
photograph in figure 1.1. Ordinary emulsions are milky turbid dispersions with 
particle size reaching few microns (see, vial C) whereas, microemulsions are optically 
clear dispersions of particle size ranging from 5-50nm (as in vials A &B). There are 
three types of microemulsions (a) oil-in-water microemulsion, (b) water-in-oil and (c) 
bicontinuuous microemulsion. The difference between these types will be discussed 
in detail next. These systems have the capacity to incorporate typically 20% and up to 
approximately 40% volume fraction of dispersed phase in the continuous phase [22^ .
1.2.3. Formation of Microemulsions
The main driving force for microemulsion formation arises from a reduction of the 
interfacial tension (interfacial free energy per unit area) which results from adsorption 
of surfactant at the oil water interface. The Gibbs free energy equation is shown in a 
simplified form in Equation 1, where AG is the change in the Gibbs free energy (J) on 
dispersion, AS is the entropy change (JK'1), T is the temperature in Kelvin, AA is the 
increase in surface area of the interface (m2) and y is the interfacial tension (Nm'1).
AG = yAA - TAS. (1)
On mixing oil, water and surfactant to form a microemulsion there is an increase in A 
of several orders of magnitude compared to that in a phase separated system. In order 
to compensate for this effect there must be a dramatic reduction in the interfacial 
tension when surfactant is adsorbed at the interface. This is achieved essentially by 





Photograph showing the difference between a microemulsion and an ordinary 
emulsion. (A) An emulsifier dissolved in oil with no added water (B) A 




monolayer film, thus preventing oil and water from coming into direct contact[23]. In 
this way, the interfacial tension is reduced from ~ 50 mNm'1 to <1 mNm’1. However, 
entropy changes also influence the free-energy term. The dispersion of one liquid in 
the other in the form o f large numbers of very small droplets will clearly increase the 
entropy of the system which is favorable. However, the adsorption of surfactant 
molecules at the oil-water interface might be expected to reduce the overall entropy 
increase. The latter unfavorable entropy change is thought to be reduced by the fluid­
like nature of the interface. For example, lateral surfactant motion in the interface 
occurs, which decreases ordering in the surfactant monolayer. The net change in 
entropy associated with microemulsion formation is positive and therefore contributes 
to the lowering of the free energy term. Thus a negative free energy of formation is 
achieved when large reductions in surface tension are accompanied by significant 
favorable entropic change. In such cases, microemulsification is spontaneous and the 
resulting dispersion is thermodynamically stable.
The extent and position of the single-phase microemulsion region for a typical 
surfactant is shown in Figure 1.2a. In the oil rich domain of the single region (the 
right side shaded portion, L2 region) W/O microemulsion is preferred; towards the 
water rich comer (Li region) O/W microemulsion is found. By their very nature O/W 
microemulsion droplets generally have a large effective interaction volume than W/O 
droplets. In the case of ionic surfactants this is attributable to the presence of the 
electrical double layer formed at the surface of the O/W droplet which introduces a 
strong repulsive force. Yet, in the case of nonionic surfactants, although there is 
hydration shell associated with polar headgroups, the predominant repulsive factor 
can be attributed to steric interactions. For single-phase mixtures of oil, water and 
surfactant which fall outside these well defined regions, it is possible that 
bicontinuous microemulsions may form, where the amounts of water, surfactant and 
oil are similar. In the latter case, both oil and water exist as a continuous phase in the 
presence of a continuously fluctuating surfactant-stabilised interface with a net 
curvature of zero. Figure 1.3 shows schematic representation of the three types of 
microemulsions discussed above which are most likely to be formed depending on 
composition. Bicontinuous systems are structurally more difficult to study but they 
may be regarded as a single-phase system in which both the oil and water have 
extensive connected domains so they behave as if both are continuous phase; i.e. there 
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Winsor's description of the various types 
of the multiphase emulsion systems
Figure 1.2a: Schematic triangular phase diagram of an oil-surfactant-water system. Shaded area indicates existence of fields of the 






Schematic representations of the three most commonly encountered microemulsion 




sides of continuous, interconnecting, surfactant-coated channels [26]. Such 
bicontinuous microemulsions may posses relatively high viscosities compared to O/W 
or W/O microemulsions because of the presence of extended structures. For those 
microemulsions where droplets are present, the radii fall within the range 1-1 Onm. 
Early measurements were made using the sodium salt of Aerosol-OT as surfactant, the 
droplets being essentially monodisperse. Droplet sizes and shape are most commonly 
measured using scattering techniques such as small-angle neutron scattering (SANS) 
and photon correlation spectroscopy (PCS).
In certain systems microemulsion formation is achieved by adding with the surfactant, 
a suitable co-surfactant such as a medium chain-length alcohol (typically hexanol), 
alkanoic acids, alkanediols, alkyl amines [27], medium chain-length (Cs/Cio) 
mono/diglycerides such as Imwitor 988 as illustrated in this thesis, or even a co­
solvent such as chloroform, propylene glycol etc. Co-surfactants act as surfactants in 
their own way; they stabilize the interface by keeping similarly-charged headgroups 
further apart, thus minimizing headgroup coulombic repulsions. The need for a co­
surfactant is related to the fact that each head group unit is hydrophilic. Therefore, the 
addition of an extra unit causes a considerable increase in the hydrophilic nature of 
the surfactant. This makes it harder to achieve the correct HLB required for the 
production of a microemulsion; instead this balance has to be achieved by the use of a 
co-surfactant. Co-surfactants need not necessarily be capable of forming association 
structures on their own right. However, co-surfactants generally partition between the 
interface and the external oil phase. This means that their effect on the system, for 
example in changing the droplet size, depends on the partition coefficient of the co­
surfactant concerned. Importantly, in some cases nonionic surfactants such as 
polyoxyethelene H-alky ethers (CnEm) are able to form microemulsions without the 
need for co-surfactant [28’ 29\  Although microemulsions appear at first to be rather 
complex fluids, their preparation is simple and straightforward. AOT microemulsions 
are readily prepared by dissolving the surfactant in the non-polar oil and then adding 
water with gentle shaking. This results in the formation of an optically-clear single­
phase solution containing droplets.
Multiphase microemulsion-containing systems, first described by Winsor are also 
important. These are located in the two phase region of the phase diagram as shown in 
Figure 1.2a. The affinity of the surfactant for oil or water at a particular temperature
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and or salinity results in three different types according to Winsor classification 
system, see figure 1.2b. Winsor's type I systems, the affinity of the surfactant for the 
water phase exceeds its affinity for the oil phase. Thus, the interface will be convex 
towards water. A system in the two-phase region will split into an oil phase 
containing dissolved surfactant monomers at CMC0 (critical micelle concentration in 
the oil phase) and an aqueous microemulsion-a water phase containing solubilised oil 
in normal surfactant micelles (O/W). In Winsor's type II systems, the affinity of the 
surfactant for the oil phase exceeds its affinity for the water phase and the interface 
will be convex towards oil. A system in the two-phase region will split into a water 
phase containing surfactant monomers at CMCW (critical micelle concentration in the 
water phase) and an oleic microemulsion which is an oil phase containing solubilised 
water in reverse surfactant micelles (W/O). In Winsor's type III systems, the 
surfactant's affinity for the oil and the water phases is balanced. The interface will be 
flat as in bicontinuous microemulsions. In the multiphase region, type HI nSOW (non­
ionic surfactant-oil-water) system co-exists as a three phase-phase; a water phase 
containing surfactant monomers at CMCW, an oil phase containing surfactant at CMC0 
and a surfactant phase. The surfactant phase is composed of cosolubilised oil and 
water separated from each other by an interfacial layer of surfactant. This layer is 
sometimes called the middle phase as its intermediate density causes it to appear 
between the oil and the water phases in type HI nSOW systems.
1.2.4. Microemuision Stability
A convenient and commonly encountered means of representing the thermal stability 
of a single-phase microemuision system is the use of phase profile (Figure 1.4). The 
plot is generally one of R (% w/w water content) versus temperature for a 
microemuision of fixed surfactant concentration. The phase profile defines the 
maximum amount water that can be solubilised in the oil solvent at any particular 
temperature. Also, the temperature range over which a given microemuision is stable, 
limited by the upper and lower temperature phase boundaries, T u  and T l, respectively. 
The schematic stability diagram shown in Figure 1.4 would be typical for sodium 
bis(2-ethylhexyl)-sulfocucinate (AOT)/water/«-alkane mixtures and also for nonionic 
surfactants/water/mixed glycerides (optimized ratios of medium chain 
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Figure 1.4
Schematic stability diagram of water content %(w/w) versus temperature for a single­
phase emulsion. A represents the single-phase microemuision. B represents the 
Regions where the system is phase-separated (adapted from Ref. 24). Tu and Tl are, 




One distinguished feature of this phase profile is the fact that, a single-phase 
microemulsion system is not associated with the formation of liquid crystalline 
structures.
A major consideration in the stability of microemulsions is the miscibility behavior of 
the two-component surfactant-water and surfactant-oil systems. It is worth noting that 
ionic surfactants such as AOT and nonionic surfactants such as C 12E6 
(hexaethyleneglycolmono-tt-dodecyl ether) behave in opposite ways with 
temperature. In the case of AOT, the conversion is Winsor II to Winsor I with 
increasing temperature, whereas the change for C12E6 is Winsor I to Winsor II. This 
could be attributed to the fact that microemulsions stabilized by non-ionic surfactants 
are very susceptible to temperature because a decrease in surfactant solubility occurs 
with increasing temperature. In contrast, microemulsions stabilized by ionic 
surfactants have little or no sensitivity to temperature [25]. The phase inversion of 
Winsor I to Winsor II or vice versa can be induced not only by a change in 
temperature but also by changes in ionic strength or through the addition of additives 
such as co-surfactants.
1.3. Basic Principles of Phase Inversion
The nature of an emulsion (O/W or W/O) depends on variable factors such as, 
oil:water ratio, electrolyte concentration, temperature and mainly the nature of the 
surfactant. If the surfactant is more soluble in the water phase than in the oil phase 
(hydrophilic surfactant) O/W emulsion is produced. On the other hand, if the 
surfactant is more soluble in the oil phase (lipophilic surfactant) W/O emulsion is 
formed. In order to explain the behavior of emulsified systems, three basic concepts 
related to the surfactants need to be understood: solubility, formation of micelles and 
interfacial adsorption.
13.1. Dissolution State of Nonionic Surfactant
The most important properties of a surfactant are its solubility and its interfacial 
activity. When a nonionic surfactant is added to a two-phase liquid-liquid system, it 
preferentially adsorbs at the interface forming an adsorbed layer. At low surfactant
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concentrations an equilibrium exists between surfactant monomers dissolved in the oil 
phase, surfactant monomers dissolved in the water phase and the interfacial surfactant. 
In the case of a' separated system (constant interfacial area), as the concentration of 
surfactant in the system increases, the amount of surfactant at the interface reaches a 
maximum possible concentration. Excess surfactant, on further increase in surfactant 
concentration, will form micelles in either the oil or aqueous phase, or form a 
surfactant phase depending on it’s affinity for the oil and water phases. The break 
point is termed the critical micelle concentration (CMC). A surfactant micelle is 
generally depicted as sphere of surfactant molecules with a liquid phase core. The 
surfactant must be present at a concentration above the CMC in order to stabilize an 
emulsion.
1.3.2. Change of Phase Behavior with Temperature
One way of altering the surfactant affinity in an nSOW system is by changing the 
temperature. This change in temperature will change the surfactant's affinity for the 
two phases. At high temperature the nonionic surfactant become more soluble in the 
oil phase while at low temperature it becomes more soluble in the water phase. 
Shinoda and Friberg t31] showed that, for surfactants with cyclohexane and water, the 
phase behavior changed with temperature at a constant surfactant concentration. In 
that system, a rise in temperature increased the surfactant's affinity for the oil phase, 
hence the system moved from Winsor's type 1 to type 2 phase behavior with increase 
temperature. The water phase was continuous at low temperature. Satio and Shinda 
[32] also showed that the interfacial tension changed during the transition from type 1 
to type 2 phase behavior.
1.3.3. Factors Affecting Phase Inversion
The phase inversion in nSOW systems has several controlling factors. Among these 
factors the following can be identified:
(1) Type of oil, (2) Surfactant type and concentration, (3) Temperature of the system, 
(4) Water to oil ratio, (5) Additives in the oil and water, (6) Mixing conditions and (7) 
Rate and order of additives of the different components; the first five factors affect the 
surfactant's affinity while the last two factors are dynamic variables.
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Various techniques and concepts have been used to correlate surfactant affinity 
variables and hence the emulsion type; these are described below:
A. Hydrophile-Lipophile Balance (HLB)
B. Phase Inversion Temperature (PIT)
C. Emulsion Inversion Point (EIP)
D. Equilibrium Water-Oil Ratio (WOR) Maps 
The first two will be discussed in this thesis.
I.3.3.I. Hydrophile-Lipophile Balance (HLB)
Full descriptions of the Hydrophile-Lipophile Balance (HLB) concept are given by 
Becher [17\  and Becher and Shick [33]. Griffin f34] first defined the affinity of a non­
ionic surfactant in terms of an empirical quantity, the HLB. Surfactants are assigned 
an HLB number at 25°C on a scale of 1 to 20. Low HLB numbers represent lipophilic 
surfactants and high HLB numbers represent hydrophilic surfactants. Application of a 
surfactant can be derived from its HLB number in accordance with table 1.1 [35l  
HLB numbers are calculated for a surfactant from simple formulae based either on 
analytical or composition data [36]. For polyoxyethylene nonylphenyl ethers (NPE), 
HLB=E/5 where E is the % weight of polyoxyethelene in the surfactant. For example, 
for NPE 12 (12 oxyethylene groups in the hydrophilic chain) HLB= 14.2. For a 
polyhydric fatty acid ester, HLB=20(l-S/4), where S= saponification number of the 
ester and A = acid number of the fatty acid. For example, for polyoxyethylene (20) 
sodium monolaurate (Tween 20), S= 45.5 and A= 276; HLB= 16.7.
Table 1.1: Application of surfactant based on their HLB number








Many attempts have been done to assign HLB numbers to various oils to predict 
which surfactants will produce the most stable emulsion i.e. the required HLB. 
However, many researchers have found no correlation between emulsion type and 
HLB number of surfactant
I.3.3.2. Phase Inversion Temperature (PIT)
The sensitivity of emulsions to temperature was recognized by Shinoda et a l [37, 381. 
They suggested the use of the PIT as a method of preparing emulsions. They found 
that at the PIT oil-water interfacial tension is at its minimum and the oil water 
interface does not show preferential curvature. Phase Inversion Temperature (PIT) 
was defined by Friberg et al. t39] as being the temperature at which the emulsifier 
shifts its preferential solubility from water to oil phase at high temperatures. Below 
and above the PIT the interfacial curvature is towards the oil and water respectively 
forming o/w or w/o emulsions. The PIT is a characteristic feature of an emulsion 
system which is influenced by specific non-ionic surfactant- oil and water 
components. Phase inversion temperature is affected by:
(l)The oil type, (2) Surfactant HLB (hydrophilic chain-length), (3) The effect of 
phase volume ratio on the PIT and (4) The addition of dissolved solutes
1. Effect of Oil Type on the PIT
Generally, as shown in figure 1.5, the greater the solubility of the surfactant in the oil 
phase the lower the PIT of the system. Sato and Yuasa [40^ have shown that, the 
greater the affinity of the oil for the surfactant the smaller the reduction in HLB 
required allowing surfactant to dissolve in oil. Nonpolar oils, such as pure 
hydrocarbons result in high PIT's whereas polar oils, like for example aromatic 
hydrocarbons, result in low PITs.
2. Effect of Surfactants on the PIT
Non-ionic surfactants often become increasingly more lipophilic at elevated 
temperatures. The level of hydration of polyoxythelene chains is decreased by 
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Figure 1.5
The correlation between surfactant HLB number and the PIT in various oil/water (1:1) 
emulsions stabilized with non-ionic surfactant at concentration of 1.5% w/w (adapted 
from Ref. 41). The HLB value of the surfactant was changed by increasing the 
number of ethoxy residues in the surfactant molecule.
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surfactant is no longer soluble in water. Shinoda [41] has shown that, for a number of 
different oils, the HLB is a function of temperature (see figure 1.5). HLB numbers are 
normally assigned to surfactants by measuring the PIT of an emulsion containing the 
surfactant and checking this against a PIT vs. HLB calibration curve. Shinoda and 
A ria[42] correlated surfactant HLB and PIT for a range of commercial NPE surfactants 
with cyclohexane. Generally, HLB numbers derived from PIT measurements differ 
from formula values by <2 HLB numbers. It can be seen from figure 1.5 that, for any 
oil, the higher the HLB of a surfactant the higher the PIT. Shinoda and Friberg f31] 
also found that the solubility of a nonionic surfactant in particular oil was inversely 
proportional to the PIT. Graciaa et a l [43^ showed that hydrocarbon chain branching in 
nonionic surfactant-oil-water systems decreases the PIT and effective HLB, This is 
attributed to the fact that hydrocarbon branching leads to an increased tendency for 
the surfactant to partition into oil phase.
Surfactant mixtures
The efficiency of a surfactant in emulsifying and stabilizing a liquid-liquid system is a 
function of the relative degrees of interactions of the various portions of the surfactant 
molecule with both the oil phase and the water phase. The HLB of an emulsion 
system, in which a mixture of surfactants is used (HLB mix), has been generally 
assumed to be an algebraic mean HLB of the individual surfactants:
HLB mix = /aHLBa + ( 1 - / a )  HLb 
Where^/a is the weight fraction of surfactant A and is the weight fraction of 
surfactant B (I -/a )
More stable emulsions are produced when a blend of surfactants is used 3^1]. PIT data 
indicate that when the difference of HLB of the surfactants in a blend is small, the 
surfactant mixture HLB is approximately that of the weight average HLB. However, 
this was not the case for blends with large differences in HLB.
3. The effect of Phase volume ratio on the PIT
The effect of the phase ratio of emulsions on the PIT depends on the kind of oil, the 
concentration of surfactant and the distribution of the polyoxyethylene chain lengths 
in the surfactant. Shinoda and Friberg [31] showed that the PIT does not vary
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significantly with the phase ratio in non-polar oil systems with surfactant 
concentration >5% wt, but it changes in solutions containing surfactants at 
concentrations <3%. This has been attributed to the fact that the saturation 
concentrations of nonionic homologues surfactants in water are very small, but those 
in hydrocarbons are much larger and depend on the ethylene oxide chain length. 
Lipophilic homologues (shorter chain lengths) dissolve better than hydrophilic 
homologues in the oil phase. Hence, there will be a selection of more hydrophilic 
surfactant to be adsorbed at the oil/water interface. This effect is amplified in dilute 
solutions and when the volume fraction of oil is large. However, in the case of 
aromatic hydrocarbons and polar oils, Shinoda and Fribrerg have shown that the 
phase volume ratio has a marked effect on the PIT
4. The effect of additives on the PIT
Although the exact mechanism by which various additives affect the PIT is not fully 
understood, their presence in nSOW systems has been shown to affect the PIT. The 
phase inversion temperature varies with the amount and chemical type of additives in 
the water phase. Shinoda and Takeda [44] showed that inorganic salts can affect the 
PIT more strongly than their parent acids. As seen in figure 1.6 , the salt depresses all 
phase boundary temperatures, and hence PIT, in a linear fashion across the whole 
diagram. This might be due to the fact that some salts depress the PIT by reducing the 
surfactant HLB and thus its aqueous solubility. However acids increase the PIT and 
hence the temperature required to achieve maximal O/W or W/O solubilisation. This 
is comparable to the salting in and salting out phenomena used in crystal purification 
processes. Shinoda and Friberg [31] have shown that the effect of fatty acids and 
alcohols on the PIT for 1:1 volume ratio paraffin-water systems was independent of 
the chain length of the acid or alcohol. They have also shown that the more polar the 
dissolved solute, the greater the reduction in PIT.
1.4. Applications of Microemulsions
Microemulsions and reverse micellar systems are already applied in certain industrial 
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Figure 1.6
The effect of added salts, acids and alkali on the phase inversion temperature (PIT) of 
cyclohexane/water emulsion (1:1 volume ratio) containing 3% w/w of the nonionic 
surfactant C gH i^IT iO tC fhC FhO ^jH  in water (adapted from Ref. 44).
20
Introduction
to demonstrate their significance and potential. However, pharmaceutical applications 
of microemulsions, mainly oral drug delivery, will be dealt with in more details as it 
is the basis of this work.
1.4.1. Enhanced Oil Recovery (EOR)
Various potential techniques are already applied today in pilot experiments for EOR 
such as, flooding with surfactants, microemulsions and microemulsion-polymer 
systems. The method is based on the very low interfacial tensions and good wetting 
properties of these systems. It considerably enhances the mobilization of oil droplets 
or oil ganglions entrapped in the rock pores. The interfacial tension (a) between crude 
oil and water is typically 50 mNm*1, whereas values of 10"* to 10' 6 mNm" 1 can be 
obtained in a suitable microemulsion. This technique implies that an oil reservoir is 
flooded with surfactant solution and then an external temperature is applied. The 
interfacial tension between the surfactant solution and the oil decreases with rising 
temperature. As soon as ct is decreased below a certain limit, a steep increase in oil 
recovery is observed. Nevertheless, the complete mechanism is not yet understood, as 
not only the interfacial tension between water and oil is of significance for enhanced 
oil recovery, but also the coalescence of oil ganglion, emulsification processes and 
interactions with polymers added to the systems in order to adjust the viscosity. This 
technique of oil recovery has already been studied intensively due to its high 
economic significance [45^ .
1.4.2. Liquid-Liquid Extraction
Liquid-liquid extraction is mainly o f industrial significance for the extraction of 
metals from ores with low metal contents. The mineral substances are dissolved in a 
strongly acidic or strongly alkaline aqueous medium from which they are then 
recovered by two-phase extraction using a specific extractant. These extractants are 
generally large organic molecules which can be dissolved in the oil-rich domains of 
the microemulsions. The metal ions, on the other hand, are found in the water-rich 
domains. Since the interfacial area in microemulsion is much larger than in
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conventional stirred two-phase systems, extraction rates can be achieved exceeding 
those in conventional two-phase systems by a factor of 1 0  to 1 0 0  [46].
1.4.3. Lubricants and Cutting Oils
These liquids very often contain surfactants and water as additives, i.e. 
microemulsions or reverse micellar solutions are formed with certain compositions. 
This has two effects: the surfactants cause corrosion inhibition and the increased 
water content compared to pure oils leads to higher heat capacity. Corrosion inhibition 
is based, on the one hand, on solubilization and thus on the inclusion of corrosive 
agents, which can then no longer react with the metal surface. On the other hand, the 
metal surface is protected by the adsorbed hydrophobic surfactant film. Because of 
their thermodynamic stability, Microemulsions have succeeded over unstable 
emulsion systems in this field. The first composition of such a system was patented in 
1930[471.
1.4.4. Chemical Reactions in Microemulsions
Chemists in many fields of activity have studied chemical reactions microemulsions 
[48]. In one of the first studies entitled “ Catalysis in Water Pools”  Menger described 
in 1973 the accelerated hydrolysis of esters in w/o microemulsions 4^9]. A large 
number of publications are available describing organic, inorganic and biochemical 
reactions in microemulsions.
I.4.4.I. Nanoparticles Preparation
Discrete nanoparticles with controlled chemical composition and size distribution are 
readily synthesized using reverse micelles and microemulsions as confined reaction 
media [50]. Yet their assembly into well-defined superstructures amenable to practical 
use remains a difficult and demanding task. Generally, two microemulsions of the 
same composition, but containing different reactants in the aqueous fraction, are 
mixed and the precipitate is then isolated. This technique uses w/o microemulsion 
droplets as a template for particle growth whereby water can be regarded as 
microreactors. Mei Li et a l [52] reported that the interfacial activity of reverse micelles
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and microemulsions can be exploited to couple nanoparticles synthesis and self- 
assembly over range of length scales to produce materials with complex organization 
arising from the interdigitation of surfactant molecules attached to specific 
nanoparticle crystal faces. Robinson et a l [53] studied the formation of cadmium sulfide 
particles in AOT/water/w-heptane systems. Superconducting material YBa2Cu3 0 7  was 
synthesized by microemulsion precipitation, particles of 1 0  folds lower than the 
smallest particles formed by bulk solution precipitation was achieved [54]. Particle 
synthesis in microemulsions is a promising technique yet the mechanism of particle 
formation is not fully established. However, certain factors of influence can be 
specified and general trends described. Osseo-Asare [55] described five aspects to be 
taken into consideration for particle synthesis in microemulsions: phase behaviour and 
solubilization, average concentration of the reacting species in the aqueous domains, 
intramicellar interactions, water/surfactant ratio and structure and properties of the 
solubilizing water, and dynamic behavior of the microemulsions.
I.4.4.2. Biochemical Reactions
Biotechnological applications of microemulsions have received a great deal of 
attention since the discovery that enzymes could be solubilized in the droplet cores of 
W/O microemulsion droplets with retention of activity and stability. The catalytic 
behavior of Phospholipase A2 t56] and also a large number of enzymes have been 
studied after being solubilised in W/O microemulsions as reverse micelles. If 
hydrophobic substrates are added to the enzyme containing microemulsion, it can be 
observed that the enzyme-dissolved in the aqueous domains converts the substrate 
dissolved in hydrocarbon phase. Enzyme-catalyzed syntheses with water-insoluble 
substrates in microemulsions can be carried out by selecting the components for 
preparing the microemulsions so that no inhibition or denaturation of the enzyme 
occurs t57]. A study of an enzyme-catalyzed reaction including enzyme recovery by 
extraction from the reaction solution is described by Larsson [58J. He has shown that 
reaction control, product isolation, and enzyme recovery from the microemulsion can 
be achieved once the phase diagram of the system is established. The isolation of 
proteins from aqueous solutions by liquid-liquid extraction with a microemulsion is a 
mature technique f59]. By varying the pH value, ionic strength or temperature, the 
distribution coefficient of a protein can be adjusted between a w/o microemulsion and
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the coexisting aqueous phase so that the protein can be absorbed in or released from 
the microemulsion t60l  Large scale recovery of industrial enzymes, proteins and 
metal/metal ion extractions has been demonstrated using a continuous reactor system. 
In the forward extraction step the pH is adjusted in the aqueous phase (Winsor I) to 
favor protein uptake into the reverse micellar phase, whilst in the back extraction, the 
pH of Winsor II is adjusted to favor release of the protein from the reverse micellar 
phase.
1.4.4.3. Electrochemical and Electrocatalytic Reactions
Electrochemistry often faces the problem of finding a solvent which simultaneously 
dissolves an organic substrate and has a sufficient amount of conducting electrolyte. 
The use of o/w microemulsions as the reaction medium offers very interesting new 
possibilities of electrochemical analysis and catalysis. The electrochemical syntheses 
of polyparaphenylenes [61] or the dehalogenation of vicinal dihalogen compounds [62] 
are new synthesis paths.
1.4.4.4. Polymerizations
Microemulsions can be used in a similar way to produce polymer particles with a 
better-defined size and stmcture in both W/O and O/W microemulsion systems. 
Tetrahydrofurfurylmethacrylate has been polymerized in an AOT based 
microemulsion to produce monodisperse microlatices [63]. Microemulsions in which 
these polymerizations can be carried out contain higher surfactant concentrations than 
the formulations of emulsion polymerization. The monodisperse microlatices obtained 
from microemulsions are in discussion as carriers for pharmaceuticals. Perez-Luna et 
al [64] gave a good survey of polymerizations in microemulsions and demonstrate in 
detail the experimental procedure using the example of styrene polymerization.
1.4.4.5. Organic Reactions
Organic syntheses are often faced with the problems of reacting water-soluble 
inorganic reactants with water-insoluble organic reactants. In microemulsions with the 
aid of amphiphiles, high concentrations of both water soluble and water-insoluble
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compounds dissolve simultaneously. This has been recognized in the past 20 years by 
several groups who used these solutions as reaction media for various organic 
reactions with reactants such as acids, bases, cyanide, bromide, hypochlorite or 
permanganate. There are many examples in the literature of organic reactions in 
microemulsions; alkaline hydrolysis f49] using anionic surfactant (AOT) at reactant 
concentrations of 10' 3 to 10-2 (mol/L), oxidations e.g. of sulfides t65] at reactant 
concentration of 1 mol/L. Generally, the aim is to work with the maximum possible 
reactant concentrations in conjunction with the minimum possible amphiphile 
concentrations. After the reaction is complete, the microemulsion is cleaved by 
changing the temperature so the product and the surfactant will be in two different 
phases.
1.4.5. Microemulsion-Based Organogels (MBGs)
A number of papers have recently appeared describing the preparation of MBGs by 
the addition of gelatin to w/o microemulsions. The addition of gelatin to water at 
sufficiently high concentrations results in the formation of a rigid gel matrix. Gels of 
similar strength may be easily formed on addition of gelatin to w/o microemulsion. 
Atkinson [66, 67-1 and co-workers have proposed a structure based on small-angle 
neutron scattering data which involves an extensive network of surfactant-coated, 
gelatin- containing conducting aqueous channels coexisting with microemulsion-type 
droplets. This proposed structure for MBGs is given in figure 1.7. In practical terms, 
the preparation of MBGs is straightforward. The parent microemulsion is incubated at 
50°C and added to a solution of gelatin in water at the same temperature. The 
resulting mixture is vigorously shaken and then allowed to cool to room temperature 
when an optically transparent single phase gel is formed. The rigidity of MBGs is 
controlled in the main by the added amount of gelatin. The MBGs are prepared using 
different varieties of surfactants and oils including AOT/isoctane [68] and Tween 
80/IPM (isopropyl myristate) [69l  The organogels are optically clear and 
thermorevesible, and have been suggested as novel delivery vehicles for drugs and 
antigens f70]. Recently, lipases have been immobilized in MBGs and the synthesis of a 








Structure of microemulsion-based organogels (MBGs); aqueous (w/o) microemulsion 
droplets in equilibrium with a network of rods of gelatin and water surrounded by the 
surfactant AOT (adapted from Ref. 66).
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1.4.6. Pharmaceutical Applications of Microemulsion Systems
I.4.6.I. Pharmaceutically Acceptable Excipients for Microemulsions
Although several microemulsion systems have been described in the literature, the 
challenge for the pharmaceutical formulator is to predict which oil(s) and surfactant(s) 
to select for a particular application.
Pharmaceutically acceptable oils tend to be more polar and of much higher molecular 
weight than the more commonly used aliphatic or aromatic oils. Medium chain 
glycerides derived from coconut oil (such as Miglyol 812, a mixture of Cg/Cio 
triglycerides) are particularly attractive for formulating orally active microemulsions 
for many reasons:
1 . They are stable food grade products and generally recognized as safe (GRAS) 
by the Food and Drug Administration agency [71].
2. Microemulsions incorporating these excipients can be formulated at ambient 
temperature over a wide range of compositions [72].
3. Medium-chain glycerides (mono-, di-, and triglycerides) are reported to 
improve the intestinal absorption of co-formulated drugs [73,74].
4. They could be easily formulated and presented in soft gelatin capsules, or 
recently in sealed hard gelatin capsules.
Recently polyglycolyzed glycerides (PGG) with varying fatty acid and polyethylene 
glycol (PEG) chain lengths and thus varying HLB, in combination with vegetable oils 
have been used to solubilize poorly water-soluble drugs and improve their 
bioavailabilityfl4].
Ionic surfactants are frequently used for the production of microemulsions; they 
however have only a very limited use for pharmaceutical purposes [75], where the 
surfactants of choice are either nonionic or zwitterionic. This is because of the lower 
toxicity of nonionic and zwitterionic surfactants, in particular membrane toxicity, 2nd 
their greater stability towards the changes in ionic strength and pH that are to be 
encountered in the biological environment [76l
The nonionic surfactants studied include; polyoxyethylene hydrogenated caster oil, 
sucrose esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene n-alkyl 
ethers, polyglycerol fatty acid esters and polyoxyethylene monoglyceride. A number 
of nonionic surfactants such as the polyoxyethylene n-alkyl ethers [75^ , and
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polyoxyethylene hydrogenated caster oil [77] do not require a cosurfactant for the 
formation of microemulsion. Sucrose esters and polyglycerol fatty acid esters, on the 
other hand, are suitable for pharmaceutical purposes yet the presence of an alcohol 
cosurfactant is required to produce microemulsions 7^8’79^ .
The use of a cosurfactant is generally considered to be undesirable in pharmaceutical 
applications [75]. The majority of studies have used medium chain length alcohols as 
the cosurfactant of choice. There are significant toxicity and irritancy issues with 
these materials, which preclude their use in pharmaceutical formulations. The aqueous 
solubility of cosurfactants in o/w microemulsion systems is often higher than that of 
the principal surfactant. Consequently, when the o/w microemulsion is diluted, the 
cosurfactant partitions more strongly to the aqueous phase. As a result, depletion of 
the cosurfactant at the oil/water interface occurs, thereby destabilizing the 
microemulsion droplet. As a consequence, workers have examined alternative co- 
surfactants such as medium chain mono- and diglycerides [74], alkan-1 , 2  diols [80], 
ethanol and polyhydric alcohols such as sorbitol and sucrose *81,82V 
Lecithin-based microemulsions, both o/w and w/o, have recently been considered as 
alternative drug delivery systems that avoid problems of toxicity associated some of 
the nonionic surfactants [83]. However, since lecithin is too hydrophobic (HLB = 4) 
and has a tendency to form lamellar liquid crystalline phases, short-chain alcohols are 
often included to alter the HLB and aid emulsification by destabilizing the liquid- 
crystalline phases [84]. Therefore, phospholipid microemulsions have primarily been 
used for topical drug delivery[83].
The choice of emulsifiers is determined by the average HLB requirement of the 
proposed microemulsion (see section 1.3.3). Water-in-oil microemulsions are formed 
using emulsifiers within the HLB range of 3-8 while o/w microemulsions are formed 
within the range of 8-18. Some of the oils and surfactants used to formulate 
microemulsions for oral drug delivery along with their HLB values are listed in table 
1.2.
I.4.6.2. Drug Incorporation into Microemulsions
In spite of a large number of therapeutic agents of varying physicochemical properties 
being incorporated into microemulsions, very little work has examined the influence 
of drugs on the phase behavior and stability of the microemulsion. Phase diagrams
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Table 1.2: Some of the common excipients used to formulate lipid microemulsions for oral delivery (modified from Ref. 76)
Excipient HLB Value Chemical Definition Manufacturer
Arlacel 80 4.3 sorbitan oleate ICI Americans
Arlacel 186 2 . 8 monooleimpropylene glycol (90:10) ICI Americans
Capmul MCM 5.5-6 Cg/Cio mono-/diglycerides from coconut oil Abetic
Captex 200 oil Cg/Cio diesters of propylene glycol from coconut oil Abetic
Captex 355 oil Cg/Cio triglycerides from coconut oil Abetic
Centrophase 31 4 liquid lecithin Central Soya
Cremophor EL 3.5 35-polyoxyethylene caster oil BASF
Cremophor RH 40 14-16 40-polyoxyethylene hydrogenated caster oil BASF
Labrafac CM 10 1 0 Cg/Cio polyglycolized glycerides from coconut oil Gattefosse
Labrafil M 1944 3-4 oliec acid (Cig;i) polyglycolized glycerides from apricot kernel oil Gattefosse
Labrafil M 2125 3-4 linoleic acid (Cig:2) polyglycolized glycerides from apricot kernel oil Gattefosse
Labrasol 14 Cg/Cio polyglycolized glycerides from coconut oil Gattefosse
Miglyol 812 oil Cg/Cio triglycerides from coconut oil Huls
Myvacet oil distilled acetylated monoglycerides Eastman chemicals
Myverol 18-92 3.7 distilled sunflower oil monoglycerides Eastman chemicals
Soyabean oil oleic (25%) and linoleic (54%) triglyceride ^ Croda
Tagat To 11.3 polyoxyethylene (25) glycerol trioleate Goldscmidt Chem.
Tween 80 15 polyoxyethylene (2 0 ) sorbitan oleate BASF
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should be constructed in the presence of a particular drug, particularly if  the drug is 
surface active and thus expected to affect significantly the microemulsion region. 
Also in cases where lipophilic drugs are incorporated into o/w microemulsions, such 
drugs frequently act as oils themselves and therefore influence phase behavior. 
However, low levels of potent water-soluble drugs such as, peptides added to w/o 
microemulsions probably will not have a significant effect on initial phase studies.
The amount of drug incorporated into a given microemulsion is dependent on its 
relative solubility in the various component systems, particularly on its oil/water 
partition coefficient. Pre-formulation data that includes aqueous solubility, as well as 
solubility in selected microemulsion excipients should precede any microemulsion 
formulation work.
In selecting an appropriate type of microemulsion for a particular drug certain 
physicochemical data are required, in particular, aqueous and/or oil solubility or even 
better partition coefficients t?3] along with, for all routes of delivery except 
intravenous, its in vitro membrane permeability [76J. The drug classification by 
Amidon et al. based on drug solubility and intestinal permeability best describes 
some of the factors controlling the drug dissolution and absorption process. This 
biopharmaceutical drug classification to address drug dissolution and absorption for 
each of the four drug classes along with the recommended microemulsion systems is 
presented in table 1.3
1.4.6.3. Water-in-Oil Microemulsions
Water-in-oil microemulsions have been designed to overcome metabolic and physical 
barriers to water soluble drug molecules, particularly peptides and proteins. One of 
the reasons why microemulsions in general are attractive for the delivery of labile 
proteins and peptides is that they do not require high temperatures and/or 
homogenization for their preparation [76]. Water-in-oil microemulsions improve the 
oral bioavailability of drugs by protecting these sensitive drugs from the harsh 
proteolytic environment of intestine and also they enhance their intestinal absorption
[76]per sec 1 .
Water-in-oil microemulsions as an oral drug delivery enhanced the absorption of 
insulin, calcitonin and growth hormone [86]. Ritschel and co-workers 8^7] showed that
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Table 1.3: Potential microemulsion systems for drugs based on physicochemical 











Class I High High w/o or o/w Protection against enzymatic 
and hydrolytic degradation
Class II Low High o/w Improved solubilization and 
dissolution, enhanced 
bioavailability
Class III High Low w/o Protection against enzymatic 
and hydrolytic degradation, 
enhanced bioavailability
Class IV Low Low o/w Improved solubilization and 
dissolution, enhanced 
bioavailability
** Compounds are considered to have low aqueous solubility (So) and apparent 
permeability (P app) at So <100pg/ml or at P apP < 2x1 O'6 cm/s, respectively.
Table 1.4: Composition of Neoral® compared with Sandimunn® (adapted from 
Ref. 96)
Neoral® Amount Sandimunn® Amount
Cyclosporin lOOmg Cyclosporin lOOmg
1 , 2  propylene glycol 75mg Ethanol lOOmg
Ethanol 150mg Maize oil 416mg
Partial glycerol 345mg Transesterified triglyceride and 300mg
transesterified com oil Polyalkaline polyol (Labrafil M2126)
Cremophor RH 40 405mg
Total amount per dose 1075mg Total amount per dose 916mg
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absorption of vasopressin in rats from ligated small intestinal segments was increased 
by about two-fold when the peptide was formulated in the microemulsion as 
compared to an aqueous solution. Water-in-oil microemulsions encapsulating water- 
soluble biologically-active materials, such as peptides, have been reported by Owen et 
al. [88]. It is obvious that upon oral administration a w/o microemulsion undergoes a 
considerable dilution and, as a consequence, a phase inversion to an o/w 
microemulsion releasing the encapsulated water-soluble molecule.
Both o/w and w/o microemulsion formulations for topical or transdermal application 
have been investigated by various workers. It was shown that it is possible to 
formulate an effective topical preparation of the local anesthetic pentacaine chloride 
[89^ in a w/o microemulsion. Skin permeation of felodipine, a calcium antagonist, has 
also been investigated from o/w microemulsions stabilized by a surfactant mixture 
containing Tween 20 and taurodeoxycholate [90]; Isopropyl meristate (IPM) was used 
as the oil phase with benzyl alcohol as a cosurfactant. Water-in-oil microemulsion 
formed from diclofenac dimethylamine and phospholipids have been examined as 
transdermal delivery vehicles 9^1]. The formulation was based on a combination of 
Tween 80 and span 20 with IPM. Diclofenac dimethylamine was released at a much 
faster rate from the microemulsion formulations than an aqueous solution of the drug 
or from gels and liposomes.
Water-in-oil microemulsions have been shown to form thermodynamically stable 
gels, known as microemulsion-based gels (MBG, see section 1.4.5) upon the addition 
of gelatin. These oil-based, electrically conducting gels have been recently 
successfully developed for the transdermal delivery of water-soluble drugs using a 
technique called iontophoresis. A small direct electric current is applied to the skin in 
order to drive small charged molecules into the body and into the blood circulation
[92]
I.4.6.4. SMEDDS & Oil-in-Water Microemulsions
Self-Micro-emulsified drug delivery system (SMEDDS) is the name given to a drug 
vehicle consisting of oil or modified oils, surfactant and co-surfactant mixtures, solid 
or liquid at ambient temperature, which emulsifies spontaneously when mixed with 
water at 37°C under gentle agitation [93]. This system is able to form a microemulsion
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of droplets with diameters between 5 and 140nm when they are in contact with the 
aqueous media such as gastro intestinal fluids, so they potentially increase most drug 
dissolution and bioavailability. SMEDDS performance depends on: firstly, the 
mixtures ability to emulsify when diluted in a large quantity of water. Secondly, the 
HLB value which is related to the solubilizing behavior of the preparation [94]. Drug 
delivery advantages offered by microemulsions include: improved drug solubilisation 
and protection against enzymatic hydrolysis, as well as the potential for enhanced 
absorption afforded [95].
The most notable example of SMEDDS is the oral delivery of cyclosporin A as a 
commercial formulation Neoral®. Cyclosporin A is a cyclic undecapeptide used as an 
immunosuppressant in transplantation surgery, and in contrast to most peptide drugs 
is hydrophobic. The original Sandimmun® formulation was based on a solution of 
cyclosporin A in vegetable oil (table 1.4). It formed, after oral administration, a crude 
o/w mixture which had to be emulsified by the bile salts present in the small intestine 
in order to initiate the digestion of the oil droplets and therefore the release of the 
cyclosporin. Although the co-administration of triglyceride with the cyclosporin A 
improved its bioavailability, there was considerable pharmacodynamic inter- and 
intra-patient variability [9?1, bioavailabilites as low as 1% and as high as 89% have 
been reported ^  This variation can be attributed to factors such as food intake and 
the mechanism of uptake in vivo which is considered to be related to the lipolysis of 
the triglyceride. The new Sandimmune Neoral® formulation (table 1.4) is described as 
a microemulsion pre-concentrate which apparently produces an oil-in-water 
microemulsion on contact with the gastrointestinal fluids without the requirement for 
the involvement of endogenous compounds such as bile salts, and consequently the 
bioavailability and reproducibility of delivery is greatly enhanced. The available data 
has been reviewed by Noble and Markham who confirm the conclusion that Neoral® 
offers more predictable and more extensive drug absorption than the standard 
Sandimmune® formulation [98]. Almost 2-fold increase in the oral bioavailability of 
cyclosporin was observed in the case of Neoral® compared with the old formulation. 
Recently, an o/w microemulsion of insulin was gelled using Carb-O-Sil and orally 
administered in polymer-coated gelatin capsules designed so that release of the insulin 
would occur mainly in the colon [99]. Oil-in-water microemulsions have also been 
proposed as aqueous-based vehicles for the pulmonary delivery of lipophilic drugs via
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nebulization [100l  This interest is a consequence of the imminent ban by 2005 on 
chlorofluorocarbon propellants used in inhalers and the problems experienced with 
the reformulation of existing drugs in the alternative hydrofluoroalkanes. The 
formulation of a water-in-HFA propellant microemulsion stabilized by fluorocarbon 
non-ionic surfactant has been investigated by Patel et al. [101] for pulmonary delivery. 
The development and characterization of o/w microemulsions designed for parenteral 
tl02] and ocular use has also been reported recently [103].
1.5. Classification of Lipid Delivery Systems
A very recent attempt has been made by Pouton [104] to classify lipid formulations for 
the enhancement of bioavailability of hydrophobic drugs. He suggests three main 
criteria with which lipid formulations can be distinguished:
a) Does the formulation self-emulsify or remain poorly dispersed in water?
b) When the formulation makes contact with water are some of the components 
lost by dissolving in the aqueous phase?
c) Is the dispersed formulation digestible by lipases?
Answering these proposed questions Pouton has derived three major types of 
formulations with lipid systems. These types result from blending up to five classes of 
excipients; ranging from pure triglycerides oils, through mixed glycerides, lipophilic 
surfactants, hydrophilic surfactants and water soluble co-solvents. Table 1.5 describes 
the typical properties of the different types of lipid formulations 
Type (I): easily digestible formulations which consist of triglycerides and/or mixed 
glycerides in the absence of surfactant. Type (II): self-emulsifying formulations which 
comprise triglycerides and/or mixed glycerides, and lipophilic surfactants (HLB<12). 
Type (III): self-emulsifying systems which comprise triglycerides, mixed glycerides, 
hydrophilic surfactants (HLB >12), and water-soluble co-solvents.
1.5.1. Type I Lipid Formulations
Formulations which comprise drug in solution in triglycerides and/ or mixed 
glycerides are classified as Type I (Table 1.5). When an appropriate dose of the drug 
can be dissolved, this type of formulations will be the system to be considered for its
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Table 1.5:Typical properties of Type 1,11. lllA and 111B lipid formulations (adapted from Ref. 104)
Increasing hydrophilic content —— ►
Type 1 Type II Type IIIA Type IIIB
Typical composition (%) 
Triglycerides or
Mixed glycerides 100 40-80 40-80 <20
Surfactants 0 20-60 (HLB<12) 20-40 (HLB>12) 20-50 (HLB>12)
Hydrophilic
cosolvents 0 0 0-40 20-50
Particle size of 






Some loss of 
solvent capacity
Significant phase 
changes and potential 




Not crucial but 
likely to occur
Not crucial but 
may be inhibited
Not required and 
unlikely to happen
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simplicity and biocompatibility. If sufficient solvent capacity cannot be achieved 
using pharmaceutically acceptable mixtures of triglycerides, mixed glyceride or other 
lipophilic esters, this type will not be an option. Type I formulations on dilution forms 
coarse O/W macro-emulsion thus, the dispersion of the drug into colloidal solution is 
likely to be dependent on digestion by lipolysis, a process which takes place mainly in 
the small intestine. During digestion the drug is solubilised in mixed micelles of bile 
salts and digestion products and thus high bioavailabiiity can be expected yet without 
rapid onset of action. If the dmg has a low therapeutic index Type I formulation will 
be more favorable than other types. This type has the advantage that on dilution in 
aqueous media, the solubilised dose of the drug faces no risk of precipitation. From a 
clinical and toxicological perspective, Type I formulations may be safer with 
reference to the generated pharmacokinetic profile and also since they avoid the 
chronic administration of surfactants.
Table 1.6 : Selected examples of Type I lipid formulations
Compound Lipid Reference
Triamterene Peanut oil, oleic acid 105
Cyclosporine Olive oil 106
Griseofulvin Com oil 107
Penclomedine Mineral oil 108
Prbucol Liquid paraffin 109
Vitamin E LCT, MCT 1 1 0
1.5.2. Type II Lipid Formulations
These systems are defined as self-emulsifying formulations that consist of water 
insoluble components. Nonionic ester ethoxylate surfactants with HLB of 10-12, such 
as polysorbate 85 (Tween 85) or polyoxyethylene 25-glyceryl trioleate (Tagat TO) 
form the core component of Type II to promote emulsification of triglycerides or 
mixed glycerides, especially medium chains. These surfactants do not form micelles 
in water, and are described by their manufacturers as water dispersible. Yet, in an
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excess of water they form a fine stable emulsion as they interact strongly with water 
forming liquid crystal phases. Self-emulsification of this system is closely related to 
the formation of dispersed lamellar liquid crystals on dilution with water. The 
lipophilic surfactant concentration in Type II systems requires optimization. As the 
surfactant content in the blend is increased there is a threshold at approximately 25% 
(w/w) surfactant beyond which self-emulsification occurs f1111. At high surfactant 
concentrations, more than 65%, emulsification is compromised by viscous liquid 
crystalline gels which form at the oil-water interface. This type of formulation is 
likely to retain its solvent capacity for the drug after dispersion in aqueous media. 
Type II systems consisting of medium chain triglycerides and polyoxyethylene - (25) 
- glyceryl trioleate (Tagat TO) have produced particles as fine as 100-250 nm, 
depending on the surfactant concentration [7]. Self-emulsification of Type II 
formulations can be further improved; this is reflected in the dramatic reduction of 
droplet size, by incorporating medium-chain glyerides, particularly Cg/Cio 
mono/diglycerides such as Imwitor 988 which acts as a co-surfactant. Yet, the ratio of 
medium chain triglycerides to (mono/diglycerides) as well as the surfactant 
concentration should be optimized. Many type II systems will be digestible unless the 
surfactant concentration is too high. However, lipolysis of this type of systems is not 
crucial for the enhancement of bioavailability of lipophilic drugs, though it is likely to 
occur.
Table 1.7 : Selected examples of Type II lipid formulations
Compound Formulation Reference
WIN 54954 Neobee-M5 (MCT)/T agat TO 13
CCKg receptor antagonist Labrafil M2125/Tween 80 1 1 2
Benzoic acid Miglyol 812/Tween 85 5
Ro 15-0778 Neobee-N5/Peanut oil 14
1.5.3. Type III Lipid Formulations
This type of formulations fulfils the need to improve the solvent capacity of lipid 




• Examples of hydrophilic surfactants (HLB>12): Cremophor RH40, 
Cremophor EL, Emuline and Tween 80. These surfactants form micellar 
solution when transferred to the aqueous phase on dispersion.
• Examples of hydrophilic co-solvents: Ethanol, Propylene glycol, Polyethylene 
glycol, Glycerol, Glycofurol and Transcutol.
The introduction of more hydrophilic components reflects on the mechanism of 
emulsification of this type of formulations, the droplet size produced and also the 
lipolysis of these systems. The mechanism of emulsification involves diffusion of the 
hydrophilic components away from the bulk oil into the aqueous phase, thus 
‘diffusion and stranding’ becomes a predominant mechanism for emulsification 
which will be discussed in more detail next. These systems are also called self- 
microemulsifying systems, as optical clarity can be achieved with these formulations. 
When the surfactant content is high (for example, >30% w/w) or co-solvents are 
included in addition to surfactants, very fine dispersions (50-1 OOnm) can be produced 
under conditions of gentle agitation [113]. Type ID systems have been shown to act 
independently of bile, which suggests that they are not necessarily digested before the 
drug is absorbed [114]. The purpose for formulating with Type El systems may also be 
to increase the solvent capacity for drugs with log P 2-4. As this type of formulations 
has water soluble components, there is a tendency to be loss of solvent capacity on 
dilution in the aqueous phase. The consequence may be that the drug is partially 
precipitated when the formulation disperses. The risk of precipitation is greater when 
the formulation contains a higher proportion of hydrophilic components. Pouton has 
further sub-classified Type III formulations into Type IHA and Type IIIB addressing 
the degree of hydrophilicity of this type. Both Type IIIA &B have hydrophilic 
surfactant and co-solvent yet they differ in the oil content. A typical Type IIIA 
formulation contains approximately 50-60% triglycerides or mixed glyceride content, 
whereas Type IIIB has less than 20%. This renders type IEEB the most hydrophilic 
type of lipid formulation, which is likely to result in a colloidal solution of drug and 
oil in aqueous micelles. As a result, Type IIIB presents the highest risk of 
precipitation. It also produces the finest dispersions, due to their high content of 
water-soluble solubilising agents. An archetypal example of a Type HI system is the 
reformulation of cyclosporine A as Neoral® [104]. The drug was more available from 
the Neoral than the earlier ‘Sandimmune’ formulation, which was a coarsely
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emulsifying system [115]. This might be due to the fact that the coarse emulsion 
produced by the Sandimmune formulation could not be reduced to colloidal 
dimensions because of limited digestion [111].
1.6. Mechanisms of Emulsification
1.6.1. Emulsification of Type II Lipid Formulations by Interfacial Liquid Crystal 
Formation (ILCF)
A general mechanism for spontaneous emulsification in nonionic surfactant based on 
pesticide formulations was proposed by Groves t1161. Self-emulsification was 
suggested to be a result of dynamic formation of liquid crystalline units at the 
interface promoting further water penetration into the oily phase down aqueous 
channels. The resulting increase in surface pressure would lead to interfacial 
disruption and dispersion of the oil as droplets into the bulk aqueous phase [7]. As 
illustrated in figure 1 .8 a, water initially diffuses into the nonionic surfactant-oil 
mixture and associates by hydrogen bonding with the surfactant molecules. This will 
occur until the solubilisation limit is reached close to the interface. Figure 1.8b shows 
further aqueous penetration which will result in the formation of dispersed lamellar 
liquid crystal phase (LCa) shown as parallel lines. This material has a loosely 
associated lamellar lattice structure. As the aqueous penetration proceeds, eventually 
almost all material close to the interface will be liquid crystalline. The actual amount 
of the liquid crystals formed depends on the surfactant concentration in the binary 
mixture. Once these have been developed water continues to penetrate into the oil- 
surfactant mixture through the aqueous channels in the liquid crystals or gel matrix 
(figure 1.8c). The rate of this penetration will be dependent on the degree of 
orientation within the structured phase and the size of the aqueous pores. The increase 
of the water transport through the aqueous cores is accompanied by an increase of the 
surface pressure close to the interface. The interfacial instability, in conjunction with a 
reduced interfacial tension due to the increase in surface pressure aided by the gentle 
agitation during the emulsification process, causes a rapid expansion of the water -  
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Schematic Representation of Self-Emulsification Mechanism proposed by Wakerly et 




Surfactant molecules will continue to diffuse to the interface to replenish the liquid 
crystal layer due to the induced diffusion gradient.
1.6.2. Emulsification of Type III Lipid systems by ‘Diffusion and Stranding9 
Mechanism.
This mechanism was first proposed by Gurwistch tll7] as an alternative to spontaneous 
emulsification, which would take place without interfacial turbulence. It deals with 
emulsification resulting from differential solubilities of a third component in the oil 
and water phases. Generally, systems which do not contain surfactants, for example 
the ethanol/toluene/water system examined by Haydon [118], are quoted as examples of 
this mechanism. In this approach the dissolved third component (ethanol) has a 
considerable solubility in the receptor phase (water) as well as the phase in which it is 
initially dissolved (toluene). The dissolved material therefore diffuses across the 
interface from one phase to the other. In so doing it can carry with it some of the 
solvent phase (toluene) into the receptor phase (water). Once this has occurred the oil 
phase, having a low solubility in water, forms droplets which increase in size as more 
oil transported. These droplets slowly move away from the oil-water interface due to 
the kinetic energy imparted by the mass transfer process.
In the multi-component systems examined by Gilbert 1^19^ , surfactants are initially 
contained in the oily phase. It is proposed that water penetrates into the oil phase prior 
to exudation of oily jets from the interface subsequently, the surfactant becomes more 
hydrated. This will increase the surfactant solubility in the aqueous phase and render 
it less soluble in the oil phase. As a result the surfactant diffuses into the aqueous 
phase carrying oily components with it. This is an example of the diffusion and 
stranding mechanism specific to systems containing hydrophilic surfactants.
Rang et al. recently investigated the spontaneous emulsification of H-hexadecane/w- 
octanol(C80H)/hexaethyleneglycolmono-«-dodecyl ether (C12E6) [120^ and n-
hexadecane/oleylalcohol(Ci8 :iOH)/Ci2E6 [121] mixtures. In the first system as shown in 
figure 1.9a, diffusion of water into the oil phase converted it to a microemulsion that 
subsequently became supersaturated in oil due to diffusion of octanol into the water. 
As a result small oil droplets (of order 1 pm) nucleated spontaneously from the 
microemulsion. Further diffusion of octanol out of the now oil-lean microemulsion 






















Schematic diagram showing spontaneous emulsification process for drops of (a) n -  
hexadecane/>?-octanol(C80H)/C12E6 containing water or (b) w-hexadecane/oleyl 





Thus, for some optimal range of initial drop compositions, an emulsion of small oil 
droplets in water resulted. It is noteworthy that no liquid crystalline phase was 
involved in first system. However, using the longer chain alcohol 
oleylalcohol(Ci8;iOH) as in the second system, the injected oil drop is completely 
converted to La (lamellar liquid crystal) and also to microemulsion. Thus, any oil 
present in the final state must have been nucleated from one of these phases; La or 
microemulsion. The process is shown schematically in figure 1.9b.
1.7. Lipid-Water Interaction &Liquid Crystalline Phases 1
Liquid crystals are ordered structures, without the stiffness of crystalline solids. They 
contain a polar, a non-polar and an amphiphilic component and are 
thermodynamically stable, i.e. they self-organise spontaneously. In theory, based on 
mathematical symmetry calculations, eighteen possible structures can be formed 1^22, 
122\  many of which have been identified by Rosevear 1^24^ . However, in two 
component systems only three major types of liquid crystal are formed, these being 
classified by the number of dimensions in which the crystal structure pattern is 
repeated. The lamellar, hexagonal and cubic forms are the most likely to be found 
using lipid based components.
1.7.1. Lamellar Liquid- Crystalline Phase (La)
More commonly in lipids a liquid crystalline phase is formed in the presence of water, 
as shown in figure 1.10. Above a critical hydrocarbon-chain melting temperature, 
water penetrates the polar region and a lamellar lipid-water structure (La) is formed 
with water layers alternating with lipid bilayers (figure 1.10c). The surfactant 
molecules are oriented in the bilayer such that the lipophilic hydrocarbon chains of the 
molecule are intermeshed in a central sandwich core with the hydrophilic portions 
localized on both sides. The lamellar structure (also known as the neat phase) has a 
one dimensional periodicity and is capable of liquid flow in two directions by means 
of sliding over one another. Due to the relative ease of flow the viscosity of this phase 





Polymorphic phases available to 
hydrated liquid crystalline lipids 
(a) Hexagonal Hi, (b) Hexagonal 
Hu, (c) Lamellar (La) and (d) Cubic
Illustration adapted from The Lipid Handbook (Ref. 125).
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1.7.2. Hexagonal Phase (Hi&Hn)
The hexagonal or middle mesophase is periodic in two dimensions. The two 
hexagonal structures shown in figure 1 . 1 0  (a, b) are termed Hi and Hu respectively. 
The Hi phase consists of infinite cylinders of lipid molecules with their polar groups 
oriented toward the outer (continuous) water phase, and the surfactant of hydrocarbon 
chains filling out the core of the cylinders. Because of the continuous water phase, Hi 
can be diluted indefinitely forming spherical o/w micelles. The Hn phase is the inverse 
of Hi, i.e. water forms cylinders in a continuous medium of surfactant molecules with 
the polar groups oriented toward the water phase and the hydrocarbon chains filling 
out the exterior between the cylinders. Unlike Hi phase, Hu has a limited swelling 
capacity, and it can only accommodate approximately 40% water in the cylindrical 
aggregates. The lamellar and hexagonal phases can be identified from their X-ray 
diffraction patterns. The lamellar phase shows a series of reflections corresponding to 
one-dimensional periodicity. From the X-ray data it is possible to determine the 
thickness of the liquid bilayer, the cross-section per polar headgroup and the water 
layer thickness. In the same way the diameter of the cylinder in the Hi and Hu phases 
can be determined as well as the cross-sectional area per polar headgroup and the 
distance between adjacent cylinders. These procedures are described in the 
fundamental work by Luzzati et a l [126].
1.7.3. Cubic Phase
The viscous isotropic cubic phase, which is periodic in three dimensions, exists 
mainly in monoglyceride-water systems at chain lengths above C 14 (figure 1.11). It 
was originally thought to consist of spherical water aggregates arranged with cubic 
symmetry in a lipid matrix with the polar groups surrounding the water aggregates 
and the hydrocarbon chains filling the gaps between the water spheres [126]. Studies of 
the cubic monoglyceride-water phase indicated that the structure was closely related 
to that of the lamellar phase [127l  Furthermore, it was concluded from NMR diffusion 
measurement that the local environment of the lipid molecules was similar to the 
lamellar phase and different from phases with molecules arranged in rod system. It 
was also concluded that the structure was both lipid-and water-continuous, and was 
proposed to consist of lipid bilayer units with hexagonal shape connected into a
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network. The hexagonal units would be expected to be curved in order to avoid sharp 
edges (figure 1.1 Od, far left from bottom). Later it was realized by Larsson et a l [128]. 
That such a structure is identical to the primitive cubic alternative of an infinite 
periodic minimal surface (IPMS). The structure is shown in figure 1.10, to the right. 
The methyl endgroup gap of the bilayer is identical to the IPMS, and the infinite lipid 
bilayer thus formed separates two identical water channel systems. A new type of 
cubic structure has recently been reported by Luzzati et a l [129]; it consists o f two types 
of reversed micelles embedded in a continuous hydrocarbon-chain matrix. This phase 
is formed in many systems of water-swelling lipids mixed with lipids that do not form 
aqueous phases.
1.7.4. Lipid-Water Phase Diagrams
I.7.4.I. Binary-Phase Diagrams
Generally, phase equilibrium in binary lipid-water systems are illustrated by 
composition-temperature phase diagrams. There are two types of lipid-water phase 
diagrams. The first type is obtained from polar lipids whereby, the solubility in water 
is quite small; monolaurin for example has a solubility of about 10'5M. Figure 1.11 
illustrates the principles of phase equilibrium in this type of lipid-water system. A 
homologous series of monoglycerides is used here as an example. Phase diagrams of 
pure 1-monoglycerides-water systems were first published by Lutton [131], who 
described the phase behavior of monoglycerides with chain lengths from C 12 to C2 2 . 
Larsson [I32] described detailed phase diagrams for short-chain length monoglycerides 
C6-C 1 0. As shown in figure 1.11, at chain lengths C8-C12, only the lamellar La is 
formed. When the chain length is increased, there is also a cubic region with the two 
phases discussed in a previous section. Finally, at chain length above Cs, a phase 
termed L2 is formed when the temperature is increased. Lj is used for a normal 
micellar solution, whereas water aggregates in a hydrocarbon chain medium is termed 
L2 [133] seconc] type of binary system is obtained when the lipid is soluble as 
micelles in water. Examples of such lipids are fatty acid salts and lysolecithin. An 
aqueous soap system is depicted in figure 1.12. When the lipid concentration in the 
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Figure 1.11
Main features of monoglyceride-water phase diagrams at different hydrocarbon chain 
lengths (Lam, Cub, and Hex corresponds to regions of lamellar, cubic and hexagonal 
Hu phases, respectively). Below the hydrocarbon-chain melting temperature, there is 
solid (S) material in equilibrium with water. Small shaded areas represent two phase 
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Figure 1.12
Phase diagram of sodium myri state-water. The phases are shown only to the right of 
the broken line at water concentrations >15% w/w (adapted from Ref. 130)..
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micelles. At still higher lipid concentrations the lipid cylinders are hexagonally 
arranged and the liquid-crystalline phase is formed. The lamellar liquid-crystalline 
phase La is usually formed in the region between Hi and the anhydrous lipid. Reviews 
of the association behavior of amphiphiles of this type have been published [I34, l35\
I.7.4.2. Temary-Phase Diagrams
A ternary system consists of a non-polar lipid such as triglycerides, water and an 
emulsifying agent. An example of such a ternary lipid system [136] is shown in figure 
1.13. The triglyceride component, as well as the monoglyceride component, contains 
numerous compounds with different chains and both behave as one component with 
respect to the phase rule. The transition La—>Cubic->Hn—»L2 , obtained by heating the 
binary monoglycerides system (figure 1 .1 1 ), is also obtained by solubilization of 
triglyceride molecules into the bilayer according to this phase diagram (figure 1.13). 
Increase in temperature or water content results in increased molecular disorder, and 
this disorder corresponds to an increased wedge shape of the average lipid molecule, 
as the disorder within the lipid molecule builds up towards the end of the hydrocarbon 
tail. The slope of the transition line La to cubic and of the transition cubic to Hn in 
figure 1.11 clearly illustrates these effects. A quantitative theory relating the wedge 
shape of the amphiphile molecule to the phase that is formed with water has been 
introduced by Israelachvili et a l [137].
1.7.5 The Use of Liquid Crystal Vehicles in Pharmacology
Liquid crystal vehicles offer the possibility of dissolving water soluble, non-water 
soluble and amphiphilic compounds. Substances which are soluble in any of the 
phases and which go through extensive degradation in an acid environment increase 
their stability when incorporated in a liquid crystal matrix. The matrix structure does 
not permit gastric juice to enter the vehicle, which thus prevents • degradation [138]. 
Extended release of larger water-soluble substances and non-polar substances is easily 
managed with liquid crystal-based vehicles. The actives are trapped in the liquid 
crystal formulation. When the liquid crystal vehicle comes into contact with the 
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Figure 1.13: Phase equilibrium of the ternary system soybean oil-water-monoglycerides of sunflower oil. The liquid crystalline (LC) 
phases are Lamellar (L-LC), cubic (C-LC) and hexagonal (H-LC), axes are in percentages (adopted from Ref. 136).
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reaches the surroundings liquid. As the drug slowly clears and dissolution progresses, 
new surface zones appear-releasing the next layer of drug, and so on. The dissolution 
does not occur instantly at body temperature it can take hours. Optimization of release 
rate is therefore needed. In the dilution process in the gastrointestinal fluids, liquid 
crystals are dissolved and transformed to an emulsion or a microemulsion / micellar 
system depending on the type of surfactant used. The transformation increases the 
solubility and effective area of the poorly soluble substances in the gastrointestinal 
lumen, which in turn increases the bioavailability.
An excellent review has recently been published by Drummond et a l [139] outlining 
the application of surfactant self-assembly objects based on hexagonal, cubic, 
‘intermediate’ and L3 (‘sponge’) phase structures as novel drug delivery vehicles. 
Norling et a l [140^ have described the development of a stable, sustained release 
formulation of an antimicrobial agent, metronidazole, to treat periodontol disease. The 
product is based on a mixture of monoglycerides and triglycerides and formulated as 
water-free suspension that transforms to the reversed hexagonal phase in the 
periodontol pocket. The reversed hexagonal phase has been observed to form upon the 
complexation of cationic and neutral lipids with DNA in aqueous solution [141]. This 
work by Kotover et a l [141] suggests that there is a possibility that non-lamellar 
lyotropic liquid crystalline phases may be utilized in the future as a non-viral method 
of gene delivery.
Glyceryl monooleate (monoolein or GMO), a Food and Drug Administration- 
approved food additive, is a mixture of the glycerides of oleic acid and other fatty 
acids, consisting mainly of the monooleate, and has the ability to form different types 
of lyotrobic liquid crystals in the presence of water [142]. The use of liquid crystalline 
phases of GMO as drug delivery systems has been widely investigated by many co­
workers t142'145^  The unique properties of cubic liquid crystalline phases formed from 
GMO systems have been utilized for the preparation of controlled release systems; 
and in topical and mucosal drug delivery systems due to their adhesive properties. A 
wide variety of drugs with different physicochemical properties have been 
incorporated in GMO [139l  A recent study by Sallam et al [146] has investigated the 
properties of the cubic liquid crystalline phases of GMO to formulate an oral dmg 
delivery system for furosemide.
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Liquid crystalline mesophases with rhombohedral, monoclinic and tetragonal 
symmetry, also known as ‘intermediate’ phases, have been identified in some 
surfactant-water system [147], e.g. sodium dodecyl sulfate (SDS)-water system. 
Engstrom et a l [148] have also reported the formation of ‘sponge’ phases in solvent- 
GMO-water systems. The L3 or ‘sponge’ phase is considered to be a disordered 
version of the cubic phase [149, 150]. However, these exotic mesophases, termed’ 
‘intermediate’ and ‘sponge’ phases, have not yet been investigated as drug delivery 
systems.
1.8. Bioavailability Control of Poorly Absorbed Drugs.
The enhancement of oral bioavailability of poorly water-soluble drugs remains one of 
the most challenging aspects of drug development. Salt formations, particle size 
reduction, solubilization, and solid dispersion have been used to increase dissolution 
rate and thereby oral absorption and bioavailability of such drugs [151]. The salt 
formation is not feasible for neutral compounds and the synthesis of appropriate salt 
forms of drugs that are weakly acidic or weakly basic may often not be practical. Yet 
when salts can be prepared, re-conversion of salts into aggregates of their respective 
acid or base might occur thus an increased dissolution rate can not necessarily be 
achieved. Particle size reduction is commonly used to increase dissolution rate, 
however there is a practical limit to how much size reduction can be achieved by 
controlled crystallization, grinding, etc. The use of very fine powders in a dosage 
form may also raise problems because of handling difficulties and poor wettability. 
Administration of a hydrophobic drug dissolved in a lipidic solvent or using solid 
dispersion method is thought to improve bioavailability and hence a more consistent 
profile of drug absorption with time is observed. These last two methods will be 
discussed in more details in following subsections.
1.8.1. Absorption of Drugs from Solution
The dissociation constant and lipid solubility - of drug, as well as the pH at the 
absorption site, dictate the absorption characteristics of a drug from solution. The 
interrelationship among these parameters is known as the pH-partition theory of drug
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absorption. This theory is based on the assumption that the gastrointestinal tract is a 
simple lipid barrier to the transport of drugs and chemicals. Accordingly, the 
nonionized form of an acid or basic drug, if sufficiently lipid-soluble, is absorbed but 
the ionized form is not. The larger the fraction of drug in the nonionized form at a 
specific absorption site, the faster is the absorption. Acid and neutral drugs may be 
absorbed from the stomach but basic drugs are not. The rate of absorption is related to 
the oil-water partition coefficient of a drug; the more lipophilic the compound, the 
faster is its absorption.
1.8.1.1. Drug pJTa and Gastrointestinal pH
The fraction of drug in solution that exists in the nonionized form is a function of both 
the dissociation constant of the drug and the pH of the solution. The dissociation 
constant is often expressed for both acids and bases as a pKa.. The p£a values of 
several drugs and the relative acid or base strengths of these compounds are shown in 
figure 1.14. The relationship between pH and pKa. and the extent of ionization is given 
by the Henderson-Hasselbalch equation: 
for an acid
pKa. -  pH = log (fu/fi)
and for a base
pKa -  pH = log (fi/fu) 
where fu and fi are fractions of the drug present in the un-ionized and ionized forms, 
respectively. Most acid drugs are predominantly un-ionized at the low pH of gastric 
fluids (see figure 1.15) and may be absorbed from the stomach as well as from the 
intestines. The pH range found in the GIT from the stomach to the colon is about 1 to 
8. Very weak acids (pKa. >8) such as, phenytoin, theophylline, or glutethemide are 
essentially un-ionized throughout the GIT thus, they are very much equivalent in the 
gut to non-electrolytes. The ionization of weak acids with pKa. values ranging from 
about 2.5 to 7.5 is sensitive to changes in pH. More than 99% of the weak acid aspirin 
(pKa =3.5) exist as un-ionized drug in gastric fluids at pH 1. On the other hand, only 
about 0.1% of aspirin is un-ionized at pH 6.5 in the fluids of the small intestine. 
Despite this apparently unfavorable ratio of non-ionized to ionized drug, aspirin and 
most weak acids are well absorbed in the small intestine. A large surface area and a 













































The pKa values of certain acidic and basic drugs. Those drugs denoted with an 




















Figure 1.16: Relationship between absorption rate of salicylic acid (pKa = 3) and 
ephedrine (pKa = 9.5) against bulk phase pH in the rat small intestine in vivo. Dashed 
lines indicate curves predicted by the pH- partition theory in the absence of an 
unstirred layer (adapted from Ref. 153).
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These factors minimize the need for a large fraction of the drug in an un-ionized form 
in the small intestine. Strong acids (such as cromolyn pKa 2) are ionized throughout 
the GIT and are poorly absorbed.
Most weak bases are poorly absorbed, if at all, in the stomach since they are largely 
ionized at low pH. Codeine, a weak base with a pKa of about 8 will have only 1 of 
every million molecules in the non-ionized form in gastric fluid as it is mainly ionized 
at pH 1. The pH range of the intestines from the duodenum to the colon is about 5 to 
8. Weakly basic drugs (pKa < 5), such as dapson, diazepam, or chlorodiazepoxide, are 
essentially un-ionized throughout the intestines, this makes them more equivalent to 
non-electrolytes in intestines. Stronger bases, such as mecamylamine or guanethidine 
are ionized throughout the GIT and tend to be poorly absorbed.
The pH-partition theory provides a basic frame work for understanding drug 
absorption; however it is an oversimplification of a more complex process. The theory 
indicates that the relationship between pH and permeation or absorption rate is 
described by an S-shaped curve corresponding to the dissociation curve of the drug. 
For a simple acid or base, the inflection point of the pH-absorption curve should occur 
at a pH equal to the pKa of the drug. This is rarely observed experimentally. In 
general, pH-absorption curves are less steep than expected and are shifted to higher 
pH values for acids and to lower values for bases. The pH-absorption curves for 
salicylic acid (a weak acid with a pKa. of about 3) and for ephedrine (a weak base with 
a pKa of about 9.5) have inflection points at about pH 8 and pH 6.5 [153^ respectively, 
see figure 1.16. Theory predicts little absorption of salicylic acid at pH 8 because at 
this pH the drug would be almost completely ionized. As shown in figure 1.16, the 
absorption rate of salicylate across the small intestine at pH 8 is about 50% of the 
maximum absorption rate. Several factors may contribute to the deviations from the 
pH-partition theory; the absorption of the ionized form of the drug, the presence of an 
unstirred diffusion layer adjacent to the cell membrane, and a difference between 
lumenal pH and the pH at the surface of the cell membrane.
I.8.I.2. Absorption of Hydrophobic Drugs from GI Tract
The rate of absorption of non-electrolyte from the ciystalline state depends on drug 
dissolution rate and the intrinsic rate of absorption across the epithelia of the intestine.
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As depicted in figure 1.17, it is clear that dissolution for hydrophobic drugs is a rate 
limiting step. In the case of crystalline non-electrolyte compounds (Figure 1.17a), 
dissolution is too slow due to low intrinsic water solubility. However, many drugs are 
weak electrolytes and often absorbed to an adequate extent because their p£a(s) allow 
them to exist predominantly as ionized species in the lumen of the gut. In such cases 
the drug is absorbed as the unionized species but the ionized species represents a 
reservoir of drug from which the unionized species is immediately available. 
Therefore, the slow dissolution of the unionized species is avoided (figure 1.17b). 
Weak bases, for this discussion with p£a less than 7, will not be highly soluble in the 
small intestine, and indeed may dissolve in the stomach, only to precipitate after 
gastric emptying delivers them to the small intestine. Thus when weak bases are 
administered in a solid dosage form, they will not benefit from a substantial reservoir 
of dissolved drug. Their absorption is likely to be dissolution rate-limited, analogous 
to biopharmaceutical properties of non-electrolytes. Therefore, when the drug is a 
non-electrolyte or an electrolyte with pXa(s) which are unfavorable for dissolution in 
the gut, there are a number of formulation approaches one can take to improve 
absorption. One commonly used technique is to solubilise the drug in a water- 
miscible co-solvent system, such as polyethylene glycol. This may have sufficient 
solvent capacity for the drug in the unit dosage form. However, there is a tendency 
that the drug will crystallize on dilution of the co-solvent in the lumen of the gut. This 
has been elucidated in later chapters of this thesis. The effect of the formulation 
strategies on the absorption of non-electrolytes or electrolytes with unfavorable 
p£a(s) from the GIT is presented in figure 1.18. The co-solvent approach could be 
convenient if the drug precipitates as a microfine suspension after dispersion finer 
than could be achieved by micronisation. A better strategy is to maintain solubility of 
the drug throughout its passage through the gut. As shown in figure 1.18, this can be 
achieved using different types of lipid systems (Type I, II and HI), assuming that they 
provide sufficient solvent capacity to dissolve the drug in a small volume for 
administration as a unit dose. As a consequence, non-electrolytes, weak acids with 
pKdi >8 and weak bases with pKa. <5 may benefit from reformulation in lipids, which 
can provide a reservoir of drug dissolved in either lipid or micellar solution (figure 
1.19). Some of these formulations will be expected to be digested during their passage 








Gastro-intestinal absorption of hydrophobic crystalline drugs: (a) non-electrolytes and (b) weak electrolytes; if pKa is appropriate 
ionized drug provides a reservoir of unionized drug (adapted from Ref. 104). Introduction
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Figure 1.18
Schematic diagram of the influence of formulation strategies on the GI tract absorption of crystalline hydrophobic 








Gastro-intestinal absorption of hydrophobic drugs as (a) crystalline forms (b) oil systems. Self-emulsified drug delivery systems 
(SEDDS) can provide a reservoir of drugs in oil (adapted from Ref. 104).
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solution will depend on the solubilization of drug by mixed micelles of bile and the 
products of lipolysis. This will be further discussed in following subsections.
I.8.I.3. GI Tract Absorption of Drugs from Digestible Oil Formulations
Following passage into the small intestine, the formulation will become exposed to 
local secretions of lipase and bile salts from the pancreas and gall-bladder 
respectively. These secretions will together facilitate lipolysis, wherein orally ingested 
triglycerides are rapidly digested in the upper small intestine, through the integrated 
action of pancreatic lipase, colipase and bile. Colipase binds to the surface of fat 
droplets in the presence of bile salts and provides an attachment site for lipase [155]. 
Lipase sequentially attacks the two outside ester bonds of the triglyceride molecule, 
producing first a molecule of diglyceride and fatty acid, and then a molecule of 
monoglyceride and fatty acid. The lipolysis products are removed from the oil-water 
interface and incorporated into mixed micelles by bile salts [156]. Thus, in effect, a 
direct pathway exists for the flow of solubilized drug from digesting oil droplets to the 
final product phase, mixed micelles, which provide a strong solubilizing environment 
for hydrophobic drugs. This provides the reservoir of drug from which partitioning 
will occur, allowing absorption of free drug from the lumen of the gut, see figure 
1.20. The rate of lipolysis depends mainly on the size of emulsion particles. In order 
to maximize the rate of drug partitioning into aqueous intestinal fluids, and hence the 
absorption rate, the formulation should be highly dispersible.
1.8.2. Bioavailability Enhancement Using Lipid Systems
Most drugs are administered orally as solid dosage forms either as tablets or powder 
filled hard gelatin capsules. Before the drug can be absorbed it must pass through a 
number of stages presented in figure 1.21. Lipophilic drug lipid deliveiy systems can 
have biopharmaceutical advantages over conventional tablet or powder-filled hard 
gelatin capsules. The dissolution process from solid dosage forms often limits the rate 
of absorption of the drug; if this step is removed, improved bioavailability can result. 
This increase in control of absorption from the gastro-intestinal tract can therefore 
provide a more effective dosage. The use of a simple solution of drug in lipid is rarely 
possible due to the limited solubility of some hydrophobic drugs in lipids.
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This generally leads to the design of more complex lipid-based formulations 
containing other components such as co-solvents. Administration of medicinal 
compounds as solutions in oil may still lead to erratic bioavailability as the degree of 
emulsification that occurs in-vivo can be very variable or may not occur. This depends 
on the state of the stomach contents (fed or fasting) as well as the level of enzymes, 
acid and bile salts present in the gastro-intestinal tract at the time of dosing. The 
alternative is to present the lipophilic drug in a surfactant-oil-cosolvent mixture 
(SEDDS or SMEDDS) which, on contact with water forms an emulsion or 
microemulsion with minimal energy input. Dispersion of the oil as small droplets 
results in much larger interfacial area between oil and water. Hence the rate of drug 
transfer by diffusion from the oily to the aqueous phase (gastro-intestinal tract fluid) 
is increased. On oral ingestion of such a dosage form, the gentle agitation provided by 
the gastro-intestinal tract would cause emulsification of the oily solution once the soft 
elastic gelatin capsule had been ruptured. More recently, lipid mixtures are being 
formulated in sealed hard gelatin capsule forms. It is potentially possible to control 
the resulting oil droplet size distribution after the dispersion of the formulation by 
altering the constituents and the composition of the self-emulsifying surfactant-oil 
mixture. The bioavailability of a given drug candidate will be governed by the 
resultant available surface area for diffusion of the drug from the oil into the aqueous 
phase, which is defined by the emulsion droplet size distribution, and the partition 
coefficient of the compound between aqueous and oily phases [158]. If absorption was 
not limited by the gut membrane, then the ratio of absorption of a drug would be 
greater from a microemulsion. Secondary factors which can modify the rate and the 
route of absorption of a drug from an oily vehicle relate to the digestibility of the oil 
and the lipophilicity of the drug.
As early stimulus for the use of lipid vehicles for drug formulation were the findings 
of improved bioavailability when poorly-water soluble drugs were co-administered 
with food. This prompted investigation of simple lipid solutions and suspensions of 
powdered drug. Well known examples include com oil suspensions of griseofulvin 
[159] and phenytoin [160]. These simple formulations improved oral bioavailability 
compared to administration of an aqueous suspension. Abrams et al. studied the oral 
proportionality of a lipophilic steroid derivative when administered to rats as either 
solution or suspension formulations using sesame oil [161^ . The bioavailability from a
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sesame oil solution was three-fold higher than when the same dose was administered 
as an aqueous suspension of solid drug.
Bloedow and Hayton [162* have suggested that polar digestible lipids increases the 
bioavailability of lipophilic poorly water soluble drugs, while non-digestible lipids 
such as mineral oil (liquid paraffin) and sucrose polyesters have no effect on 
bioavailability and may however decrease the absorption rate. Non-digestible lipids 
essentially remain unabsorbed in the intestinal lumen, and can actually limit or reduce 
drug absorption by retaining a proportion of the co-administered drug [163]. Myers and 
Stella [108] investigated the effects of non-digestible and digestible lipid vehicles on 
the oral bioavailability of penclomedine, a highly lipophilic cytotoxic agent. Highest 
bioavailability was from trioctanion due to rapid digestion of MCT, lower 
bioavailability from the LCT due to slower and incomplete digestion, and still lower 
bioavailability from the non-digestible mineral oil. However, bioavailability from 
short chain triglyceride (SCT) tributyrin vehicle was very low, despite the expected 
rapid digestion of the SCT lipid. It was suggested that digestion of tributyrin was 
followed by rapid dissipation of tributyrin and its water soluble digestion products. 
This would predispose the associated proportion of administered drug to precipitation 
as crystalline drug with the same inherent dissolution limitations as the aqueous 
suspension formulation.
Oil digestibility can alter the pathway by which a compound is removed from the 
gastrointestinal mucosa. Fatty acids of carbon chainlengths greater than 14 are 
considered to be assembled into chylomicrons and transported by the lymphatic 
system. Carbon chainlengths between 8  and 12 diffuse passively into the systemic 
circulation via the portal vein [164]. Major routes for absorption of a lipophilic drug 
from an oil based formulations are summarized in figure 1.20. Palin and Wilson 
examined [109] the effect of different lipids on the absorption of probucol. The drug 
was administered as a LCT solution (arachis oil), a MCT solution (miglyol) or a 
liquid paraffin solution. Plasma concentrations were markedly higher after 
administration as an arachis oil solution compared with a miglyol solution, and were 
negligible from the liquid paraffin vehicle. It was concluded that digestion of the 
vehicle facilitated absorption, the subsequent incorporation of the long chain fatty 
acids into the lipoprotein-dependent (chylomicron) lymphatic transport path, 




Emulsification of the lipid vehicle has the obvious advantage of increasing the surface 
area for release of drug from the vehicle. Furthermore, emulsification will increase the 
available surface area for binding of the lipase/colipase complex thereby facilitating 
the kinetics of lipid digestion, while the presence of intefacially active components 
could also affect lipase binding and associated processes. A new lipid-based 
formulation of cyclosporin (Sandimmune Neoral® which contains drug, hydrophilic 
surfactant, co-solvent and lipids) produces a finely dispersed microemulsion when 
diluted in an aqueous phase. This microemulsion pre concentrate formulation was 
shown to increase the oral bioavailability of cyclosporin by an approximately 2 -fold 
factor, compared with the previous commercial capsule formulation (Sandimmune® 
which contains drug, com oil, ethanol and polyglycolised long chain triglyceride) and 
which produces a cmde oil-in-water emulsion when added to water[165].
1.8.3. Bioavailability Enhancement Using Solid Dispersions
The use of solid dispersions of drugs in water-soluble carriers to increase the 
dissolution rate and hence bioavailability of poorly soluble drugs has been studied 
extensively [166’ 167] since the early work of Sekiguchi and Obi [168] in 1961. This 
method, which was later termed solid dispersion [166], involved the formation of 
eutectic mixtures of chugs with water-soluble carriers by the melting of their physical 
mixtures. Sekiguchi and Obi [168] suggested that the drug was present in a eutectic 
mixture in a microcrystalline state. Later, Goldberg et al. [169,170^ demonstrated that all 
the drug in a solid dispersion might not necessarily be present in a microcrystalline 
state; a certain fraction of the drug might be molecularly dispersed in the matrix, 
thereby forming a solid solution. In either case, once the solid dispersion is exposed to 
aqueous media and the carrier dissolves, the drug is released as very fine colloidal 
particles. Because of greatly enhanced surface area obtained in this way, the 
dissolution rate and the bioavailability of poorly water-soluble chugs are expected to 
be high. Sheen et al. [I71^ enhanced the bioavailability of a poorly water-soluble 
investigational compound (RP 69698, Leukotriene B4 antagonist) with solid 
dispersion formulations in PEG 3350, Transcutol and Labrasol. They achieved about 
2 -fold improvement over bioavailability observed with an aqueous suspension of the 
drug in 0.5% methylcellulose. The bioavailability of ritonovir (Norvir, Abbot), a 
poorly soluble HTV protease inhibitor, was enhanced by formulation as a solid
66
Introduction
dispersion in a mixture of Gelucire 50/13, polysorbate 80 and polyoxyl 35 caster oil
[172]
The advantage of solid dispersion, compared with conventional capsule and tablet 
formulations, is shown schematically in figure 1.22. From conventional capsules and 
tablets, the dissolution rate is limited by the size of the primary particles formed after 
the disintegration of dosage forms. In this case, an average particle size of 5 pm is 
usually the lower limit, although higher particle sizes are preferred for ease of 
handling, formulation, and manufacturing. On the other hand, if a solid dispersion or a 
solid solution is used, a portion of the drug dissolves immediately to saturate the 
gastrointestinal fluid, and the excess drug precipitates out as fine colloidal particles or 
oily globules of submicron size. During the last three decades following the initial 
work of Sekiguchi and O b i[168] only two products were marketed as solid dispersion; 
griseofulvin in polyethylene glycol (Gris-PEG, Novartis) and nabilone in povidone 
(Cesamet, Lilly).
There are certain limitations which hinder the commercial application of solid 
dispersion systems. These limitations were reviewed by Serrajuddin [I73], they 
involve:
(a) method of preparation, (b) reproducibility of physicochemical properties, (d) 
dosage form development, (d) scale up of manufacturing processes and (e) physical 
and chemical stability of drug and vehicle.
The stability issue will only be discussed in this thesis as this project involves 
producing stable solid self-emulsified lipid systems.
The physical instability of solid dispersions is mainly due to crystallization of drugs. 
In a solid dispersion prepared by the melt method, a certain fraction of the drug may 
remain molecularly dispersed, depending on its solubility in the carrier used, thus 
forming a solid solution. It may however form a supersaturated solution, separate out 
as an amorphous phase, or crystallize out. The supersaturated and amorphous forms 
may, in turn, crystallize out on aging. This defeats the purpose of the solid dispersion 
systems which are designed to improve the dissolution rate and thus enhance 
absorption, see figure 1.22. Chiou [174J reported that griseofulvin precipitated out in an 
amorphous form in a griseofiilvin-PEG 6000 solid dispersion during the time of its 
preparation. The amorphous material crystallized out on aging, except when the drug 
concentration in the dispersion was 5% or less. Ford and Rubinstein [175] attributed 




















Figure 1.22: schematic representation of the bioavailability of enhancement of a poorly water-soluble drug 






indomethacin-PEG 6000 solid dispersion with time. The decrease was greater for a 
higher drug concentration because a larger fraction of drug crystallized out. In another 
study, Suzuki and Sunada [176] observed that on exposure of a nifedipine- 
nicotinamide-hydroxypropylmethycellulose (HPMC) solid dispersion to 60% RH at 
30 °C or 75% RH at 40 °C for 1 month, nifedipine converted from the amorphous to 
the crystalline state, thus lowering the dissolution rate of nifedipine drastically. 
Stabilization of drugs in amorphous forms in solid dispersions is an active area of 







2.1.1.1. Tagat® Surfactants (Polyoxyethylene glycerol fatty acid esters)
The Tagat products are non-ionic surfactants and can be used on their own or in 
combination with anionic or cationic surfactants, with which they are compatible. The 
main field of application is the production of liquid and paste-like emulsions, for 
which blends of Tagat products are recommended. The Tagat products are used e.g. 
for paraffin emulsions, microwax emulsions, polyethylene emulsions, wax-paraffin- 
solvent emulsions, mineral oil emulsions, emulsions of all kinds of solvents, textile 
auxiliary emulsions, emulsions of paint binding agents and synthetic resins. Some of 
Tagat products have strongly hydrotropic properties and therefore excellent 
solubilisers.
Table 2.1: TAGAT® Products manufactured by Goldscmidt, Germany
Product name Chemical name
TAGAT®L PEG-30- Glyceryl Laurate
TAGAT®L2 PEG-20- Glyceryl Laurate
TAGAT® 0  2 PEG-20- Glyceryl Monooleate
TAGAT® R 40 PEG-40- Hydrogenated Caster Oil
TAGAT® R 60 PEG-60- Hydrogenated Caster Oil
TAGAT® S PEG-30- Glyceryl Stearate
TAGAT® S 2 PEG-30- Glycerl Stearate




Tagat TO (polyoxyethylene-(25)-glyceryl trioleate) was mainly used in this work; it 
is lipophilic surfactant with an HLB value of 11.3. According to the manufacturer 
(Goldschmidt Chemical, Germany), Tagat® TO is soluble in oil but not in water rather 
it is dispersible i.e. it does not form micelles when mixed with water. It is produced 
by the esterefication of ethoxylated glycerol with oleic acid. Initially a known weight 
of ethylene oxide is reacted with glycerol to produce polyethylene glycol glyceryl 
ether. Esterification is then performed using commercial grade oleic acid, obtained 
from the hydrolysis and fractionation of olive oil. The resulting compound, Tagat TO, 
contains an average of 25 ethoxy residues per molecule (see chemical structure in 
figure 2.1).
CH2 O (CH2CH20 )a R 
CH2 O (CH2CH20 )b R 
CH2 0 (C H 2CH20 )cR
Figure 2.1
Chemical structure of Tagat TO surfactant, where a+b+c = 25. R is principally 
CH3(CH2)7CH=CH(CH2)7COOH
Tagat 02
Tagat 0 2 is another product of Tagat® manufactured and supplied by Goldschmidt 
Chemical, and was also used in this study. Tagat 0 2 (polyoxyethylene-(20)-glyceryl 
monooleate), contains an average of 20 ethoxy residues per molecule. It is classified 
as a non-ionic hydrophilic surfactant with an HLB value of 15. According to the 
manufacturer, Tagat® 0 2 is not soluble in vegetable oil, soluble in cosmetic alcohol 




Crillets are polyethoxylated partial esters of sorbitan, the cyclic ether/alcohol 
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Chemical structure of Crillets surfactants (Polyoxyethylene Sorbitan Esters), where R 
is the alkyl group of a fatty acid and (w+x+y+z) is the total number of moles of 
ethylene oxide.
Crillets are hydrophilic in nature and are soluble in water and dilute solutions of 
electrolytes. The solubility of Crillits in aqueous solutions increases with the degree 
of ethoxylation. For a fixed degree of ethoxylation, aqueous solubility decreases as 
the number of ester groupings increase (i.e. HLB is decreased). For a fixed degree of 
ethoxylation and esterification aqueous solubility decreases as the molecular weight
72
Materials & Methods
of the fatty acid increases Crillet products are manufactured and supplied by Croda 
Chemicals.
Crillet 4
Crillet 4 (Polyoxyethylene-(20)-sorbitan monooleate), also known as Tween 80 or 
polysorbate 80, was mainly used in this work. It contains an average of 20 ethoxy 
residues per molecule (w+x+y+z = 20, figure 2.2), and an HLB value of 15.
Crillet 4 is a clear, pale yellow to amber liquid with a faint but characteristic fatty 
odour. In cosmetic and pharmaceutical preparations Crillet 4 frictions as an emulsifier 
and dipersent often in conjunction with other appropriate surfactants; it is an excellent 
emulsifier for solvents, waxes, silicons, etc. Crillet 4 is also used as a solubiliser, 
giving clear solutions of oil in water.
Crillet 1
Crillet 1 (Polyoxyethylene-(20)-sorbitan monolaurate), also known as Tween 20 or 
polysorbate 20 was also used in this work. It contains an average of 20 ethoxy 
residues per molecule (w+x+y+z = 20, figure 2.2), and an HLB value of 16.7. It is a 
fully saturated liquid ester with low odour and pale colour. It is the preferred 
solubiliser for essential oils and perfumes in cosmetic systems. In pharmaceutical 
preparations, Crillet 1 acts as an emulsifier and dispersent for medicaments such as 
menthol, phenol, etc, which otherwise separate. It is also used in conjunction with 
other surfactants as a primary emulsifier in cosmetic creams and lotions.
2.I.I.3. Polyoxyethylene Caster Oil Derivatives
Polyoxyethylene caster oil derivatives are a series of nonionic surfactants obtained by 
reacting varying amounts of ethylene oxide with either caster oil or hydrogenated 
caster oil. They are used in oral, topical and parentral pharmaceutical formulations, 
and also in csometics and animal feeds. Several different types of material are 
commercially available the best known being the Cremophors (BASF Corporation). 
Amongst of these, Cremophor RH40 and Cremophor EL were mainly used in this 







Chemical structure of Cremophors, in the case of hydrogentaded products the double 
bond is saturated by hydrogenation, resulting in a more chemically stable structure 
with superior color and odour. The number of moles of ethylene oxide reacted per 
mole of caster oil is the sum of x, y and z which is expressed as the ethoxylation 
number.
Cremophor RH 40
Cremophor RH 40 (polyoxyethylene-(40)-hydrogenated caster oil) is a hydrophilic 
non-ionic solubilizer and emulsifying agent obtained by reacting 45 moles of ethylene 
oxide with 1 mole of hydrogenated caster oil. The main constituent of Cremphore 
RH40 is glycerol polyethylene glycol oxystearate, which, together with fatty acid 
glycerol polyglycol esters, forms the hydrophobic part of the product. The hydrophilic 
part consists of polyethylene glycols and glycerol ethoxylate. Cremophor RH 40 is a 
white to yellowish thin paste with a melting point of ~ 40°C and an HLB value 
between 14 and 16. Cremophor RH 40 forms clear solutions in water, ethanol, 2- 
propanol and other solvents. In contrast to the anionic emulsifying agents, the 
solubility of Cremophors in water decreases with rising temperature. Thus, aqueous 
solutions become turbid at certain temperature.
In aqueous alcoholic or completely aqueous solutions, Cremophor RH 40 can be used 
to solubilise vitamins (A, D, E and K) essential oils and certain drugs for oral and 
topical administration. The fact that Cremophor RH 40 has a very little taste or odor,
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is an asset for such applications. Cremophor RH 40 is also suitable as an emulsifying 
agent. It can emulsify a wide range of hydrophobic substances such as, fatty acids, 
fatty alcohols and drugs.
Cremophor EL
Cremophor EL (polyoxyeihylene-(35)-caster oil) is a non-ionic solubilizer and 
emulsifier obtained by reacting ethylene oxide with caster oil in a molar ratio of 35 
moles to 1 mole. The main component of Cremophor EL is glycerol-polyethylene 
glycol ricinoleate, which, together with fatty acid esters of polyethyleneglycol, 
represents the hydrophobic part of the product. The smaller hydrophilic part consists 
of polyethylene glycols and ethoxylated glycerol. Cremophor EL is a pale yellow, oily 
liquid that is clear at temperatures above 26°C. It has a slight but characteristic odor 
and hence, Cremophor RH 40 may be used in preference to Cremophor EL in oral 
formulations since it is almost tasteless. Nonetheless, the inherent odor of Cremophor 
EL can best be masked in many cases with banana aroma. Cremophor EL forms clear 
solutions in water ethyl alcohol, n-propyl alcohol and other solvents. The hydrophilic- 
lipophilic balance (HLB) lies between 12 and 14.
Cremophor EL is mainly used as an emulsifying and solubilizing agent, and is 
particularly suitable for the production of aqueous liquid preparations (alcoholic and 
non-alcoholic aqueous solutions) containing volatile oils, fat-soluble vitamins and 
other hydrophobic substances. Cremophor EL is also used in cosmetics industry 
preferentially for solubilizing perfume oils and for emulsifying fatty substances, 
organic solvents, and additives. A special application of Cremophor EL is the 
production of cod-liver oil emulsions in veterinary medicine.
2.1.2. Oils
2.1.2.1. Medium Chain Triglycerides (Miglyol®)
Miglyol natural oils (produced by Condea Chemie GmbH, Hiils) are clear, slightly 
yellowish esters of the saturated coconut and palmkemel fatty acids caprylic and 
capric acid with glycerol or propylene glycol as in Miglyol 840. There are different
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types of Miglyol® products according to the composition of the fatty acid fraction (see 
table 2 .2 ).
Table 2.2: Carboxylic acids composition of Miglyol® products
Amount of carboxylic acids 
in %
Miglyol
810 812 818 829 840
Caproic acid (C6 :o) Max. 2 Max. 2 Max. 2 Max.2 Max. 2
Caprylic acid (Cs:o) 65-80 50-65 45-65 45-55 65-80
Capric acid (Cio:o) 20-35 30-45 30-45 30-40 20-35
Laurie acid (Ci2 :o) Max. 2 Max. 2 Max. 3 Max. 3 Max.2
Myristic acid (Ci4 ;o) Max. 1 Max. 1 Max. 1 Max. 1 Max. 1
Linoleic acid (Ciss) — — 2-5 — —
Succinic acid — — — 15-20 —
Miglyol 812, a saturated medium chain triglyceride, was used in the majority of the 
formulations. It is produced by the hydrolysis of coconut oil followed by fractionation 
to yield the required fatty acids which are then re-esterfied with glycerol. The general 
structure of Miglyol 812 is shown in figure 2.4. The composition of the fatty acid 
fraction is given in table 2 .2 .
CH2 O O C  (CH2)6-8 CH3 
CH2 O O C (CH2)6-8 CH3 
CH2 O O C  (CH2)6-8 CH3
Figure 2.4
Chemical structure of Miglyol 812
Medium chain triglycerides (MCTs) have been used in a variety of pharmaceutical 
formulations including oral, parentral and topical preparations. In oral formulations, 
MCTs are used as the base for the preparation of oral emulsions, solutions or 
suspensions of drugs unstable or insoluble in aqueous media. They have also been
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investigated as intestinal absorption enhancers and have additionally been used as 
filler in capsules and sugar-coated tablets, and as a lubricant or anti-adhesion agent in 
tablets. In parenteral formulations, MCTs have similarly been used in the production 
of emulsions, solutions or suspensions intended for intravenous administration. 
Medium chain triglycerides have been particularly investigated for their use in total 
parenteral nutrition (TPN) regiments in combination with long chain triglycerides. In 
cosmetics and topical pharmaceutical preparations, MCTs are used as a component of 
ointments creams and liquid emulsions.
2.I.2.2. Partial Glycerides (Imwitor®)
Partial glycerides are usually mixtures of monoesters, diesters and triesters containing 
small proportions of unesterified glycerol. Some types have very high monoester 
content such as Imwitor 308, 312 and 191. The fatty acids used are derived 
exclusively from natural fats and oils, and have a chain length of 8-18 carbon atoms. 
The partial glycerides are produced either by transesterification of fats with an excess 
of glycerol or by controlled esterification of fatty acid fractions, followed by refining 
processes. Both methods yield products containing approximately 40-60% 
monoglycerides. Monoglyceride contents of over 90% can be obtained by subsequent 
molecular distillation.
The degree of surface activity (hydrophilic or lipophilic nature) is determined by the 
number of free unesterified hydroxyl groups and the length of the fatty acids. Partial 
glycerides with high monoglyceride content have high HLB values (i.e. more polar) 
and may form liquid crystalline states, micelles and vesicles in the presence of water. 
HULS partial glycerides are widely used in the pharmaceutical, cosmetic and 
nutritional fields. They function as emulsifiers, co-emulsifiers for o/w creams and 
lotions, solubilisers, dispersants, plasticizers in tablet coating, lubricants, skin and 
mucous membrane protecting agents and absorption promoters for active ingredients 
which are not soluble on their own in oral drug forms. Monoglycerides of the C8-C14 




Imwitor 988 and 308 were mainly used in the majority of formulations investigated in 
this study, see table 2.3 for fatty acid composition and figure 2.5 for chemical 
structure.












Water content Max. 1 Max. 2
Properties
Appeamace White Crystalline Colorless Semisolid
Melting point (°C) 30-34 Liq. at 25
HLB value 6  4-6
CH2— OOC8H i6









CH2— OOC8H i6 
Tricaprylate
Figure 2.5
Chemical structure of Imwitor 988 and 308.
2.1.3. Co-Solvents Used in Lipid Formulations
Propylene Glycol:







Chemical structure of Propylene glycol 
Polyethylene Glycol 400:
Poly(oxy-l,2-ethandiyl), molecular weight = 400, obtained from Sigma, UK.
HO—  [CH2—CH2—O—]„—H 
Figure 2.7
Chemical structure of Polyethylene glycol, n = No of oxyethylene units 
Transcutol P® fEthoxvdiglvcerol):
Transcutol P® (diethylene glycol monoethyl ether or Ethoxydiglycerol) is 
manufactured by Gattefosse Corporation from raw materials of petrochemical origin; 
it has a molecular weight of 134.7. Transcutol offers superior cutaneous tolerance and 
excellent solubilization of many drugs. It is soluble in both oil and water, therefore, it 
represents the perfect bridge between the oil and water phase. It has several areas of 
applications: vaginal douches, oral, topical and injection formulations.
C2H5-O -C H 2-C H 2-O -C H 2-C H 2-O H  
Figure 2.8
Chemical structure of Transcutol 
Glvcofurol®
Glycofurol (a-Tetarahydro furanyl -w-hydroxy-poly (oxyethylene) is used as a 
solvent mainly in parenteral products for intravenous or intramuscular injection in 






Chemical structure of Glycofurol, n = 1-2.
2.1.4. Emulsification Solutions
MiliO water
Simulated Gastric Fluid fSGFf
This is a media used to simulate the composition of stomach at fasted state, see table 
2.3 for composition.
Table 2.4: Composition of the physiological media used to simulate the stomach 
at fasted state
Simulated Gastric Fluid (SGF)
NaCl Pepsin (800-2500 u/mg) HC1 Water (qs) pH
2 gm 3.2 gm 7 ml 1000 ml 1.2
Pepsin is insoluble in this media and thus forms a turbid solution which will make 
particle sizing rather difficult. Consequently, SGF was freshly prepared or obtained 
from Sigma without Pepsin.
FaSSIF and FeSSIF
Fasted state simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid 
(FeSSIF) are suitable media for simulating the composition of the proximal small 
intestine at fasting and fed states, respectively. See table 2.4 for composition.
80
Materials & Methods
FaSSIF and FeSSIF were prepared by first making the micellar solution which 
consists of bile salt (Na Taurcholate) and Lecithin (L-a phosphatidylcholin) at a ratio 
of 3:1. To prepare the mixed micellar solution appropriate quantities of bile salt and 
lecithin (see table 2.4) were dissolved in 20 ml of solvent consisted of methanol and 
chloroform at a ratio of 2:3. The resultant clear solution was placed in a 500 ml Buchi 
flask and the solvent drawn off using rotary evaporator (Buchi Rotavapor R110). The 
flask was then attached to a vacuum line overnight to ensure removal of any 
remaining chloroform. The clear film of bile salt and lecithin formed on the flask 
surface was subsequently dissolved in the appropriate buffer (see table below) to 
prepare either FaSSIF or FeSSIF at the required concentration of bile salt / lecithin.
Table 2.5: Composition of two physiological media used to simulate fasted state 
and fed state intestinal conditions.
Fasted State Simulated Intestinal Fed State Simulated Intestinal
Fluid (FaSSIF) Fluid (FeSSIF)
PH 6.5 pH 5
Osmolarity 270 ± 10 m Osmol Osmolarity 635 ± 10 m Osmol
Na Taurcholate 3m M Na Taurcholate 15 mM
Lecithin 0.75 mM Lecithin 3.75 mM
KH2 PO4 3.9g Acetic Acid 8.65g
KCL 7.7g KCL 15.2g
NaOH qs pH 6.5 NaOH qs pH 5
Milil Q water qs 1 liter Mili Q water qs 1 liter
Na Taurcholate, Lecithin and KCL were obtained from Sigma, and KH2PO4 from 
BDH Chemicals.
2.1.5. Solvents Used for Assays
Ethanol 96% w/w GPR, BDH Chemicals 




Dimethyl aminoazobenzene was used in this study as,a model drug of ‘poorly soluble’ 
weak base (log P of 4.52, pKa of 3.226 and So= 1.33pg/ml), see figure 2.10 for 
chemical structure. It occurs as yellow crystalline leaflets. It is insoluble in water and 
soluble in alcohol, benzene, chloroform, ether, petroleum ether, strong minerals acids, 
oils and very soluble in pyridine.
Dimethyl aminoazobenzene was previously used to color polishes, polystyrene and 
soap. It was also used as chemical indictor for free hydrogen chloride in gastric juice 
and as pH indicator. Dimethyl aminoazobenzene is not currently produced or used 
commercially in the United States due its environmental and health hazardous effects. 
Therefore, strict procedures were followed in accordance with the chemical safety 





Chemical structure of p-Dimethyl Aminoazobenzene also known as Dimethyl Yellow 
(DMY) which was used as a model drug for poorly water-soluble weak electrolyte 
compounds
2.2. Methods
2.2.1. Ternary Phase Diagrams
Regions of mutual solubility of various lipid formulations with wide range of 
surfactants that represent different HLB values were determined using ternary phase 
diagrams. Miscibility diagrams of Miglyol 812, Imwitor 988 and various surfactants 
(Tagat TO, Tagat 02, Crillet 4, Crillet 1, Cremophor RH 40 and Cremophor EL) were 
constructed. Each of the axes on the diagram represents the percentage contributes to 
the formulation by each of the three components (Miglyol 812, Imwitor 988 and a 
surfactant). Formulations of five grams which represent various percentages of 
Miglyol 812, Imwitor 988 and a surfactant on the ternary phase, diagrams, were
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weighed in 20 g screw-capped vials (tops were rapped with cling film before caps 
were screwed on). Mixtures were placed in a water bath at 50 °C for 2 minutes before 
the three components were thoroughly vortexed. Mixtures were then kept for 24-48 
hours in an oven set up at 25°C before visual assessment. Mixtures which formed a 
continuous single phase were classified as miscible formulations. Samples that 
displayed two or more phases were described as immiscible systems.
2.2.2. Self-Emulsification
Mixtures of oil and surfactant were produced by accurately weighing ingredients into 
screw-capped glass vials with tight closures followed by votrexing. Different 
proportions (w/w) of Miglyol 812/Imwitor 988 (10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 3:7, 1:9 
and 0:10) containing between 5 and 60% w/w surfactant were weighed first in the 
glass vials, tops were then rapped with cling film before caps were screwed on. The 
glass vials were held at 50 °C in a thermostated water bath held for 2 minute before 
lipid mixtures were thoroughly vortexed. Lipid formulations were then left to 
equilibrate over night in an oven set up at 25°C. Emulsions were prepared under 
conditions of gentle agitation at a controlled temperature of 37°C. Self-emulsifiable 
mixtures (lgm) were introduced into 100ml of Mili Q water in a 500-ml glass beaker 
held at 37°C in a thermostated water bath. All materials were pre-equilibrated to the 
appropriate temperature. Emulsification under agitation conditions considered to be a 
reasonable simulation of the in vivo situation was carried out. Agitation was provided 
by gentle shaking on a mechanical shaker at 100 oscillations per min for 15 minutes. 
Systems which appeared to emulsify efficiently were studied further by particle size 
analysis.
2.2.2.I. Effect of Emulsification Temperature
Emulsions formed by mixtures of Miglyol 812/Imwitor 988 (10:0, 7:3, 6:4 and 5:5) 
containing 15% or 30% w/w Tagat TO were investigated over temperature range 
between 5 and 60°C. Emulsions were prepared under conditions of gentle agitation at 
the required temperature as described earlier. Samples were then removed after 15
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minutes and left to equilibrate at 25°C in thermostatted water bath before particle 
sizing.
2.2.2.2. Effect of Emulsification Media
Self-emulsifiable mixtures (lgm) of different oil systems without the model drug 
were introduced into 100ml of SGF in a 500-ml glass beaker held at 37°C in a 
thermostated water bath and emulsified for 15 min as described earlier before particle 
sizing. Selected oil systems in the presence of DMY were also emulsified as described 
above in 100m of either FaSSIF or FeSSIF.
2.2.3. Analysis of Mean Emulsion Droplet Diameter (MEDD)
A wide range of techniques are available to measure the particle size of two-phase 
disperse systems. However, when considering the measurement of droplets of 
emulsions, the number of methods which can be applied is limited. The main 
techniques which can be used are; image formation, scattering or diffraction of 
radiation, and relative motion between particles and fluids.
Electron microscopy can be used to measure the submicron particle size range yet 
sample preparation can result in changes in the suspended droplets. Nonetheless, 
particle size data can be obtained however, the cost and time involved makes this 
method inappropriate for processing large numbers of samples. There are a number of 
light scattering methods available for particle size analysis in the submicron range. 
Photon correlation spectroscopy (PCS) which is based on dynamic light scattering 
theory was used in this study. PCS is used to determine the size of emulsions droplets, 
particles in suspension and molecules in solution with diameters in the range 3nm to 
3 pm. The theoretical consideration of particle size measurement by PCS is based on 
the behavior of submicron particles to forces of Brownian motion. The random 
Brownian movement of spherical particles in a dispersion medium at a constant 
temperature and viscosity is a function of particle size. For this study Malvern model 
Lo-C photon correlation spectrometer was used, the components of the instrument are 
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The system components of the Autosizer Lo-C Photon Correlation Spectrometer (PCS); the apparatus is set up at a fixed angle of 90°.
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Laser diffraction spectrometer (Malvern Masersizer X) was used also used to analyze 
self-emulsified systems containing emulsion droplets larger than ljim. The 
Fraunhofer diffraction theory which governs this technique points out that the 
intensity of the light scattered in a forward direction is proportional to the particle size 
and that the size of the diffraction pattern (scattering angle) is inversely proportional 
to the particle size. The Malvern equipment monitors the dynamic diffraction pattern 
using a 50 element concentric ring detector. The equipment was used with small 
volume cell and with a 45mm lens before the photodetector, allowing measurement of 
emulsion droplets in the 0.5pm to 80pm.The basic components of the machine are 
shown in Figure 2.12.
The two techniques mentioned above were used to measure the MEDD of the self­
emulsified systems (with appropriate dilution). Low angle laser light diffraction was 
used for emulsions with droplet distributions above 1pm. Samples were analyzed 
immediately after preparation. Samples of submicron dispersions were analyzed 
immediately using PCS. For both techniques experiments were performed in triplicate 
and the size distributions of the resultant emulsions were obtained using the volume- 
average diameters D (v, 0.5). MEDD values are expressed as mean values of all data ± 
standard error.
2.2.4. Equilibrium Phase Studies
The equilibrium phase behavior of both ternary oil-nonionic surfactant-water mixtures 
and binary nonionic surfactant-water mixtures were studied in two ways.
2.2.4.I. Static Compositions
A series of ternary phase compositions were made up by weight in screw-capped glass 
vials. For construction of the whole ternary phase diagram, for example the Miglyol- 
Tagat TO-water system, phase composition changes were made at 5%w/w intervals. 
Additional compositions were made at 2.5%w/w intervals where phase boundaries 
were observed. The various ternary and binary compositions were heated to 70°C in a 



















mixing using a Fisons orbital vortex mixer until homogeneity was achieved. The 
mixtures were then allowed to cool to 25°C and left undisturbed for 24 hours for 
phase identification by visual observation using a crossed polarised viewer.
2.2.4.2. Dynamic Compositions
For this method the weighed amounts and therefore the ratios of oil and nonionic 
surfactant in each mixture were constant, the only difference is the water content. 
Phase studies were performed using approximately 2 g samples of oil-surfactant 
mixtures diluted by sequential increasing of water content. Formulations of interest, 
Miglyol 812/Imwitor 988 at ratios 10:0, 9:1, 8:2, 7:3 and 0:10 containing 15% or 30% 
w/w Tagat TO were weighed into narrow bore glass ampoules. MiliQ water was then 
sequentially added to the oil mixtures at 0.5 % w/w intervals, ampoules were then 
sealed using an Adelphi ampoule sealer. The ampoules were then heated to 70°C for 
15 min to facilitate mixing using a votrexer. Phase boundaries were determined to ±
0.5% water. The ternary mixtures were equilibrated to the temperature of interest (4- 
65 ± 0.1 °C) for two hours and then thoroughly mixed for 5 min using a Fisons orbital 
whirlmixer. The ampoules were then returned to the thermostatically controlled water 
bath and left undisturbed for 24 hours before identification of the phase type using a 
crossed polarised viewer. In this study emphasis was placed on approximate 
identification of the phase boundary for solubilization of water in the oil-surfactant 
mixtures and the presence of liquid crystalline phases within the mixtures.
2.2.5. Solubility of the Model Drug in Lipid Excipients and Selected Lipid 
Formulations
The model drug (Dimethyl Yellow) was added in excess (~lg) to either lipid 
excipients or to lipid formulations that represent Type I, II, mA and IIIB (see table 
2.5). Lipid suspensions were then vortexed for 3 minutes and then stored for 24 hours 
in a controlled temperature oven at 25°C to reach equilibrium (samples were vortexed 
in between). One of the formulas (Miglyol 812 in excess of DMY) was kept for 1, 2, 
and 3 days to investigate the time needed to achieve equilibrium state (saturated 
solution). Oil suspensions were then transferred into 2ml eppendorphs and centrifuged
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at maximum speed (13000g) for 10 minutes. The clear saturated oil solution was then 
removed and assayed analytically by UV spectrophotometry.
Table 2.6: Selected lipid formulations used to dissolve the model drug to 











RH40, EL, or 
Crillet 4
PEG 400
Type I 70 0 30 0
Type II 49 21 30 0 0
Type IIIA 42, 49, or 49 28, 21, or 21 0 30 0
Type DIB 0 30 0 30 40
2.2.5.I. UV Assay
An ultraviolet spectroscopic method was developed to determine the concentration of 
the model drug (DMY) dissolved in the lipid solution. DMY was dissolved in 
Methanol and analyzed by scanning over a range of wavelengths using a double beam 
instrument (Perkin-Elmer Lamboda 7, UV / VIS Spectrophotometer). Peak 
wavelength (A, max) was determined (A= 407nm) and standard concentration
19//absorbance curve for DMY was then constructed. The average E 0 for DMY was 
calculated from Beer's law by measuring the absorbance of five DMY solutions. Five 
stocke solutions of DMY in Methanol were prepared by dissolving five separate 
weights (approximately O.lg) from DMY in 100 ml Methanol for each stocke 
solution. Series of dilutions were carried out for the five stocke solutions to enable 
measuring the absorbance; values between 0.1 and 0.9 were achieved and considered 
to be acceptable. According to Beer's law which is modified and presented below, the
measured absorbance for each solution was divided by its corresponding
• 10/  concentration to determine E 0 for DMY.
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Where E is the absorptivity for a particular absorbing species (in units of 100ml g '1 
cm'1), A is the absorption, L is the length of the path of radiation passing through the 
sample (1 cm) and C is the concentration of the absorbing substance in g/lOOml.
The calculated E1% was the basis to determine the concentration of DMY dissolved in 
the oil solution. Representative samples ’(in triplicate) of the oil solutions in the 
presence of the model drug (DMY) were dissolved in methanol and assayed according 
to the procedure described above. The measured absorbance which represents each 
sample was divided by the E1% of DMY to determine the concentration of DMY 
(%w/w) in that sample. Blank solutions were made by dissolving representative 
samples oil formulations without DMY in methanol.
1 ®/In the case of determining the solubility of DMY in cosolvent-water systems, E 0 for 
DMY was obtained by dissolving particular amounts of DMY in a solvent composed 
of Methanol/water at a ratio of (50/50). Peak wavelength (k  max) was determined and 
the measured absorbance for each solution was divided by its corresponding 
concentration.
2.2.5.2. Self-emulsification of Oil Systems Containing Dissolved DMY
A range of SEDDS representing Type I, II and HI were prepared to probe the effect of 
the inclusion of water-soluble surfactants and cosolvents in the pre-concentrate 
mixture on precipitation of the drug after dispersion, lg of each formulation 
containing approximately 40mg DMY was allowed to emulsify, as explained in 2.3, 
in either 100 ml of water or simulated intestinal fluid fasted and fed states (FaSSIF 
and FeSSIF, respectively). Dispersions were then transferred into 150ml bottles and 
placed on a mechanical shaker set up at 50 oscilations per min to simulate intestinal 
motility. The solubility of DMY was determined as a function of time using 




Self-emulsifying and Micro-emulsifying Formulations for 
Oral Drug Delivery
Introduction
One of the most persistent challenges faced by the formulation scientists has been to 
find methods of improving the bioavailability of poorly water-soluble drugs. A drug 
must almost invariably be in solution within the gastrointestinal (GI) tract before it 
can cross the GI mucosa thus poor water solubility may lead to incomplete and erratic 
absorption. Several approaches are being used to overcome these challenges, such as 
incorporation of the poorly-water soluble active component into inert lipid vehicles 
such as oils, surfactant dispersions, self-emulsifying formulations and liposomes.
Self-emulsifying drug delivery systems (SEDDS) which are isotropic mixtures of oils 
and non-ionic surfactants are recently being used for improving lipophilic drug 
dissolution and absorption [1‘3]. One characteristic of these systems is their ability to 
form fine oil-in-water emulsions upon mild agitation when exposed to aqueous media. 
It is proposed that enhancement in the water solubilisation region (L2 ) and the 
formation of interfacial liquid crystal on dilution with water are important to the 
mechanistic processes. Thus, SEDDS represent an efficient vehicle for the in vivo 
administration of oral delivery of lipophilic drugs with a possible alternative to tablets 
and capsules, provided however, that the drug has adequate solubility in the oil 
system. It is also important in order to maximize the rate of absorption and thus 
bioavailability of oily formulations; one must maintain the drug in solution and avoid 
crystallization of the drug on dilution in the lumen of the gut.
Self-emulsifying technology for oral delivery use has recently witnessed the 
introduction of self-emulsifying microemulsion formulations; Neoral (originally 
marketed as ‘Sandimmune™’) is one good example of the advances in this 
technology. However, the design for effective self-micro-emulsifying drug delivery
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systems (SMEDDS), using well-defined and pharmaceutically acceptable excipients is 
still in its early stages Pouton has recently suggested a classification system for 
lipidic formulations based on their dispersions characteristics and the physicochemical 
characteristics of the formulation components (principally the HLB of the surfactants 
and % glycerides content (Table 1.5)). Under this system, simple surfactant-free lipid 
solution formulations are classified as type I. Type II formulations are often referred 
to as SEDDS which comprise water insoluble components; blends of glycerides and 
non-ionic surfactants with HLBs less than 12. Type IE systems which contain 
hydrophilic surfactants with HLB >12 and/or water-soluble cosolvents blended with 
oils. Type IE formulations which include water-soluble components are referred to as 
self-micro-emulsifying systems (SMEDDS) as they can lead to the production of a 
microemulsion on dispersion in GI tract (particle size ~ 50nm). Type IE formulations 
can be subdivided into type EIA and type IEB according to the degree of 
hydrophilicity of these formulations. Type ETB systems are more hydrophilic and 
contain relatively little simple glycerides (<20%).
This chapter is divided into 3 parts:
Section 3.1
Evaluation of potential self-emulsifying type E vehicles based on comparison of their 
self-emulsification profiles with the system which was thoroughly investigated by 
Wakerly i.e. Tagat TO-Miglyol 812 system in an attempt to improve the in vitro 
and consequently the in vivo performance. It investigates the use of Cg/Cio 
mono/diglycerides (Imwitor 988) as a cosurfactant to enhance the emulsification of 
Miglyol 812-Tagat TO system. It also elucidates the effects of main factors, namely 
mixture composition, temperature and media, on controlling the emulsion droplet size 
distribution of Miglyol 812/Imwitor 988-Tagt TO system. This has been correlated 
with the equilibrium phase behaviour of these systems on dilution with water in order 
to provide an insight into the mechanistics of self-emulsification.
Section 3.2
This part evaluates the self-emulsifying behaviour of type III systems comprising 
mixed medium chain glycerides (Miglyol 812-Imwitor 988) and wide range of 
hydrophilic surfactants in an attempt to identify self-emulsifying microemulsion 
formulations. Non-ionic surfactants with HLB in the range 14 to 16.5 are investigated
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amongst these are; Cremophor RH40, Cremophor EL, Polysorbate 80 (Crillet 4), 
Polysorbate 20 (Crillet 1) and Tagat 02. It verifies the effect of oil component blends 
on the performance of these systems in order to find an optimum blend of Miglyol 
812-Imwitor 988 which produces the finest dispersions. It also correlates the mean 
emulsion droplet diameter profiles obtained by photon correlation spectrometer (PCS) 
for systems which have produced microemulsions with their equilibrium phase 
behaviour on dilution with water.
Section 3.3
This section investigates how different types of self-emulsifying systems (type II, IDA 
and IIIB) influence the fate of dissolved drug after dispersion of the formulation. 
Dimethyl Yellow (DY) was used as a lipophilic weak base model drug (log P of 4.52 
and pKa of 3.226). A range of self-emulsifying systems are investigated to probe the 
influence of the inclusion of water-soluble surfactants and cosolvents on precipitation 
of the drug after dispersion.
3.1. Emulsification Improvement of Class II SEDDS: Formulation 
and Mechanistic Perspectives
3.1.1. Results and Discussion
3.1.1.1. Size Analysis
Previous studies using binary systems containing medium-chain triglyceride oil and 
Tagat TO have produced system that exhibits optimum self-emulsifying behaviour at 
30°C [7,8]. In contrast to the Tween 85-Miglyol 812 investigated by Pouton the 
Tagat TO-Miglyol 812 system produced by Wakerly was shown to be capable of 
forming submicron emulsions by self-emulsification. These studies have indicated 
that emulsification of Miglyol 812-Tagat TO in water using 30% (w/w) surfactant 




The effect of incorporating, Cg/Cio mono/diglycerides (Imwitor 988) in the binary 
mixtures of Miglyol 812/Tagat TO on emulsification behaviour has been investigated 
in this study to establish the optimum requirements for good self-emulsifying systems.
Knowledge of the behaviour of triglyceride, mixed mono/di-glycerides and either 
hydrophilic or lipophilic surfactant when mixed together is considered to be a 
preliminary step in selecting a formulation which remains miscible after encapsulation 
in a soft gelatine capsule. Any phase separation of constituents after the encapsulation 
stage could result in drug crystallization and hence the addition of drug dissolution 
stage upon release of the formulation from the capsule. Therefore, a three-component 
phase diagram was constructed to examine the miscibility of Miglyol 812, Imwitor 
988 and Tagat TO, see figure 3.1.1. Each of the axes on the diagram represents the 
percentage that has contributed to the formulation by each of the three constituents. 
Therefore, the effect of varying the proportions of constituents on the formulation 
miscibility can be examined. As illustrated in Figure 3.1.1, Miglyol 812/Imwitor 988- 
Tagat TO system has produced a whole area of miscibility. This suggests the ability 
of this system of forming homogenous mixtures at all proportions of its constituents.
In order to investigate the effect of Imwitor 988 on the emulsification behaviour of the 
binary system (Miglyol 812/Tagat TO), Imwitor 988 was included by varying the 
ratio fraction of Miglyol 812/Imwitor 988 while gradually increasing the 
concentration of Tagat TO in each ratio. This inclusion in the binary system is 
depicted in the drawn lines (A-I) in figure 3.1.1. Lines (A to I) represent increasing 
ratio fraction of Miglyol 812/Imwitor 988 from 1:9 to 9:1, respectively. All points on 
each line have constant ratio of Miglyol 812/Imwitor 988 which represents that line 
diluted with increasing concentration of Tagat TO.
The emulsification profile of Miglyol 812/Tagat TO system was chosen as the starting 
point to compare the emulsification behaviour that results from the inclusion of 
Imwitor 988 in the binary mixtures. The particle size-surfactant concentration profiles 
obtained by laser diffraction analysis for the self-emulsified Miglyol 812/Imwitor 
988-Tagat TO mixtures is shown in figure 3.1.2. The self-emulsification profile of 
Miglyol 812/Tagat TO presents three regions: (1) Surfactant concentration <15% 
(w/w), region of gross instability with high creaming rate of these lower surfactant
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Percentage of Miglyol 812 (Triglyceride Source)
Figure 3.1.1
Ternary phase diagram for Miglyol 812/Imwitor 988-Tagat TO system displaying 
miscibility for formulations of various compositions. Dotted lines (A to I) represent 
increasing ratio fraction of Miglyol 812:Imwitor 988; 1:9, 2:8, 3:7 to 9:1, respectively. 
All points on each line have constant ratio of Miglyol 812:Imwitor 988 which 
represents that line diluted with increasing concentration of Tagat TO. The mean 
emulsion droplet diameter profiles for different Miglyol 812/Imwitor 988 ratios 
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Figure 3.1.2
Mean emulsion droplet diameter (MEDD) profiles for self-emulsified systems 
containing different ratios of Miglyol 812/Imwitor 988 and increasing concentration 
of Tagat TO. Lipid formulations were emulsified in water at 37°C for 15 minutes. 
MEDD values were determined by laser diffraction method using the Mastersizer. 
Bars Represent Standard Errors (n = 3). **Size droplets of dispersions of oil systems 
containing Miglyol/lmwitor ratios of 7:3 or 6:4 at Tagat TO concentrations >20% 
could not analyzed using the Mastersizer due to the size range cut off of the apparatus.
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concentration emulsions. Microscopical examination of these crude emulsions 
showed that oil droplets in excess of 500 pm were present [8]. (2) Between 20 and 
45% surfactant resulted in sub-micron emulsions of improved stability. The MEDD 
apparently reached a minimum value at surfactant concentration of 40-45%. The 
reduction in the MEDD in this second region probably resulted from increased 
interfacial stabilisation by water soluble surface active components as the surfactant 
concentration was increased. (3) At higher surfactant concentrations (> 50%) the 
MEDD increased with a doubling of the polydispersity. The turbidity of self­
emulsified systems decreased as the surfactant concentration was increased from 45- 
60%. The increase in the MEDD values for optically clear systems containing more 
than 45% surfactant may be explained by the large swollen microemulsion systems 
described by Gerbacia and Rossano [10], where the refractive indices of dispersed and 
continuous phases are very similar.
In comparison with the Miglyol 812-Tagat TO emulsification profile, the 
incorporation of Imwitor 988 at different ratios in the binary mixtures has produced 
three sets of self-emulsified systems (see figure 3.1.2). This dramatic effect on the 
emulsification behaviour has been dependent on the surfactant concentration and the 
Miglyol 812/Imwitor 988 ratio in the self-emulsifiable mixtures. (A) Less self- 
emulsifiable systems presented by an increase in the MEDD with reference to Miglyol 
812/Tagat TO emulsification profile. This comprises the emulsification of Miglyol 
812/Imwitor 1:9 and 3:7 ratios, and Imwitor 988/Tagat TO mixtures at surfactant 
concentrations above 15% w/w. The particle size-surfactant concentration profiles 
obtained for these formulations have shown two regions; at surfactant concentration 
between 5 and 25%, the increase in surfactant concentration accompanied by a 
corresponding decrease in the MEDD. Above 25% surfactant the MEDD stayed 
approximately unchanged regardless the increase in the surfactant, except for the ratio 
3:7 where the optimum value occurred at 40% surfactant. (B) Improved self- 
emulsifiable formulations which include Miglyol 812/Imwitor 988 9:1 8:2 and 5:5 
proportions. These formulations have produced particle size-surfactant concentration 
profiles comparable to the reference point (Miglyol 812/Tagat TO). However, MEDD 
values were relatively lower at all surfactant concentrations except for formulation 5:5 
at Tagat TO concentration above 35% w/w, see table 3.1.1. Formulation 5:5 has
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substantially reduced the MEDD at Tagat concentration as low as 5-15% in 
comparison to the crude or coarse dispersion produced by Miglyol 812-Tagat TO, 1:9 
or 8:2 formulations. The MEDD apparently reached a minimum value at 30% 
surfactant concentration for 9:1 and 8:2 and at 25% for 5:5 formulations. This is far 
less than the optimum Tagat TO concentration required to obtain comparable 
minimum MEDD values in the case of Miglyol 812-Tagat TO system. (C) 
Microemulsion systems which include blends of Miglyol 812/Imwitor at 7:3 or 6:4 
proportions. These systems have produced sub-micron emulsions at veiy low Tagat 
To concentrations (>10%) compared to the crude dispersion of Miglyol 812/Tagat TO 
at same concentrations. These formulations were at the lower detection limit of the 
Mastersizer at surfactant concentration above 20% as they formed typical bluish clear 
microemulsions. Therefore, these systems were further characterized using PCS 
technique.
Table 3.1.1: Effect of Miglyol/lmwitor ratio on the self-emulsifying behaviour of 
Tagat TO-Miglyol 812 system as measured by mean emulsion droplet diameter 
using the Mastersizer.
% Tagat TO Miglyol:Imwitor Ratio Statistical
(w/w) 10:0 9:1 5:5 Difference p<0.05
MEDD (pm) 10:0/9:1 10:0/5i5
20 1.42±0.06 1.07±0.01 1.01±0.02 V ✓
25 1.14±0.01 0.73±0.01 0.59±0.00 V S
30 1.02±0.01 0.41±0.01 0.67±0.01 S S
35 0.73±0.02 0.34±0.00 0.81±0.03 S No
40 0.51±0.01 0.31±0.00 0.91±0.01
Results obtained from PCS for emulsions formed from Miglyol 812/Tagat TO and 
{Miglyol 812/Imwitor} (6:4, 7:3)-Tagat TO are shown in figure 3.1.3. Self- 
emulsifying mixtures of Miglyol 812/Tagat TO, produced a minimum MEDD at 
surfactant concentration between 25 and 30%. At surfactant concentrations between 
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Figure 3.1.3
Mean emulsion droplet diameter profiles for Miglyol 812/Tagat TO and {Miglyol 
812/Imwitor 988} (6:4, 7:3)-Tagat TO systems at increasing surfactant concentration. 
Oil formulations were emulsified in water at 37°C for 15 minutes. MEDD values were 




method were lower than expected from the laser diffraction analysis using the 
Mastersizer, as depicted in figures 3.1.3 versus 3.1.2 respectively. This may have been 
due to underestimation by PCS of the MEDD of this system which probably 
contained droplets >3pm, which would have been excluded from any PCS analysis. 
Emulsions formed by mixtures containing less than 20% were poor and therefore, was 
not possible to detect any scattered light using the PCS at the normal sensitivity level
i.e. the MEDD of such emulsions were always out of the range covered by the 
apparatus.
The particle size-surfactant concentration profiles as presented in figure 3.1.3 for 
{Miglyol 812/Imwitor} (7:3, 6:4), are of similar character exhibiting a minimum 
MEDD at about 30-40% Tagat TO. At Tagat TO concentration between 10 and 20% 
w/w, MEDD values for 6:4 system were relatively lower comparable to the 7:3 
formulation at same surfactant concentrations, see table 3.1.2. However, at higher 
surfactant concentration (25-40%), 7:3 systems produced fine and almost clear 
dispersions at Tagat TO >30% with lower MEDD values comparable to 6:4. At 
surfactant concentrations > 45% both systems 7:3 and 6:4 have produced though clear 
dispersions, yet, MEDD values have sharply increased with a doubling of the 
polydispersity. This could be attributed to the formation of swollen microemulsion 
systems.
Table 3.1.2: Self-micro-emulsifying behaviour of 7:3 Formulations versus 6:4 
with reference to Miglyol 812-Tagat TO system as measured by MEDD using 
QELS.
% Tagat TO 
(w/w)





10 off range 260.80±2.90 223.10±5.30 ✓
15 off range 176.30±1.50 130.50tl.10 ✓
20 248.10±4.38 116.30±1.00 87.00tl.30 ✓
25 224.50±3.40 66.40fcl.90 67.70tl.75 No
30 221.8±2.83 49.50±1.48 64.40±2.10 ✓
35 256.15 2.05 38.60fcl.60 67.40±2.00
40 252.85 8.84 42.80±2.20 77.50tl.70 ✓
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In order to substantiate PCS sizing data for the microemulsion systems, turbidity was 
assessed by measuring the optical density of these emulsions with increasing 
surfactant concentration, see figure 3.1.4. A progressive drop in the UV absorbance 
corresponding to increases in the concentration of surfactant included in the oil 
formulation was observed as a result of particle size reduction. For Miglyol 812/ 
Imwitor 988 at ratio of 7:3, almost optically clear dispersions with an absorbance at 
A.600 nm of 0.084 were obtained at optimum concentration of Tagat TO of 30% w/w. 
This correlates well with the particle size data presented for this system in figure 3.1.3 
and table 3.1.2 whereby, optimum dispersions with MEDD values between 40 and 
50nm and with polydispersity index around 0.061 (values between 0.1-0.15 represent 
highly mono-disperse systems) were produced.
In contrast to the crude dispersion of Miglyol 812/Tagat TO at surfactant 
concentration w/w 15% (>5pm), emulsification of (Miglyol 812/Imwitor 988} 7:3 or 
6:4 produced fine dispersion of 130.5±1.1 nm and 176.3±1.5 nm with polydispersity 
of 0.065±0.008 and 0.052+0.023, respectively. Therefore, the inclusion of either three 
or four parts of Imwitor 988 in Miglyol 812/Tagat TO using only 15% w/w Tagat TO 
has produced a system which is comparing to Miglyol 812/Tagat TO (30%), has 
lower toxicity as less surfactant is used, and lower MEDD values with narrow size 
distribution. Moreover, it is expected to have better solubilizing capacity for poorly- 
water soluble drugs as Imwitor 988 is polar oil due to monoglyceride content.
Medium-chain (C6-C12) fatty acids, mono-, di, and tri-glycerides, particularly Cg/Cio 
mono/diglycerides, have been used in mixed micelle and emulsion formulations as 
absorption enhancers of a number of different drugs tll]. In this investigation Imwitor 
988 acts as a co-surfactant of similar effect of short chain alcohols in aiding the 
emulsification process of oil based formulations. The role of co-surfactant, such as a 
short chain alcohol, is to increase the interfacial fluidity by penetrating into the 
surfactant film and consequently creating a disordered film due to the void space 
among surfactant molecules [12^ .
A crucial factor in forming a self emulsified system with fine droplets is the polarity 
of the resulting oil droplets which also promotes the fast release of the active 
ingredients into the aqueous phase. The polarity of oil is dependent on HLB, chain 
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Figure 3.1.4
The effect of increasing Tagat TO concentration on the optical density for {Miglyol 
812/Imwitor 988} (7:3)-Tagat TO system after dispersion in water as measured 
spectrophotometery. Oil formulations were emulsified in water at 37°C for 15 
minutes. Absorbance at >.=600 nm using the UV was measured to evaluate the 
turbidity of the resultant emulsions.
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It is very well established amongst researchers the correlation between good 
emulsification and HLB of the oil mixture. However, this relation is highly affected 
by type and chemical structure of the surfactant; an issue which will be dealt with in 
forthcoming sections.
Theoretical HLB of the oil mixture can be calculated according the following 
equation:
HLB mixture =fA  x HLBa + JB x HLBb +JC x HLBc 
F  is the fraction of each excipient present in the formulation (A, B, or C).
Table 3.1.3: Effect of HLB oil mixture on emulsification of Miglyol 812-Tagat 









HLB mixture 4 4.84 5.12 5.40
Droplet size 221.80±2.83 49.5±1.48nm 64.4±2.1nm 215.60±3.90
As table 3.1.3 shows, the HLB margin for self-micro-emulsification in Miglyol 812 
/Imwitor 988-Tagat system is very narrow, values between 4.84 and 5.12 are required 
The inclusion of three to four parts of Imwitor 988 has produced an oil droplet with 
the optimum polarity and HLB required for micro-emulsification. It is important to 
emphasize that Imwitor 988 has equal proportions of mono and di-glycerides and 
considered to be polar oil due to monoglyceride content (HLB ~ 5). Hence, oil 
polarity is enhanced by increasing the monoglyceride percentage as for example seen 
in Imwitor 308 which has 90% of mono-caprylate. The implication of using Imwitor 
308 on emulsification behaviour in Miglyol 812 using various nonionic surfactants 
will be investigated from mechanistic perspective in sections to come.
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3.1.1.2. Phase Behaviour: Mechanistics of Self-emulsification
Although self-emulsification is a dynamic non-equilibrium process involving 
interfacial phenomena, information about the self-emulsification can be obtained 
using investigations of equilibrium phase behaviour [13^ . Emulsification efficiency of 
oil-surfactant systems (as determined from particle size) has been characterized and 
yet correlated with equilibrium phase diagrams.
Wakerly ^  profoundly studied binary mixtures of Miglyol 812-Tagat TO in an 
attempt to elucidate the mechanistic processes of emulsification and to highlight the 
important involvement of liquid crystalline phases forming at the interface in such 
processes, see section 1.6.1 in chapter 1. Therefore, the initial work was dedicated to 
studying the phase behavior of Miglyol-Tagat TO system as described by Wakerly. 
Hence, the effects of incorporating Imwitor 988 on the efficiency of emulsification of 
the binary mixtures will be established using equilibrium phase diagrams. Equilibrium 
phase behaviour was studied in two ways (1) Static composition dilution method and 
(2) Dynamic composition dilution method, described in sections 2.2.4.1 and 2.2.4.2, 
respectively.
In the phase diagrams, depicted in figures 3.1.5-10, aqueous-based liquids are denoted 
Lj, oil-based liquids L2 , and liquid crystalline phases LC. Multiphasic mixtures were 
clearly distinguished by their turbidity, and the presence of significant quantities of 
liquid crystalline material was established by strong birefringent patterns observed 
using the polarizing viewer. No attempt had been made to quantify the composition or 
volume fraction of the phases present in the multiphasic mixtures. Such studies are 
extremely tedious and were un-necessary for the purpose of this work. Turbid 
mixtures, which tended to separate on storage into a water-rich phase and an oil-rich 
phase, were designated (Li +L2 ) or (Li +L2+LC) when LC material was clearly 
present. Two types of LC phases were identified: (1) The LC phase, was viscous and 
exhibited “white” birefringence (2) The LCa phase, transparent liquid crystalline 
dispersion exhibited low viscosity and “multicoloured” birefringence, typical of 
lamellar liquid crystalline phases. The phase diagram notation that was used for all 
subsequent phase diagrams is based on Mitchell[14J and is summarised in table 3.1.4.
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Table 3.1.4: Summary of Phase Diagram Notation
Phase Notation Description of Phases
l 2 Isotropic oil continuous phase which contain 
dissolved water
Li Isotropic water continuous phase which contain 
dissolved oily component
L1+L2 Two phase system which can be either a stable emulsion, 
or separate aqueous s and oily continuous layers.
LC Liquid crystalline phase
LCa Metastable liquid crystalline dispersion
Equilibrium phase behaviour using static compositions
The.triangular equilibrium phase diagram for the Miglyol 812-Tagat TO-water system 
at 25°C is shown in figure 3.1.5. Phases were identified as isotropic (Li or Li), liquid 
crystal (LC) or liquid crystal containing phase (e.g. L2+LC), or combination phase 
regions (e.g. L1+L2). For simplicity no differentiation was made between the different 
liquid crystal phases in the initial equilibrium phase diagram studies.
In the self-emulsification experiments presented in figure 3.1.3, binary or ternary 
mixtures were diluted with water to give a final composition which was close to the 
water apex in the triangular phase diagram. It may be assumed that if stable emulsions 
are formed in these regions, good self-emulsification would be observed.
Considering the dilution of a 30% Tagat TO-Miglyol 812 mixture with water at 25°C 
(Figure 3.1.5), as depicted by the line A-B, the initial binary mixture (L2 phase) could 
pass through L2—*►LC—►L1+L2+LC—>Lj+L2 phases. However, during self- 
emulsification of the binary mixture non-equilibrium multiple phases could have been 
formed. Therefore, the complete route depicted by line A-B may not be followed. 
Also, self-emulsification is a dynamic process hence, using equilibrium phase 
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Figure 3.1.5
Triangular equilibrium phase diagram for the Miglyol 812-Tagat TO-water system at 
25°C. Line A-B represents the dilution of Miglyol 812-Tagat TO oil mixture of ratio 
70/30 with water. Aqueous-based liquids are designated Li, oil-based liquids (L2) and 
liquid crystal phases “white” birefringence (LC).
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exist. Therefore, Equilibrium phase behaviour using the dynamic composition dilution 
method (section 2.2A.2) will be re-evaluated for all diagrams and presented in later 
sections. Construction of phase diagrams with respect to water content and 
temperature described by Shinoda and Friberg [15] enables detailed evaluation of the 
important areas of the diagrams in the region 0 to 40%
In his study Wakerly by constructing the. triangular equilibrium phase diagrams for 
the Tagat-Miglyol-water system at 25, 30 and 40°C concluded that, the presence of a 
L 1+L2+LC region which only occurred to a great extant at 25°C is not essential for 
self-emulsification. It is the phases adjacent to the isotropic L2 region which probably 
control self-emulsification. Also, as different liquid crystal phases (LC) was not fully 
classified, it might have reflected in the difficulty of explaining the observed self- 
emulsifying behavior of Miglyol 812/Tagat TO system.
The triangular equilibrium phase diagram for {Miglyol 812/Imwitor 988} (7:3)-Tagat 
TO-water system at 25°C is shown in figure 3.1.6. The dilution with water of the 
{Miglyol 812/Imwitor 988} 70/30-Tagat TO system at ratio fractions of Tagat TO < 
40 (area between line A-C and below), produced initial ternary isotropic mixtures (L2) 
that could pass through L2 —>Li+ L2 . This region of the phase diagram, with respect to 
the Miglyol-Tagat TO-water system (Figure 3.1.5), has two significant features: (1) a 
huge enhancement in the L2 region and (2) no presence of liquid crystal phases. 
Maximum solubilization of water in the isotropic oil phase (L2) occurred at ratio 
fractions of {Miglyol 812/Imwitor 988} 70/30-Tagat TO between 70(70/30)30 and 
60(70/30)40, as depicted by the lines A-B and A-C, respectively (Figure 3.1.6). The 
amount of water that could be contained in the oil mixtures at these ratios is 35-40% 
and 45-50% w/w, respectively. This indicates the fact that the enhancement in the L2 
region is of paramount importance in the mechanistics of emulsification when 
Imwitor 988 is included in the system, especially as the region is clear from any 
presence of LC phases. This correlates well with the self-emulsification data for 
Miglyol 812/Imwitor 988 (7:3)-Tagat TO presented in figure 3.1.3. This system 
produced a minimum MEDD at surfactant concentration between 30 and 40%. The 
importance of L2 in the mechanistics of emulsification will be reflected upon when 
phase diagrams with respect to water content and temperature are discussed in 
sections to come. Nonetheless, at Tagat TO ratio fractions in the oil mixture of > 40 
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Figure 3.1.6
Triangular equilibrium phase diagram for the {Miglyol 812/Imwitor 988}(7:3)-Tagat 
TO-water system at 25°C. Lines A-B and A-C represent the dilution of oil mixtures of 
compositions [70(70/30)30] and [60(70/30)40] with water, respectively.
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however, to the right of the phase diagram retrospective to the LC phases seen 
adjacent to the L2  region in the case of Miglyol-Tagat-water system, see Figure 3.1.5. 
The existence of LC regions at high Tagat TO concentration could be due to the 
ability of Imwitor 988 as polar oil to solubilise to a certain extent these liquid crystals 
at that particular temperature. This ability is up to a point beyond which Tagat TO 
becomes the dominant concentration in the system, and yet it is well known for 
nonionic surfactants to form LC phases on dilution with water.
The triangular equilibrium phase diagram at 25°C for {Miglyol 812/Imwitor 988} 
(3:7)-Tagat TO-water system is shown in figure 3.1.7. This system has shown a 
relative enhancement in the L2 region, vis-a-vis Miglyol-Tagat TO-water system 
(Figure 3.1.5). At Tagat TO ratio fractions in the oil mixture of 30 or 40 (lines A-B 
and A-C, Figure 3.1.7); the amount of water that could be solubilized in the oil 
mixtures is 15-20 and 25-30%, respectively. Yet, this increase in the L2 is relatively 
small in comparison with the enhancement observed at same Tagat TO ratios when 
only 3 parts of Imwitor was included (Figure 3.1.6). This might have reflected in the 
less self-emulsifiability of this system in comparison with Miglyol 812/Imwitor 988 
(7:3)-Tagat TO, as depicted in figure 3.1.2. On the other hand, despite the 
enhancement in the L2 region in the case of Miglyol 812/Imwitor 988 (3:7)-Tagat TO 
retrospective to Miglyol/Tagat TO system, the latter system produced relatively less 
self-emulsifiable mixtures which reflects the importance of LC phases forming at the 
interface adjacent to the L2 phase when the expansion in the L2 is within certain limit. 
Maximum water solubilization of 30-35%w/w occurred at ratio fraction of Tagat TO 
of around 50, as depicted in the line A-D figure 3.1.7.This aqueous enhancement is 
comparable to the increase in the L2 region observed in the Miglyol/lmwitor (7:3) at 
Tagat TO ratio fraction of 30, see figure 3.1.6, yet, emulsification of Miglyol 
812/Imwitor 988 (3:7)-Tagat TO system at ratios of 50(30/70)50 did not produce 
relatively fine dispersions. This could be due to the formation of large “swollen” 
microemulsion systems when relatively high surfactant proportions are used [10]. 
Similar trend of phase behaviour was observed when no Miglyol 812 was used in the 
system. The triangular equilibrium phase diagram at 25°C for the Imwitor 988-Tagat 
TO-water system is shown in figure 3.1.8. At Imwitor-Tagat To ratios between 70/30 
and 40/60 concentrations, maximum solubilization of water of 20-25%w/w resulted. 
This enhancement in the L2 region was not enough, compared to Miglyol/lmwitor 
(7:3)-Tagat TO (Figure 3.1.6), to produce good self-emulsification, as reflected in the
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Figure 3.1.7
Triangular equilibrium phase diagram for the {Miglyol 812/ Imwitor 988}(3:7)-Tagat 
TO-water system at 25°C. Lines A-B, A-C and A-D represent the dilution of oil 






Triangular equilibrium phase diagram for the Imwitor 988-Tagat TO-water system at 
25°C. Lines A-B and A-C represent the dilution of Imwitor 988-Tagat TO oil 
mixtures at ratio fractions o f 70/30 and 60/40 with water, respectively.
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particle size data presented in figure 3.1.2. This emphasises the importance of Miglyol 
812 in aiding the emulsification process when Imwitor 988 is used in these systems.
Equilibrium phase behaviour using dynamic compositions
Figures 3.1.9 and 3.1.10 depict the equilibrium phase behaviour for different mixtures 
of Miglyol 812/Imwitor 988-Tagat TO, on dilution with water. Comparative 
equilibrium phase studies are carried out on Miglyol-Tagat TO system with and 
without Imwitor 988 at Tagat TO concentrations 15 and 30%. This enables insight 
into the mechanistics of the observed changes in self-emulsification behaviour of 
these systems. Figure 3.1.9a displays the equilibrium phase diagram for a system 
containing 85 % (w/w) Miglyol 812 and 15%w/w Tagat TO diluted with water. The 
isotropic L2 region occurs below approximately 1% water at temperatures below 
45°C. At temperatures between 45°C and 55°C water solubilization reached its 
maximum (2%). The dilution of the binary mixture by water (1 to 3.5%) resulted in a 
phase transition to L2+LCa at temperatures below 60°C. At higher water contents or at 
temperatures above 60°C Phase separation to L1+L2 occurs. The presence of the small 
amount of LCa in the L2 phase aided in the disruption of the oil continuous phase and 
thus slightly improved self-emulsification occurred [6]. Yet at 30% Tagat TO (Figure 
3.1.10a) an extensive area of liquid crystal phase occurred which can be attributed to 
the optimum self-emulsification observed over the range 30 to 45% surfactant.
In his study Wakerly has shown that the enhancement of the LCa area corresponds 
to the increase of Tagat TO concentration. This enhancement is up to a point (50% 
surfactant) beyond which partial or total separation of LCa into L2 and LC occurs and 
thus self-emulsification is impaired. He indicates also that the LCa phase is in fact a 
dispersion of liquid crystals in isotropic L2 phase. At surfactant concentrations 
between 30 and 45% separation of LCa into L2 and LC was rather difficult due to 
similarities in refractive indices and densities of the two components. Typically LCa is 
optically clear and shows no tendency to separate even after storage for several 
months. However, ultra centrifugation at controlled temperature will enable partial 
separation of these dispersion phases.
The equilibrium phase diagram for a system containing Miglyol 812/Imwitor 988 


















Equilibrium phase diagrams for Tagat TO-Miglyol 812 system at 15% (w/w) 
surfactant on dilution with water (A) with no Imwitor 988 (B) with a Imwitor 988/ 
Miglyol 812 ratio of 30/70. Aqueous-based liquids are designated Li, oil-based 
liquids (L2 ); liquid crystal phases “white” birefringence (LC); and liquid crystal 
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Equilibrium phase diagrams for Tagat TO-Miglyol 812 system at 3 0 %  (w/w) 
surfactant on dilution with water (A) with no Imwitor 988 (B) with a Imwitor 988/ 
Miglyol 812 ratio of 30/70.
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Imwitor 988 has extended the area of L2 to almost 8% water at the emulsification 
temperature (37°C), with maximum solubilization of almost 22% water at 12°C. 
Whereas, in the previous system without Imwitor 988 (Figure 3.1.9a) the non-aqueous 
solubilization limit was approximately 2%. Improved emulsification observed in 
Miglyol 812/Imwitor 988 (7:3)-Tagat TO (15%) system was attributed to the 
enhancement in the L2 region (see table 3.1.5).
In the system containing 70 %(w/w) Miglyol 812 and 30%w/w Tagat TO (Figure 
3.1.10a), maximum water solubilization (L2) extended to 7% at 45°C. Moreover, large 
area of liquid crystal phase (LCa and L2+LCa) occurred on further dilution with water 
by 6 to 10%w/w at temperatures below 50. On the other hand, the effect on phase 
behaviour of incorporating 3 parts of Imwitor in the system containing Miglyol 812 
and 30% Tagat TO is shown in figure 3.1.10b. Substantial extension to the L2 region 
was observed reaching a maximum of almost 32-33 % water at 20°C. Water 
solubilsation at 37°C (emulsification temperature) was approximately 22-23%. This 
means that there is almost 4-fold enhancement in the L2 region at 37°C when 3 parts 
of Imwitor 988 was included in the Miglyol 812-Tagat TO (70/30) system. This has 
reflected in the fine dispersion obtained from the emulsification data of that system, 
see table 3.1.5.
As depicted in these phase studies, there are two distinctive features that may 
correlate to the efficiency of emulsification; (a) a region of enhanced water 
solubilization typical of non-ionic surfactant systems and thought to be a phase 
inversion region (b) the formation of a lamellar liquid crystalline dispersion phase on 
further incorporation of water. The occurrence of such stable or metastable liquid 
crystal dispersions at the oil-water interface, based on loosely associated aggregation 
structures was suggested to allow rapid penetration of water and disruption of the 
interface [16]. The resulting disruption will promote rapid self-emulsification.
The enhancement in the water soubilisation region (L2) becomes primarily the 
putative mechanism of self-emulsification when oil systems do not form any liquid 
crystalline dispersion. The importance of the L2 region in the mechanistics of 
emulsification will be further clarified when the changes on the phase behaviour 
induced by Imwitor 988 are discussed below.
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The inclusion of Imwitor 988 in the binary mixtures (Miglyol-Tagat TO) has 
substantially transformed the phase behavior of these oil systems. It has induced three 
major changes in the phase diagram structure of the binary mixtures:
(1) Changes in L2 regions
An extensive enhancement in the L2 region reaching up to 35-40% water in some 
systems is observed. The inclusion of Imwitor 988 adds to the total polarity of the oil 
droplets as it is classified as polar oil due to the high content of monoglyceride 
(-50%). This renders the propensity of the oil system to solubilizing more water up to 
a point beyond which phase transition to L1+L2 occurs. Initially, aqueous penetration 
into the oily phase results in hydration of the oxyethylene part of the surfactant and 
also other polar components in the formulation. When the limit of the non-aqueous 
solubilization is reached phase separation to L1+L2 occurs. It is likely that further 
dilution of these dispersions (L1+L2) results in crude emulsions in systems such as 
Miglyol 812 at low Tagat TO concentrations 5, 10 and 15% whereby, L2 phase does 
not exceed 2%. Yet, in some oil systems such as Miglyol 812/Imwitor 988 (7:3)-30% 
Tagat TO whereby L2 region extends to -35% water at 25°C, further dilution of L1+L2 
dispersions transforms the system into micellar solution (Li).
Therefore, L2 phase is crucial in the mechanistics of self-emulsification and thus the 
particle size distribution of the emulsified systems. It is rather important to address the 
properties of the L2 phase on the molecular level to enable insight into the self- 
emulsification process. According to criteria for the identification of microemulsions, 
L2 phase in aqueous systems of polar lipids and triglyceride oil is w/o microemulsion. 
On the basis of an X-ray study obtained by cooling L2 phases [17], it was proposed that 
the structure consists of water lamellae separated by lipid bilayers corresponding to 
liquid-crystalline phase (see Figure 1.10c). It is important to note here that the 
increase in water content results in increased molecular disorder within the lipid 
molecule towards the hydrocarbon tail, this disorder corresponds to the swelling of 
the lamellar phase (L2 ). Therefore, the ability of these systems to solubilise water is 
due to the swelling behaviour of the L2 phase.
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Based on a study by Rang and Millar [18’ 19] investigating the emulsification o f oils 
containing hydrocarbon, nonionic surfactant and w-octanol, the following mechanism 
for the self-emulsification of Miglyol 812-Imwitor 988-Tagat TO system can be 
proposed. Addition of the oil mixture to water results in the formation of interface 
between the oil and aqueous-continuous phases. Solubilization of water with the oily 
phase results from aqueous penetration through the interface. This will occur until 
maximum solubilization (L2) is reached close to the interface. Further aqueous 
penetration results in diffusion of the polar component of Imwitor 988 (1- 
Monocaprylate) and also to some extent Tagat TO into water. Subsequently, the 
system becomes supersaturated in oil and thus spontaneous nucleation of small oil 
droplets from the microemulsion occurs (i.e. phase transition from L2 to L 1+L2). 
Further diffusion of Tagat TO and monocaprylate out of the L2 phase forms a system 
that is ever more hydrophilic so that it eventually becomes miscible with water. The 
particle size of the nucleated oil droplets formed due to the diffusion process is 
expected to be related mainly to the interfacial and rheological properties of the L2 
phase; the larger the (L2) area in the phase diagram the smaller the size of the 
nucleated oil droplets and vice versa.
Optimal range of initial drop compositions is required to obtain an emulsion of small 
oil droplets. According to our findings spontaneous micro-emulsification yielding 
uniformly fine dispersions was achieved when the injected drop was slightly 
lipophilic; i.e. the ratio of Imwitor 988-to-Miglyol 812 was slightly greater than that 
of the excess oil phase in equilibrium with a bicontinuous microemulsion at the 
experimental temperature, and when sufficient Tagat TO was used. As depicted in 
figures 3.1.11 and 3.1.12, smaller MEDD values were seen for oil formulations with 
Imwitor 988/Miglyol 812 ratios of 30/70 and 40/60. The need for this slightly 
lipophilic oil composition is attributed to the relatively low HLB value of Tagat TO 
(H LB -ll). However, in the case of surfactants with higher HLB values, less 
lipophilic oil composition is required, as will be presented in section 3.2.
(2) Changes in the Phase Boundary Temperatures (PBT)
The phase inversion temperature (PIT) as defined by Friberg et at t20] is the 
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Figure 3.1.11
Three-dimensional graph of the effects of surfactant concentration and ratio of 
Imwitor 988/Miglyol 812 in the oil blend on the self-emulsifying performance of 
Miglyol 812/Imwitor 988-Tagat TO system as measured by mean emulsion droplet 
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Figure 3.1.12
Three-dimensional graph and contour plot representations of MEDD data for the 
emulsification of Miglyol 812/lmwitor 988-Tagat TO system as a function of 
surfactant concentration and ratio of Imwitor 988/Miglyol 812 in the oil blend. The 
highlighted area represents the optimum blend of Miglyol 812 and Imwitor 988 which 
produced the finest dispersions. MEDD values were determined using QELS.
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at elevated temperatures. The prime intension of this phase study has not been 
specifically directed to determine the PIT of these systems as this has to be 
investigated inextricable from droplet size analysis which will be addressed when we 
discuss the effect of emulsifying temperature. More importantly, however, 
equilibrium phase studies have been used to investigate the isotropic oil continuous 
phase (L2) and the lamellar liquid crystalline phase (LC), and how they interplay in 
the mechanistic processes. The minimum temperature at which phase transition from 
L2 to LC and L1+L2 occurs is referred to here as phase boundary temperature (PBT) 
and has a significant role which underlines the PIT of the system. This temperature 
(PBT) apparently is not equivalent to the PIT whereby phase inversion from Winsor I 
to Winsor II takes place somewhere in the L1+L2 region. Nonetheless, any depression 
in the PBT due to for example, increase in the temperature of the system, inclusion of 
polar oil, or addition of electrolytes reflects monotonically on the PIT of the system.
The equilibrium phase diagram for Miglyol 812-Tagat TO depicted in figure 3.1.10a 
displays PBT at around 45°C. Yet, it is evident from figures 3.1.13(a, b) that the 
inclusion of 1 part or 2 parts of Imwitor 988 in the system depresses PBT to 30°C and 
to 15°C, respectively. This could be attributed to the fact that Imwitor 988 as polar oil 
increases the solubility of the surfactant in the oil phase thus less temperature is 
needed to exert phase inversion. Therefore, it is expected from Imwitor 988 to reduce 
the PIT of the oil system when it is included in the Miglyol 812-Tagat TO mixtures.
(3) The Formation o f  Gel Phase
As figures 3.1.9b and 3.1.10b show, the inclusion of 3 parts of Imwitor 988 in the 
Miglyol 812-Tagat TO system results in the formation of gel phase at temperatures 
below 15°C for the first system and below 20°C for the second. The gel phase 
normally consists of crystalline lipid bilayers alternating with water layer. When the 
La phase is cooled below the temperature at which the hydrocarbon chains crystallize, 
a gel phase can be formed which is metastable.
As it has been discussed earlier, L2 phase is regarded as a lipid bilayer type of 












Equilibrium phase diagrams for {Miglyol 812/Imwitor 988}-Tagat TO system at 30% 
(w/w) surfactant on dilution with water (A) {Miglyol 812/Imwitor 988} ratio o f 90/10 
(B) Miglyol 812/Imwitor 988 ratio of 80/20.
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phase which was seen in figures 3.1.9a and 3.1.10b could be due to the cooling of L2 
phase below the hydrocarbon-chain crystallization temperature. Moreover, it might be 
attributed to the monoglyceride content in Imwitor 988 viz monoglycerides in water 
form mesophases which by cooling can form gel phases.
Table 3.1.5: Summary of the effects of Miglyol 812/Imwitor 988 blends on the 
phase behaviour description of (Miglyol 812/Imwitor 988}-Tagat TO system.
Miglyol 812 at Tagat TO 
(15%)
Miglyol 812 at Tagat TO 
(30%)
No of parts of Imwitor 988 Description 
Of phase 
Behaviour
No of parts of Imwitor 988
0 3 0 1 2 3
2% 22% L2 max. 7% 12% 16% 32
+ - LCa +++ ++ + -
- + Gel phase -  ■ - - +
60 15 PBT (°C) 45 30 15 20
coarse 176.30 Particle 221.80 202.40 173.40 49.5
dispersion size (nm)
3.1.13. The Effect of Emulsifying Temperature and Medium on the Self- 
emulsification of Miglyol 812/Imwitor 988-Tagat TO Mixtures.
Temperature variation
It is important from stability prospective in emulsions to investigate the optimum 
temperature for stable emulsifications, the optimum hydrophilic chain length and the 
phase inversion temperature (PIT) of emulsifiers. Non-ionic surfactants often become 
increasingly more lipophilic at elevated temperatures. The change in micellar shape, 
size and eventual loss of aqueous solubility with increase in temperature is due to 
decreased hydration of the surfactant. Hydrogen bonding forces, which account for
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aqueous solubility, are reduced at elevated temperatures. This is analogous to 
reducing the HLB of the surfactant.
In a similar manner an alteration of the hydrophilic chain length of the emulsifier 
should have an effect similar to the temperature change of the system since the 
interaction between the hydrophilic moiety and water is modified with variation in 
temperature [151.
The change in nonionic surfactant-oil-water system (nSOW) phase behaviour with 
temperature can result in the phase transitions Winsor's type I to type III to type II 
(see figure 1.2b in chapter 1). Therefore, the higher the emulsification temperature is 
than the PIT of the emulsifier, the larger the emulsion droplets will be. Emulsification 
at temperatures slightly below the PIT (about 2-4°C below) affords optimum oil 
droplets of an o/w-emulsion type. On the other hand, emulsions are most unstable 
against coalescence at the PIT, due to the ultra-low interfacial tensiont21].
The effect of the emulsification temperature on the mean volume diameter of o/w- 
type emulsions of Miglyol 812-Tagat TO system with or without Imwitor 988 is 
shown in figures 3.1.14 to 3.1.16. For the system containing 85% Miglyol 812 and 
15% Tagat TO as figure 3.1.14 illustrates, at emulsification temperature 35°C 
minimum oil droplets was obtained. A sharp increase in the mean emulsion diameter 
(from 4.22 ± 0.05 to 8.16 ± 0.32 pm) occurred at emulsification temperatures above 
40°C. This suggests that phase inversion to w/o-type emulsion due the loss of the 
surfactant's affinity for the aqueous phase has occurred which resulted in larger 
emulsion droplets.
Nonetheless, optimum temperature for emulsification occurred at 20°C when the 
system above contained 3 or 4 parts of Imwitor 988 (7:3, 6:4), and at 30°C when 5 
parts of Imwitor was used (Figure 3.1.15). There is obvious increase in the MEDD 
values concomitants the emulsification at increasing temperatures which reflects a 
sort of phase inversion behaviour. Nonetheless, due to the presence of Imwitor 988 
which acts as a cosurfactant in enhancing the emulsification process, there has been 
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Figure3.1.14
The effect of self-emulsifying temperature on the mean emulsion droplet diameter for 
the Tagat TO-Miglyol 812 system at 15% (w/w) surfactant as determined by the 
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Figure 3.1.15
The effect of self-emulsifying temperature on the self-emulsifying performance of 
different ratios of Miglyol 812/Imwitor 988 at 15% (w/w) Tagat TO as measured by 
mean emulsion droplet diameter using QELS. Bars represent standard errors (n = 3).
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Figure 3.1.16 illustrates the effect of temperature on the MEDD of Miglyol 812/Tagat 
TO, and {Miglyol 812/Imwitor 988} (7:3), (6:4) and (5:5) using 30% w/w Tagat TO. 
These mixtures exhibit good self-emulsifying behaviour in terms of producing fine 
dispersions. Optimum MEDD values were obtained for Miglyol 812/Tagat TO and 
Miglyol 812/Imwitor 988 (5:5) using 30% Tagat TO at emulsification temperature 
30°C. For Miglyol 812/Imwitor (7:3) and (6:4) using 30% w/w Tagat TO, almost clear 
microemulsion dispersions of minimum particle size were produced at temperatures 
between 35 and 40°C.
Quantitatively, oil systems depicted in figure 3.1.16 had shown no large increase in 
the MEDD at high emulsification temperatures comparable to the particle size 
increase observed when these systems contained 15% surfactant (figures 3.1.14 and 
3.1.15). Qualitatively, however, clear dispersions obtained by the emulsification of 
Miglyol 812/Imwitor 988 (7:3) or (6:4) using 30% w/w Tagat TO turned turbid at 
temperatures above 45°C, yet on cooling to the room temperature for size 
measurement they became clear again. This phenomenon has been observed by many 
researchers and considered to be one of the distinctive criteria for microemulsions.
Formulations presented in figure 3.1.16 are considered robust oil systems in terms of 
self-emulsifying behaviour. Moreover, due to relatively high surfactant concentration 
(30% w/w), any reduction in the surfactant's aqueous solubility due to temperature 
variations will not result in significant increase in the MEDD as there will be enough 
surfactant to aid in the emulsification.
These studies show that in terms of minimum particle size and therefore potential 
ability to penetrate between the micro-villi of the gastrointestinal mucosa thus 
presenting drug to the absorption site, including 3 or 4 parts of Imwitor 988 in the 
system would be preferable when Tagat TO is used at concentrations 30 or 15%, 
respectively.
Emulsification Media
Since the luminal environment in the proximal GI tract varies considerably with site 
and meal ingestion, it is essential to consider the use of several different sets of
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Figure 3.1.16
The effect of self-emulsifying temperature on the self-emulsifying performance of 
different ratios of Miglyol 812/Imwitor 988 at 30%  (w/w) Tagat TO as measured by 
mean emulsion droplet diameter using QELS. Bars represent standard errors (n = 3).
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emulsification conditions to assess the dissolution behaviour of the oil formulations 
with and without drugs.
The United States Pharmacopoeia t22] calls for the Simulated Gastric Fluid (SGF) to 
simulate dissolution in the stomach. SGF simulates pH conditions in the fasted 
stomach. In the fed state, however, composition in the stomach will be highly 
dependent on the ingested meal. Long-life milk [23] and clinical nutrition products, e.g. 
Ensure® HN [24] have been suggested as media suitable for simulating fed state in the 
stomach.
For simulation of small intestine contents in both fasted and fed states, Dressman et 
al. [23] recently proposed the fasted state simulating intestinal fluid (FaSSIF) and the 
fed state simulating intestinal fluid (FeSSIF). In contrast to gastric media, these media 
contain bile salts and have pH values which mimic the small intestine environment. 
Also, their buffering capacity and osmolarity have been adjusted to simulate the 
average physiological values.
In this investigation SGF was used without Pepsin or any surfactant due to 
perturbation in size measurement as Pepsin is insoluble in this media (see table 2.4 in 
chapter 2). The effect of SGF in relation with water on the emulsification profile of 
Miglyol 812/Imwitor 988-Tagat TO system is presented in figure 3.1.17. The 
emulsification in both systems (water, SGF) has shown equivalent MEDD values for 
Miglyol 812-Tagat TO with no Imwitor 988 or with Imwitor 988 / Miglyol 812 ratio 
of 10/90.
Wakerly in his equilibrium phase behaviour evaluation of the Tagat TO-Miglyol 
812 system with 0.1M HC1 found that the extent and quality of the LCa region was 
reduced comparable to the equivalent phase diagram with water. Yet, the level of 
effect on the LCa had not been significant at 37°C thus equivalence of MEDD data 
would be anticipated. However, this reduction in the quality of the LCa phase was 
attributed to the slightly reduced self-emulsifying performance in acid at a higher 
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Figure 3.1.17
The Effect of self-emulsifying media on the self-emulsifying performance of different 
blends of Miglyol 812/Imwitor 988 using 30% (w/w) Tagat TO as measured by 
emulsion droplet diameter using QELS. Bars represent standard errors (n = 3).
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Nonetheless, as depicted in figure 3.1.17, the emulsification of oil systems containing 
Imwitor 988/Miglyol 812 at ratios of at least 20/80 and 30% surfactant in acid results 
in significant increase in the MEDD values in relation with water. Oils with Imwitor 
988/Miglyol 812 ratios of 30/70 and 40/60 exhibited approximately 3-fold increase in 
the MEDD on emulsification in SGF.
Shinoda and Takeda [25] investigated thoroughly the effect of salts on the phase 
behaviour of nonionic surfactant system whereby a linear depression of phase 
boundary temperatures occurs across the whole phase diagram. The increase in the 
MEDD of oils with Imwitor 988/Miglyol 812 ratios of 30/70 and 40/60 can therefore 
be explained by a depression in the PIT of the system. Also a reduction in the water 
solubilization region (L2) would be anticipated in relation to the equivalent phase 
diagram with water. This suggests a phase inversion from o/w to w/o at temperatures 
lower than the preferable optimum temperature for emulsification (37°C). For use in 
vivo it would obviously be preferable to have optimum emulsification at 37°C yet this 
might be achieved by using slightly more hydrophilic surfactants such as, Cremophor 
RH 40 and Tween 80. Nonetheless, this does not preclude the use of this system in 
vivo since particles around 150nm are still achievable.
It is also worth noting that in vitro emulsification using SGF does not bring about a 
full picture of what is going on in the stomach. Hence the media excludes the human 
gastric lipase which initiates gastric lipolysis; a process that aids the emulsification as 
it facilitates the hydrolysis of triglycerides to diglycerides and fatty acids. It has 
recently been suggested [26] that a suitable surfactant be added to this media better 
simulate the surface tensions typical of the fasted stomach. However, in vivo studies 
are worth carried out to verify the performance of this genuine system in a suitable 
animal model.
3.1.2. Concluding Remarks
This present study was designed to develop stable o/w microemulsions comprising 
Miglyol 812 (medium chain, C6-C12, triglycerides), Cg/Cio mono/diglycerides 
(Imwitor 988) and non-ionic surfactant polyoxyethylene-25- glyceryl trioleate (Tagat
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TO). This type of formulation is referred to as type II and is likely to retain its solvent 
capacity for the drug after dispersion as it is comprised of water in-soluble 
components. The resulting emulsions as assessed by particle size analysis showed to 
be dependent on the glycerides blend {Miglyol 812/Imwitor 988}, surfactant 
concentration, emulsification temperature and media. Manipulation of these 
parameters can result in emulsion formulations of controlled droplet size and hence 
surface area. Such considerations are important when the partition of lipophilic drugs 
into the aqueous phases and drug release rates are considered.
Miglyol 812-Tagat TO system exhibits optimum self emulsifying behaviour (MEDD 
of 215.30±11.30 nm) at 30°C. Nonetheless, Self-emulsifying oil in water (o/w) 
microemulsions has been obtained by incorporating medium-chain glycerides, 
particularly CyCio mono/diglycerides (Imwitor 988). An optimized formulations 
consisting of Miglyol 812/Imwitor 988 (7:3) or (6:4) using 30% (w/w) Tagat TO has 
spontaneously emulsified in water at 37°C with gentle agitation, producing 
dispersions with mean droplet diameters of ~50 and 60 nm, respectively. These 
systems appeared to be affected by emulsification in the presence of electrolytes yet 
this has to be further investigated in vivo to establish whether there is a significant 
difference in bioavailability between systems which produce sizes of 250 versus 
50nm.
Equilibrium phase behaviour studies have shown that good self-emulsification 
observed in Miglyol 812-Tagat TO system is related to the formation of lamellar 
liquid crystalline dispersion phase. For Miglyol 812-Tagat TO systems containing at 
least 3 parts of Imwitor 988, no liquid crystalline phase is involved in the mechanistic 
processes. However, the amount of water solubilized as w/o (L2 phase) is of 
paramount importance for the observed good emulsification in these systems.
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3.2. The Choice of Hydrophilic Surfactants for Formulation of Type 
HI Self-micro-emulsifying Drug Delivery Systems (SMEDDS)
3.2.1. Results and Discussion
Microemulsions as drug delivery systems are designed to improve the drug 
solubilization and protection against enzymatic hydrolysis, as well as the potential for 
enhanced absorption. The exact mechanism(s) by which lipid enhances absorption of 
hydrophobic drug molecules is not fully understood, but is believed to involve 
transfer into the bile-salt mixed-micellar phase, from which absorption across the 
intestinal epithelium readily occurs.
The choice of a suitable microemulsion system for drug delivery requires substantial 
knowledge about the physicochemical properties of the microemulsion system such as 
miscibility of the oil mixture, drug solubility in the pre-concentrate, phase equilibrium 
behaviour on dilution with water and particle size of the resulting dispersions. 
Cyclosporin A which is an immunosuppressant for organ transplant patients has been 
reformulated as a microemulsion system. The advent of Neoral® (Novartis) has given 
new impetus to this evolving technology as an important approach to improve the oral 
absorption and thus enhance the bioavailability of hydrophobic active molecules. A 
full literature search reveals well over a hundred recent publications on the 
formulation, biopharmaceutics and pharmacokinetics of cyclosporin A [27]. The 
previous formulation of Cyclosporin was an oil-based solution called Sandimmun® 
which, after oral administration, formed crude o/w dispersion which had to be 
exposed to local secretions of lipase and bile salts from the pancreas and gall-bladder 
respectively, in order to facilitate the digestion of the oil droplets and therefore the 
release of Cyclosporin. Neoral®, on the other hand, readily forms a microemulsion on 
contact with the gastrointestinal fluids without the involvement of lipolysis, and as a 
consequence the bioavailability and reproducibility of delivery of cyclosporin is 
substantially enhanced.
The optimization of cyclosporin as Neoral® is the archetypal example of Type IHB 
according to the classification system proposed by Pouton [5]. The Neoral® 
formulation uses approximately 20% co-solvent, 30% oil and 40 % hydrophilic
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nonionic surfactant (Cremophor RH40) and 10% drug. Apparently, the use of 
Cremophor RH40 (polyoxyethylene-(40)-hydrogenated caster oil) has significantly 
contributed to the success of this formulation as a microemulsion delivery system. Yet 
the role of this surfactant in the emulsification process from mechanistic and phase 
behaviour perspective has not been reported.
In this study blends of Miglyol 812, Imwitor 988 and Cremophor RH40 were 
optimized to produce microemulsions. The effect of varying the weight ratio of each 
component on the emulsification performance for various microemulsion systems as 
determined by size measurement was investigated. Equilibrium phase behaviour study 
is also conducted to establish the mechanism by which Cremophor RH40 influences 
the emulsification process.
Hence Cremophor RH40 is a waxy material at room temperature as it has a high 
melting point of ~ 40°C; it restricts the range of oil mixtures which can be used in the 
system. It also implicates the scale-up production of lipid formulations as special 
considerations are needed to handle and process a molten formulation on automated 
equipment. Solidification of the lipid system and thus drug precipitation can also 
occur during processing and storage due to variations in the environmental 
temperature. Therefore, in order to circumvent the crystallization of monoglycerides 
and/or highly ethoxylated surfactant molecules, alternative hydrophilic surfactants 
were investigated here for microemulsion systems.
3.2.1.1. Miscibility of Ternary Oil Systems
Figure 3.2.1 (a, b, and c) depicts ternary phase diagrams displaying the miscibility of 
Miglyol 812/Imwitor 988-Cremophor RH40 system at various storage temperatures 
15°C, 25°C and 45°C, respectively. This system contains two pairs of partially 
miscible liquids at temperatures 15°C and 25°C, viz Cremophor RH40 and Imwitor 
988 also Cremophor RH40 and Miglyol 812. Yet, it is important to note that blends of 
Cremophor RH40 and Imwitor 988 might be completely miscible and what we see 
from the area of immiscibility close to the Imwitor 988 line is due to the solidification 
of Cremophor RH40 at temperatures below the melting point (40°C). This is 
substantiated, however, as the area of immiscibility between Cremophor RH40 and 
Imwitor 988 has disappeared when the waxy Cremophor RH40 is replaced with its
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liquid unsaturated form Cremophor EL, see figure 3.2.2. At 45°C, however, only 
Cremophor RH40 and Miglyol 812 show partial miscibility as they form one bimodal 
curve. On the other hand, Miglyol 812 and Imwitor 988 are completely miscible at all 
temperatures used. Generally, increasing the temperature leads to a reduction in the 
areas of immiscibility and thus miscibility is promoted. The line A-B depicted in 
figure 3.2.1 (a, b and c) represents the dilution of Miglyol 812/Imwitor 988 ratio of 5:5 
with increasing concentration of Cremophor RH40. It shows that the maximum 
amount of Cremophor RH40 that can be used to formulate isotropic blends is 20%, 
40% or up to 90% at temperatures 15°C, 25°C and 45°C, respectively. This suggests 
that reduction of the temperature expands the area of immiscibility and prompts 
crystallization of Cremophor RH40 which could result in drug precipitation. This 
nullifies the purpose of lipid formulations which are designed to improve the 
dissolution rate of poorly water-soluble drugs and thus enhance absorption. Therefore, 
as it has been shown, the choice of Cremophor RH40 limits the range of acceptable 
oil formulations that can be used to produce microemulsion systems. The use of co­
solvent in these systems might improve the range of reliable oil systems. Yet this, 
however, raises the issue of losing the solvent capacity of these formulations on 
dilution of the co-solvent in the lumen of the gut which might ensue in crystallization 
of the drug. Alternatively, to screen other surfactants which could replace Cremophor 
RH40; in particular the liquid surfactants Cremophor EL and polysorbate 80.
Figure 3.2.2 shows the phase equilibrium in a three component system of Miglyol 
812/Imwitor 988 and Cremophor EL (polyoxyethylene-(35)-caster oil). In contrast to 
the oil systems containing Cremophor RH 40, this ternary phase diagram displays a 
huge area of miscibility, in which Cremophor EL and Miglyol 812 show partial 
miscibility as there is only one bimodal curve. The phase diagram depicted in figure 
3.2.2 reveals similar areas of phase equilibrium as the ternary oil mixtures which 
contain Cremophor RH 40 at 45°C (Figure 3.2.1c). This suggests that what causes the 
crystallization of these systems containing Cremophor RH40 and thus restricting the 
range of oil systems which can be used is the waxy nature of the surfactant. 
Especially, if we know that Cremophor EL which is obtained by reacting ethylene 
oxide with caster oil in a molar ratio of 35 moles to 1 mole, is the liquid form of 
Cremophor RH40 (polyoxyethylene-(40)-hydrogenated caster oil) with slightly lower 
HLB values (HLB, between 12 and 14) as it contains less ethoxy residues per
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P ercentage Imwitor 988 (Co-Surfactant)
Figure 3.2.2
Ternary phase diagram for Miglyol 812/Imwitor 988-Cremophor EL system 
displaying miscibility for formulations of various compositions.
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molecule. Therefore, comparable MEDD profiles would be anticipated from 
emulsification of oil systems containing either Cremophor RH 40 or EL.
The ternary phase equilibrium diagram for Miglyol 812, Imwitor 988 and Crillet 4 
(Polyoxyethylene-(20)-sorbitan monooleate) displayed in figure 3.2.3 has produced 
similar phase miscibility as oil systems containing Cremophor EL depicted in figure 
3.2.2. Crillet 4 and Miglyol 812 show partial miscibility as there is only one bimodal 
curve, Crillet 4 and Imwitor 988, on the other hand, are completely miscible. This 
could be due to the fact that both surfactants have approximately equivalent HLB 
values. Nonetheless, it is surmised that oil systems containing either Crillet 4 or 
Cremophor EL will produce different emulsification profiles on dilution with water as 
both surfactants have different chemical entities which will be elaborated further in 
next sections.
Replacing Crillet 4 (HLB =15) with a surfactant of higher HLB value (Crillet 1, HLB 
=16.7) has expanded the bimodal curve, see figure 3.2.4. Crillet 1 (Polyoxyethylene- 
(20)-sorbitan monolaurate) is considered to be more hydrophilic than Crillet 4 as the 
former contains lower chain fatty acid derivative (Laurie acid Ci2 :o) while the latter 
has an oleic acid (C n:2) residue. The extension of the area of immisciblity observed in 
figure 3.2.4 vis-a-vis the ternary phase equilibrium for oil systems containing Crillet 4 
(figure 3.2.3) is attributed to the relatively high HLB value of Crillet 1 due to the 
decrease of the molecular weight of the fatty acid residue which reduces the solubility 
in oil and increases aqueous solubility.
This is more evident in the case of using Tagat 0 2  (polyoxyethylene-(20)-glyceryl 
monooleate, HLB =15) in the three-component system depicted in figure 3.2.5. From 
one hand, it has produced similar bimodal curve as oil systems containing surfactants 
with comparable HLB values; Cremophor EL or Crillet 4 (Figures 3.2.2 and 3.2.3, 
respectively). On the other hand, the ternary oil system containing Miglyol 812, 
Imwitor 988 and Tagat TO (HLB =11) has shown area of total miscibility (figure 
3.1.1 in the previous section) while using a more hydrophilic surfactant (Tagat 02) a 
bimodal curve has appeared. This reflects the fact that Miglyol 812 and Tagat TO are 
completely miscible whereas Miglyol 812 and Tagat 0 2  show partial miscibility. This 
is attributed to the differences in the HLB values for both surfactants, in which Tagat 
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Figure 3.2.3
Ternary phase diagram for Miglyol 812/Imwitor 988-Crillet 4 system displaying 
miscibility for formulations of various compositions.
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Percentage Imwitor 988 (Co-Surfactant)
Figure 3.2.4
Ternary phase diagram for Miglyol 812/Imwitor 988-Crillet 1 system displaying 
miscibility for formulations of various compositions.
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Figure 3.2.5
Ternary phase diagram for Miglyol 812/Imwitor 988-Tagat 02  system displaying 
miscibility for formulations of various compositions.
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3.2.1.2. Emulsification Performance of Oil Systems
In vitro particle size distribution analysis is one of the most important means to 
evaluate the stability of emulsions and also its in vivo fate after oral administration of 
the pre-concentrate, that is, a drug-surfactant-oil mix. Figures 3.2.6, and 7 display the 
effect of surfactant concentration and oil blends of Miglyol 812/Imwitor 988 on the 
emulsification performance of Miglyol 812/Imwitor 988-Cremophor RH40 system as 
determined by the mean emulsion droplet diameter (MEDD). At first, oil systems 
containing Miglyol 812, Miglyol 812/Imwitior (9:1) or (8:2) blended with Cremophor 
RH40 show either complete immiscibility or isotropic single phase oil mixtures with 
very limited concentration of Cremophor RH40 <10% w/w (figure 3.2.1b, lines A-F, 
A-E and A-D). Therefore, these oil mixtures were excluded from the emulsification 
study. On the other hand, for oil blends of Miglyol 812/Imwitor (7:3), Cremophor 
RH40 was included at concentration below 25% w/w lest using more surfactant in the 
system will ensue in phase separation due to crystallization, see figure 3.2.1b (line A- 
C).
Generally, as depicted in figure 3.2.6, the mean emulsion droplet diameter for Miglyol 
812/Imwitor 988-Cremopho RH40 system decreased with increasing surfactant 
concentration at all Miglyol 812/Imwitor 988 ratios. Such a decrease in droplet size 
may be due to the availability of more surfactant to stabilize the oil-water interface. 
Furthermore, the decrease in the droplet size behaviour reflects the formation of a 
better close packed film of the surfactant at oil-water interface which stabilizes the oil 
droplets [28^ . Yet, the emulsification of Miglyol 812/Imwitor 988 blends of 7:3 ratio at 
surfactant content up to 2 0 % w/w, which is the maximum concentration to avoid 
crystallization, did not affect the droplet size significantly and thus produced 
dispersions with high MEDD values. However, with increasing the cosurfactant 
content (Imwitor 988) in the Miglyol 812/Imwitor 988-Cremophor RH40 system, the 
droplet size decreased substantially. This suggests that increasing the Imwitor 988 
content in the system reduces the surfactant concentration which produces comparable 
MEDD values. For example, Miglyol 812/Imwitor 988 (6:4) at 20% w/w Cremophor 
RH40 has produced a dispersion with MEDD of ~ 62nm yet, only 15% w/w of 
Cremophor RH40 is needed to obtain equivalent droplet size (~ 65nm) when Miglyol 
812/Imwitor 988 is blended at 5:5 ratio. This effect is up to a point beyond which 
further increment of the co-surfactant would increase the MEDD values and thus
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♦ — Miglyol/lmwitor (7:3) 
« — Miglyol/lmwitor (6:4) 
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Figure 3.2.6
Mean emulsion droplet diameter (MEDD) profiles for self-emulsified systems 
containing different ratios of Miglyol 812/Imwitor 988 and increasing concentration 
of Cremophor RH40. Lipid formulations were emulsified in water at 37°C for 15 
minutes. MEDD values were measured by photon correlation spectrometer (PCS). 
Bars Represent Standard Errors (n = 3).
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more surfactant is needed to obtain equivalent MEDD values. In order to illustrate 
that, the emulsification of Miglyol 812/Imwitor 988 (3:7) at 15% w/w Cremophor 
RH40 produced a dispersion with MEDD of ~ 137nin however, when the system had 
only 5 parts of Imwitor 988 at same surfactant concentration, MEDD of 65nm was 
achieved. Furthermore, for the Miglyol 812/Imwitor 988 (3:7) system to obtain 
approximately similar MEDD as 5:5 formulation (65nm), 20% w/w of Cremophor 
RH40 is needed.
The emulsification profile of Miglyol 812/Imwitor 988 (6:4)-Cremophor RH40 
system is comparable to 5:5 system yet, relatively lower MEDD values were obtained 
in the later. The emulsification of Miglyol 812/Imwitor 988 (5:5)-Cremophor RH40 
system produced optically clear dispersions at surfactant concentration >2 0 % w/w, 
minimum MEDD value around 30 nm was achieved at 30% w/w Cremophor RH40. 
On the other hand, Miglyol 812/Imwitor 988 ratios of 6:4 and 3:7 produced 
microemulsions at higher surfactant concentration >30%. This indicates that 
regardless Miglyol/lmwitor 988 ratio in the oil blends, microemulsions can still be 
obtained provided higher surfactant concentration is used. Yet, this raises a serious 
problem of damage to the gastrointestinal mucosa, as these systems contain a 
relatively large amount of surfactants.
The three-dimensional graph with contour plot for the emulsification performance of 
Miglyol 812/Imwitor 988-Cremophor RH40 system (Figure 3.2.7) shows an optimum 
blend of Miglyol 812/Imwitor 988 at 1:1 ratio which has produced the finest 
dispersions. A decrease in MEDD was observed with an increase in cosurfactant 
concentration from 30% to 50%, after which the MEDD was slightly increased. 
Similar observations have been reported [29,30] where further increase in cosurfactant 
concentration increased the droplet size. This was demonstrated by Gao et al. [30] 
using microemulsion systems containing Captex-355 as an oil, Cremophor EL as a 
surfactant, Transcutol as a cosurfactant and saline.
It is important to note here that the need for a cosurfactant is related to the fact that 
each head group unit is hydrophilic. Therefore, the addition of an extra unit 
considerably increases the hydrophilicity of the surfactant and hence, it is made harder 
to achieve the correct balance of the hydrophobic and hydrophilic portions of the 
surfactant required for production of a microemulsion; instead this balance has to
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Figure 3.2.7
Three-dimensional graph and contour plot representations of MEDD data for the 
emulsification of Miglyol 812/Imwitor 988-Cremophor RH40 system as a function of 
surfactant concentration and ratio of Imwitor 988/Miglyol 812 in the oil blend.
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be achieved by the use of a cosurfactant [35]. The addition of surfactant to the 
microemulsion systems causes the interfacial film to condense and to be stable, while 
the addition of cosurfactant causes the film to expand [36]. When a cosurfactant is 
added to the system with the surfactant, it lowers the interfacial tension, fluidizes the 
hydrocarbon region of the interfacial film and decreases the bending stress of the 
interface [37].
As Imwitor 988 is polar oil due to the glycerol mono- caprylate content (~ 50%), the 
polarity of oil droplets is optimized at certain ratio of Miglyol 812/Imwitor 988 after 
which, any further increase in the Imwitor 988 content would affect the hydrophilic- 
lipophilic balance (HLB) of the system and consequently the emulsification is 
affected. However, in a study by Kawakami et a l [ 3 1 , 321 they concluded that surface 
tension and polarity measurements of oil blends did not correlate with the system 
ability to form microemulsions as determined by the amount of oil solubilized in the 
surfactant-water mixtures. They demonstrated that the most effective mixing ratio to 
mimic the solubilization behaviour was 1:1 of glycerol monocaprylic ester (MCG) 
and propyleneglycol dicaprylic ester (DCPG), although the later was hardly 
solubilized in any surfactant solutions. Yet, they offered one possible assumption 
whereby the DCPG phase may be enclosed in a shell of the MCG rich phase hence 
MCG molecules may penetrate into the surfactant layer as the penetration of polar oils 
into surfactant layer has been observed [33, 341. This will be reflected upon when we 
study the mechanistic processes involved in the emulsification of Miglyol 
812/Imwitor 988-Cremophor RH40 system. On the other hand, in this investigation 
the emulsification of Imwitor 988 (Glycerol mono-/di-caprylate {l:l})-Cremophor 
RH40 system (i.e. without any Miglyol 812) produced dispersions with inconsistent 
and high MEDD values which suggest the need to include medium chain triglyceride 
(MCT) in the formulation. Apparently, this contrasts results from Kawakami et a l [31] 
in the case of Cremophor RH40 whereby maximum solubilization occurred at 
MCG/DCPG ratio of 1:1. This could be attributed to the fact that in their study the 
solubilization behaviour of ternary oil mix MCG, DCPG and MCT was not optimized 
as they investigated these ester oils each one alone or as a binary mix. Also, they have 
used one surfactant concentration that is, 1 0 % w/w which appears to be very small 
when considering forming o/w microemulsions.
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In an attempt to prevaricate the crystallization tendency of Cremophor RH40 in the 
pre-microemulsion concentrate and thus expands the range of mixtures which can be 
used, alternative surfactants were investigated such as, Cremophor EL, Crillet 4, 
Crillet 1 and Tagat 02.
The emulsification profiles with contour plot for Miglyol 812/Imwitor 988- 
Cremophor EL is depicted in figures 3.2.8 and 9. Cremophor EL (polyoxyethylene- 
(35)-caster oil) is considered to be the liquid form of Cremophor RH40 (HLB, 14-16) 
yet with lower HLB value (12-14) due to less ethoxylation number. This has reflected 
on the area of miscibility as depicted by the ternary phase diagram (Figure 3.2.2) 
which offers wide range of potential pre-microemulsion mixtures without restriction 
on the amount of surfactant to be included. As illustrated in figure 3.2.8, the 
emulsification profiles of Miglyol 812/Imwitor 988-Cremophor EL have shown 
trends similar to formulations containing Cremophor RH40 whereby droplet size is 
controlled by the surfactant concentration and the oil-cosurfactant ratio. With 
increasing the amount of surfactant or cosurfactant in the system, smaller MEDD 
could be obtained. Yet, the increase in the cosurfactant-oil ratio is up to a point 
beyond which the polarity of oil droplets is enhanced and thus the HLB of the oil 
system becomes out of the range to produce microemulsions and consequently the 
MEDD is increased.
As figure 3.2.8 depicts, the emulsification performance of Miglyol 812/Imwitor 988 
(7:3) using Cremophor EL has produced dispersions with high MEDD values. This 
system at surfactant concentration between 1 0  and 2 0 %w/w, has produced 
comparable MEDD values to formulations containing same oil blend (7:3) but using 
Cremophor RH40 (Figure 3.2.6). It is worth noting here that, the 7:3 oil blends at 
Cremophor RH40 concentration of > 20% w/w produced unstable pre-concentrate 
formulations.
Moreover, the emulsification profiles of Miglyol/lmwitor (6:4), and (5:5) at 
Cremophor EL concentration of >15% w/w (Figure 3.2.8) produced comparable 
MEDD profiles to same oil blends but containing Cremophor RH 40 (Figure 3.2.6). 
Interestingly, in contrast to the variations in the emulsification profiles o f Miglyol 
812/Imwitor 988 (6:4), (5:5) and (3:7) using Cremophor RH40 (Figure 3.2.6), these 
systems have shown equivalence of MEDD profiles in the case of Cremophor EL at 
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Figure 3.2.8
Emulsification profiles of self-emulsified systems containing different ratios of 
Miglyol 812/Imwitor 988 and increasing concentration of Cremophor EL. Lipid 
formulations were emulsified in water at 37°C for 15 minutes. MEDD values were 




and contour representations of the MEDD data (Figure 3.2.9) viz increasing the 
amount of cosurfactant from 40-70 %w/w in the oil blend at Cremophor EL >15% 
w/w has produced dispersions with comparable MEDD values. This has reflected on 
the contour lines which have been almost flat with increasing the amount of 
cosurfactant specifically from 50-70% w/w. Unlike the minimum trough observed in 
the contour representation of the MEDD for Miglyol 812/Imwitor 988-Cremophor 
RH40 system (Figure 3.2.6), Minimum MEDD of 30nm at approximately 35% w/w 
Cremophor EL has extended over a cosurfactant weight percentage from 50-70%. 
This broad range of cosurfactant amount in the oil blend which has produced 
microemulsion systems with no variations in the emulsification profiles is attributable 
to the relatively low HLB value of Cremophor EL comparing to RH 40. As discussed 
earlier, the use of cosurfactant normally adds to the total polarity of oil droplets and 
hence increases the HLB of the system. If the surfactant has already high HLB value 
as in the case of Cremophor RH40 (HLB between 14 and 16), the amount of 
cosurfactant that is needed to obtain an HLB value of the oil mix within the range for 
producing microemulsion systems is limited. However, for Cremophor EL which has 
relatively lower HLB value (between 12 and 14), the range of cosurfactant that is 
required to produce an oil mix with an HLB value which is within the range to obtain 
fine dispersions is widened.
It is important to note here that the emulsification of pure Imwitor 988 and 
Cremophor EL has produced bad quality dispersions with high MEDD values. This 
suggests that the cosurfactant weight percentage of 70% in the oil blend might be the 
maximum amount for obtaining pre-microemulsion concentrate.
Last but not the least, provided optimum oil blends are used, Cremophor EL offers a 
good alternative to Cremophor RH40 for formulation of SMEDDS (see table 3.2.1). 
In a study by Gao et al. [30] using Captex 355® as an oil, Cremophor EL® as a 
surfactant, Transcutol® as a cosurfactant and saline, microemulsion systems were 
optimized at Cremophor EL®:Transcutol®:Captex 355®, 10:5:4 i.e. oil-cosurfactant 
ratio of approximately 1:1 with 50% surfactant. Though the oil-cosurfactant ratio of 
the oil blend agrees with our findings yet the use of high content of surfactant in his 
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Figure 3.2.9
Three-dimensional graph and contour plot representations of MEDD data for the 
emulsification of Miglyol 812/Imwitor 988-Cremophor EL system as a function o f 
surfactant concentration and ratio of Imwitor 988/Miglyol 812 in the oil blend.
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Table 3.2.1: Microemulsions prepared by various oil-cosurfactant-surfactant 
systems.









Surfactant Wt % MEDD (nm)
1 0 110.40±3.70 133.80±2.30 Off range
15 65.25±0.21 83.00±0.42 Off range
2 0 45.55±0.78 54.00±1.60 220.33±4.65
25 36.50±2.40 41.50±0.57 75.10±0.40
30 28.95±1.20 35.90±0.99 38.80±1.00
35 27.2±0.00 27.20±0.00 32.80±0.20
40 unstable 25.00±2.50 28.00±1.30
Figures 3.2.10, 11 and 12 display the emulsification performance of Miglyol 
812/Imwitor-Crillet 4 (polyoxyethylene(20) sorbitan monooleate) system as analysed 
by the effect of surfactant concentration and oil-cosurfactant ratio on the droplet size. 
The emulsification of Miglyol 812/Imwitor 988 (7:3), (3:7) and (3:9)-Crillet 4 have 
produced dispersions with MEDD values between 1 and 5 pm (Figure 3.2.10). These 
formulations according to their droplet size distribution are classified as self­
emulsified drug delivery systems (SEDDS). Nonetheless, oil blends containing an 
amount of Imwitor 988 between 40% and 60% produced fine dispersions and 
therefore were further investigated using the PCS (Figure 3.2.11). Similar to oil 
systems containing either Cremophor RH40 or EL (Figures 3.2.6 and 8 , respectively); 
increasing the surfactant concentration or the cosurfactant to oil ratio in the Miglyol 
812/Imwitor 988-Crillet 4 system reduces the MEDD values. Yet, the increase of the 
cosurfactant in the oil blend is also to a point beyond which further increment would 
ensue in increase in the MEDD values. As the three dimensional graph with the 
contour plot for Miglyol 812/Imwitor 988-Crillet 4 system depict (Figure 3.2.12), 
microemulsion systems are optimised at Miglyol 812/Imwitor 988 ratio of 4:6. The 
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Figure 3.2.10
Mean emulsion droplet diameter (MEDD) profiles for self-emulsified systems 
containing different ratios of Miglyol 812/Imwitor 988 and increasing concentration 
of Crillet 4. Lipid formulations were emulsified in water at 37°C for 15 minutes. 
MEDD values were determined by laser diffraction method using the Mastersizer. 
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Figure 3.2.11
Emulsification profiles of self-emulsified systems containing different ratios of 
Miglyol 812/Imwitor 988 and increasing concentration of Crillet 4. Lipid 
formulations were emulsified in water at 37°C for 15 minutes. MEDD values were 
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Figure 3.2.12
Three-dimensional graph and contour plot representations of MEDD data for the 
emulsification of Miglyol 812/Imwitor 988-Crillet 4 system as a function of surfactant 
concentration and ratio of Imwitor 988/Miglyol 812 in the oil blend.
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of 30nm at cosurfactant-oil ratio of 60:40 and using approximately 35% w/w Crillet 4 
i.e. 65(60/40)35. This ratio of oil blend was also found to be the optimum in a study 
by Kawakami et al. [31]. They found that the combination of MCG with MCT at the 
ratio of 6:4 in the case of Tween 80 (equivalent to Crillet 4) was effective to achieve 
maximum oil solubilization.
It is important to note here that the use of either Cremophor RH40 or EL has been 
able to produce SMEDDS with wider range of Miglyol 812/Imwitor blends than in 
the case of Crillet 4 (polysorbate 80). Hence Cremophor RH40 and EL are caster oil 
derivatives, these results suggest that the type and structure of the lipophilic moiety is 
of paramount importance to the self-emulsification process. Furthermore, the freedom 
of chain movement and orientation imparted by the removal of the sorbitan ring 
should aid in the ease of molecular interactions [6\  This was based on the improved 
self-emulsifying behaviour when Tagat TO (polyoxyethylene-(25)-glycerol trioleate, 
HLB 11.0) was used instead of Tween 85 (polyoxyethylene-(20)-sorbitan trioleate, 
HLB 11.0) with triglycerides oils (Miglyol 812).
These results have shown that Cremophor RH40 is a good surfactant for formulation 
of SMEDDS yet is not a special case. It is possible to obtain very fine dispersions 
with other non-ionic surfactants such as, Cremophor EL and polysorbate 80, provided 
right oil-cosurfactant ratio is used to optimise the performance of SMEDDS (see table 
3.2.1).
Moreover, in an attempt to screen for further pre-microemulsion concentrate systems, 
new hydrophilic surfactants were investigated in this study. The emulsification 
performance of Miglyol 812/Imwitor 988-Crillet 1 system is presented in figure 
3.2.13. In contrast with mixtures containing Crillet 4, this system has shown no 
potential for pre-microemulsion formulations hence it has produced dispersions with 
high MEDD values at all Miglyol 812/Imwitor ratios. This was also observed by 
Kawakami et a l . t31] whereby Tween 80 (equivalent to Crillet 4) was able to solubilise 
23% w/w of oil mixture composed of 1:1 DCPG and MCG vis-a-vis 1% in the case of 
Tween 20 (equivalent to Crillet 1). This might be due to the fact that Crillet 1 
(Polyoxyethylene-(20)-sorbitan monolaurate) has relatively higher HLB value (16.7) 
than Crillet 4 (polyoxyethylene-(20)-sorbitan monooleate. HLB 15.0). This indicates 
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Figure 3.2.13
Emulsification performance as determined by droplet size measurement for self­
emulsified systems containing Miglyol 812/Imwitor 988 ratios of 5:5 or 3:7 at 
increasing concentration of Crillet 1. Lipid formulations were emulsified in water at 
37°C for 15 minutes. MEDD values were determined by laser diffraction method 
using the Mastersizer. Bars Represent Standard Errors (n = 3).
155
Chapter 3
Crillet 4 system for producing microemulsion systems, Crillet 1 needs to be mixed 
with oil blends of high Miglyol 812 content for example; Miglyol 812/Imwitor 988 at 
8:2 or may be 7:3 ratios. Yet, according to the ternary equilibrium phase diagram for 
Miglyol 812/Imwitor 988-Crillet 1 depicted in figure 3.2.4, these systems do not form 
stable isotropic one phase concentrates. Furthermore, it was surmised that the 
presence of oleic acid residues as the major constituent of the hydrophobic portion of 
the surfactant molecule were essential for mixtures with Miglyol 812 to exhibit good 
emulsification[61.
The emulsification profiles of Miglyol 812/Imwitor 988 (6:4), (5:5) and (4:6) using 
Tagat 02  (polyoxyethylene-(20)-glyceryl monooleate, HLB =15) are presented in 
figure 3.2.14. As this figure depicts, microemulsion systems can be optimised using 
blends of Miglyol 812/Imwitor 988 at 4:6 ratio with Tagat 02  at concentration >35% 
w/w. Interestingly, this ratio of oil blend (4:6) is similar to the optimum ratio for 
SMEDDS in the case of Crillet 4. Yet at surfactant concentration <30% w/w, oil 
mixtures containing Crillet 4 appear to be more emulsifiable than Tagat 02. Yet, both 
surfactants at concentration >35% w/w produced fine dispersions with almost 
equivalent MEDD values (see table 3.2.2). Moreover, the emulsification performance 
of oil blends at ratios (5:5) and (6:4) using Tagat 0 2  (Figure 3.2.14) produced profiles 
comparable to the emulsification of same oil mixtures and in particular 5:5 ratio but 
containing Crillet 4 (Figure 3.2.11).
These results have demonstrated that the emulsification performance of oil systems 
containing either Tagat 02  or Crillet 4 have shown comparable trend with slight 
variations. This could be attributed to the fact that both surfactants have same HLB 
value (15) and more importantly similar chemical structure, yet with the lack of 
sorbitan ring in the case of Tagat 02. This suggests that the sorbitan nucleus structure 
in the case of polyoxyethylene monoalkyl esters is not the major factor to determine 
good self-emulsification with triglyceride oils. Similar observations were made by 
Wakerly whereby Crillet 11 (polyoxyethylene-(4)-sorbitan mono-laurate) gave a 
performance similar to alcohol ethoxylates of equivalent HLB. Further evidence was 
also demonstrated from studies with Atlox 1045A, an ethoxylated sorbital (opened 
sorbitan ring) ester of mainly oleic acid (HLB 13.2). This surfactant exhibited good 
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Figure 3.2.14
Emulsification profiles of self-emulsified systems containing Miglyol 812/Imwitor 
988 ratios of 2:3, 1:1 or 3:2 at increasing concentration of Tagat 02 . Lipid 
formulations were emulsified in water at 37°C for 15 minutes. MEDD values were 




Table 3.2.2: Comparison of Emulsification performance for microemulsion 
systems prepared by either Crillet 4 or Tagat 02  as determined by droplet size 
measurement.




Surfactant Wt % MEDD (nm)
2 0 220.33±4.65 Off range





3.2.I.3. Mechanistics of Emulsification Process
General considerations of the putative mechanisms which have been proposed to 
explain spontaneous and self-emulsification processes have been discussed in detail in 
section 1.6 . In practice, disruption of the oil-water interface is caused by penetration 
of water into the formulation or diffusion of hydrophilic components such as, 
cosolvents and hydrophilic surfactants away from the formulation into the aqueous 
phase (see figure 3.2.15). Both of these phenomena can be studied using equilibrium 
phase diagrams, which along side with droplet size analysis can allow the 
optimisation performance of Self-emulsified systems.
The precise mechanisms of emulsification remain the subject of speculation. 
Nonetheless, studies by Pouton [16] and Wakerly using either Tween 85 or Tagat 
TO with Miglyol 812 have identified an empirical link between self-emulsification, 
liquid crystal formation, phase inversion temperature and enhanced water 
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Figure 3.2.15
Mechanistics of self-emulsification process; (a) Water-insoluble systems (eg. Type II 
SEDDS): penetration of water leads to the formation of liquid crystals at the oil-water 
interface which allow further penetration of water down aqueous channels, causing an 
increase in surface pressure and interfacial disruption which ensue in fine emulsion 
droplets to be exudated from the interface, (b) Systems containing a water-soluble 
component (Type HI): ‘diffusion and stranding’ mechanism is attributed to the 
emulsification of these systems which can lead to very fine dispersions. As the solvent 




Nevertheless, for Miglyol 812/Imwitor 988-Tagat TO system (Section 3.1), we have 
shown that the enhancement of water solubilization (L2 phase) is of paramount 
importance to the mechanistics of emulsification. Furthermore, the enhanced water 
solubilization is linked to ease of emulsification and low droplet size 1381. This also 
appears to be true for type IE systems investigated here which contain hydrophilic 
materials (surfactants with HLB >12 and/or water-soluble cosolvents) yet, this is 
further elaborated next.
For these systems where a hydrophilic surfactant or cosolvent is present rapid 
emulsification occurs by a mechanism which could be delineated as ‘diffusion and 
stranding’ (Figure 3.2.15). Diffusion of water into the oil phase converts it to w/o 
microemulsion (L2 phase) then there will be a significant migration of material which 
partitions and becomes diluted into the bulk aqueous phase [39]. This hydrophilic 
material dissolves the water-insoluble component into the aqueous phase as a 
solubilized system forming a bicontinuous microemulsion. On further diffusion, the 
concentration of hydrophilic component becomes too dilute to fully solubilise the oil 
and consequently the water insoluble oil separates as a second phase forming an oil 
droplet.
In order to obtain uniformly small oil droplets in water, the pre-concentrate oil 
mixture has to be either slightly lipophilic or hydrophilic depending on the 
hydrophilic-lipophilic balance (HLB) of the surfactant. Therefore, for systems 
containing lipophilic surfactants such as Tagat TO the injected drop has to be slightly 
lipophilic; i.e., the cosurfactant-to-oil ratio has to be slightly greater than that of the 
excess oil phase in equilibrium with bicontinuous microemulsion 1^9]. Weight ratio of 
oil-to-cosurfactant at 70/30 has been optimum for Tagat TO system, see table 3.2.3. 
On the other hand, in the case of hydrophilic surfactants such as Cremophor RH40, 
EL, and Crillet 4, oil blend (oil/cosurfactant) has to be slightly hydrophilic which 
means less weight ratio of oil (Miglyol 812) needs to be used (Table 3.2.3). Thus, for 
some optimal range of initial drop compositions, an emulsion of small oil droplets in 
water can be achieved.
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Table 3.2.3: Effect of surfactant hydrophilicity on the optimum weight ratio of 
oil in the oil-surfactant blend for various microemulsion systems. Surfactants 
with HLB values < 12 are considered to be lipophilic.
Surfactant type HLB of surfactant Wt % of Miglyol in 
(Miglyol/lmwitor)
Tagat TO 1 1 70%
Cremophor EL 12-14 30-60%
Cremophor RH40 14-16 30-60%
Crillet 4 15 40%
Tagat 02 15 40%
In order to give insight into the mechanistic process of emulsification in type HI 
systems, ternary equilibrium phase diagrams on dilution with water were constructed. 
Furthermore, emulsification profiles as determined by droplet size measurement were 
also analyzed in the view of equilibrium phase behaviour study. Miglyol 812/Imwitor 
988-Cremophor RH40 system was selected for this phase study as an archetypal 
example of type El formulations which forms fine dispersions.
The triangular equilibrium phase behaviour diagram for Miglyol 812/Imwitor (5:5)- 
Cremophor RH40 system on dilution with water is depicted in figure 3.2.16. The oil 
blend of Miglyol 812/Imwitor 988 at ratio of 5:5 was first investigated here as it was 
found to be the optimum for self-micro-emulsification in the case of Cremophor 
RH40. As figure 3.2.16 displays, Miglyol 812/Imwitor 988 (5:5) blend is virtually 
immiscible with water as it forms two phase system (L1+L2). On the other hand, 
Cremophor RH 40 as a hydrophilic surfactant with HLB value of 14-16 is soluble in 
water. Therefore, increasing the oil content in the formulation results, on aqueous 
dilution, in expansion of the L 1+L2 region and consequently, more surfactant is 
needed to homogenize the system into isotropic mixtures (L2 or Li). L1+L2 region 
reached a maximum when the system contained 45-65% w/w oil and hence, minimum 
Cremophor RH40 concentration of 25% w/w was required to obtain clear mixtures 
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Figure 3.2.16
Triangular equilibrium phase diagram for the Miglyol 812/Imwitor 988 (5:5)- 
Cremophor RH40-water system at 25°C. Lines A-B, A-C and A-D represent the 
dilution of Miglyol 812/Imwitor 988 (5:5) blend and Cremophor RH40 mixtures at 
ratios 70/30, 80/20 or 90/10, respectively, with water. Aqueous-based liquids are 
designated Li, oil-based liquids (L2 ) and liquid crystal phases “white” birefringence 
(LC). Turbid mixtures, which tended to separate on storage into a water-rich phase 
and an oil-rich phase, were designated (L1+L2 ) or (L1+L2+LC) when liquid crystalline 
material was clearly present.
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Interestingly, this system at Cremophor RH40 ratio fraction in the oil mixture of >20 
and on dilution with water between 20 and 50% w/w formed areas of various phases 
containing liquid crystalline material (LC, L2+LC and L1+L2+LC) which intercepted 
Li and L2 regions (see footnote in figure 3.2.16 for phase description). Furthermore, 
an area of micellar solution (Li) was obtained on further dilution with water (>50% 
w/w). The ability of this system to solubilise the oil into micellar solution is 
attributable to the robust solubilizing capacity of Cremophor RH40 provided 
sufficient concentration is used. The LC phase and in particular the typical LCa is 
generally associated with self-emulsification. The LC phase is viscous and exhibits 
white birefringence. In contrast, the transparent liquid crystalline dispersion phase, 
denoted LCa, differs from the LC phase in that it displays low viscosity and 
multicolored birefringence. The nature of the LCa is thought to consist of dispersion 
of lamellar liquid crystal in L2 phase [7,8]. There has been no attempt in this phase 
study to differentiate between various types of LC phases, as their role in the 
mechanistics of emulsification for this system appears to be not crucial. Yet, the 
formation of LC phases after maximum solubilization of water (L2) of approximately 
20% occurred, might have facilitated further penetration of water through the aqueous 
channels which resulted in further diffusion of the Cremophor RH40 away to the 
aqueous phase and consequently, the system became solubilized into micellar solution 
(Li).
The line (A-B) depicted in figure 3.2.16 represents the dilution of Miglyol 
812/Imwitor 988 (5:5) blend and Cremophor RH40 mixtures at ratio of 70/30 with 
water. The dilution of the initial oil mixture (L2) with water would pass through 
L2—>Li+L2 —>Li+L2+LCa—>Li phases. Therefore, it is likely that the MEDD profile for 
the previous system (70(50/50)30) which is presented in figure 3.2.6 is considered to 
be the dilution of the micellar solution (Li phase) with water to give a final 
composition which is close to the water apex in the triangular phase diagram. Qn the 
other hand, the emulsification of Miglyol 812/Imwitor 988 (5:5)-Cremophor RH40 at 
ratios of (90(50/50)10) depicted in figure 3.2.6 is considered to be the dilution of 
L1+L2 phase (figure 3.2.16, line A-D). Therefore, it is anticipated for this system to 
produce high MEDD values. Nonetheless, increasing the surfactant ratio in the oil- 
surfactant pre-concentrate would, on aqueous dilution, shift the L 1+L2 phase towards 
the micellar solution region (Lj) close to the water apex in the triangular phase
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diagram (lines A-D, A-C, and A-B, Figure 3.2.16), and consequently fine dispersions 
are obtained. This is in agreement with the droplet size measurements depicted in 
figure 3.2.6, whereby MEDD is reduced by increasing the surfactant concentration in 
the oil system. Furthermore, as the line A-B depicted in figure 3.2.16 shows, Miglyol 
812/Imwitor 988 (5:5)-Cremophor RH40 system at ratio of 70/30 is thought to be the 
optimum for micro-emulsification in this system, which also agrees with the contour 
representation of the MEDD depicted in figure 3.2.7.
In order to investigate the importance of triglyceride source (Miglyol 812) in the 
mechanistics of emulsification in type HI systems, equilibrium phase behaviour for 
Imwitor 988-Crmophor RH40 system on dilution with water was studied and 
presented in figure 3.2.17. The ternary equilibrium phase diagram for Imwitor 988- 
Cremophor RH40-water system shows huge extension in the L1+L2 region with 
comparison to the same system but containing Miglyol 812/Imwitor 988 at 1:1 ratio 
(Figure 3.2.16). For Imwitor 988-Cremophor RH40-water system, an optimum oil-to- 
surfactant ratio at 50/50 is required to transform two-phase mixtures into isotropic 
phases (L2 or Li) (line A-B, Figure 3.2.17) vis-a-vis 70/30 in the case of Miglyol 
812/Imwitor (5:5)-Cremophor RH40 system (line A-B, Figure 3.2.16). On the other 
hand, the emulsification of Imwitor 988-Cremophor RH40 at ratio of 70/30 is 
considered to be the dilution of L1+L2 phase (line A-C, Figure 3.2.17) and hence it is 
anticipated for this system to produce relatively high MEDD values. This indicates 
that in order to obtain pre-microemulsion concentrate in the case of Imwitor 988- 
Cremophor RH40 system more surfactant needs to be used which might raise certain 
toxicity issues. Therefore, including Miglyol 812 in the oil blend is important to 
obtain microemulsion systems in the case of type HI lipid formulations. However, 
Miglyol 812 is required at optimum ratios to produce a pre-concentrate of oil- 
cosurfactant-surfactant with right HLB miX for self-micro-emulsification.
Furthermore, in contrast to the extended areas which contained LC material in the 
case of Miglyol 812/Imwitor (5:5)-Cremophor RH40-water system, limited areas of 
LC phases were observed in the Imwitor 988-Cremophor RH40-water system 
(Figures 3.2.16 and 17, respectively). This might be attributed to the solvent capacity 
of Imwitor 988 in dissolving LC material due to high monoglyceride content and 
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Figure 3.2.17
Triangular equilibrium phase diagram for the Imwitor 988-Cremophor RH40-water 
system at 25°C. Lines A-B and A-C represent the dilution of Imwitor 988/Cremophor 
RH40 binary mixtures at ratios 50/50 and 70/30, respectively, with water.
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Generally, the emulsification performance of lipid systems which contain non-ionic 
surfactants are mostly affected by electrolytes in the aqueous phase, emulsification 
temperature and the inclusion of polar oils. These parameters cause depression in the 
PIT of the system by increasing the solubility of surfactant in oil and consequently 
phase separation occurs. In contrast to Miglyol 812/Imwitor 988-Tagat TO system 
which was thoroughly studied in the previous section, type El lipid systems described 
here appear not to be affected by the ionic strength of the aqueous phase. This is 
shown in our investigation next section of the effect of emulsification media on the 
performance of various lipid systems in the presence of a model drug. This might be 
attributed to the relatively high HLB values for these surfactants which are used in 
type HI systems. The reduction, therefore, in the hydrophilicity of such surfactants 
incurred by the presence of electrolytes in the aqueous phase would not be sufficient 
to induce phase separation and thus dispersions with almost identical droplet size are 
obtained. In a similar study by Gao et a l .[30] using a system composed of Captex 355® 
as an oil, Cremophor EL® as a surfactant, Transcutol® as a cosurfactant and saline 
they found that, microemulsions produced by adding 0.1 N HCL was of equivalence 
MEDD values to that produced by adding saline as an aqueous phase. Yet, further 
studies need to be carried out to investigate the effectiveness of these systems in vivo.
3.2.2. Concluding Remarks
The emergence of Neoral® by Novartis as a microemulsion system for drug delivery 
has generated the impetus amongst the researchers to investigate its merits as a 
replacement for the earlier ‘Sandimmune’ and moreover, to search for better 
alternatives. There have been many recent publications on the formulation, 
biopharmaceutics and pharmacokinetics of cyclosporin A formulated in a type EIB 
lipid class system (Neoral®), yet not many of these reports have investigated the 
various parameters which influence the physicochemical characteristics of the 
resultant aqueous dispersion of the lipid vehicle.
The oil-cosurfactant ratio is one of these factors which affect the physicochemical 
characteristics of the resultant microemulsion systems designed for oral delivery. Oil 
blends of Miglyol 812 as an oil and Imwitor 988 as a cosurfactant were optimized for
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microemulsion systems at ratios of 1:1 in the case of Cremophor RH40 or EL, and at 
2:3 in the case of Crillet 4 or Tagat 02. Furthermore, Chemical structure of 
surfactants and their HLB values are amongst the important factors, which affect 
microemulsion systems. For type El lipid systems to obtain small droplet size and fast 
dispersion rate, hydrophilic surfactants with HLB values between 13 and 15 were 
found to be the best. Furthermore, hydrophilic surfactants of caster oil derivative or 
with oleic acid residue were found to be the most effective for microemulsion 
systems.
Spontaneous micro-emulsification in type El lipid system was attributed to the 
“diffusion and stranding” theory whereby, diffusion of water into the oil mixture 
caused migration of the hydrophilic material away into the aqueous phase forming a 
bicontinuous microemulsion. Further migration of hydrophilic material due to further 
diffusion of water into the system caused the microemulsion to become supersaturated 
in oil, leading to nucleation oil droplets.
These microemulsion systems described here might have the potentials for 
pharmaceutical applications to improve the oral bioavailability of poorly-water 




3.3. Effect of Physicochemical Properties of Emulsions Formed by 
Self-emulsifying Drug Delivery Systems (SEDDS) on the 
Solubilization State of Drug in Vitro. 
3.3.1. Results and Discussion
Absorption of drugs from the gastrointestinal (GI) tract is often dissolution rate- 
limited. A drug may be defined as ‘poorly soluble’ when its dissolution rate is so slow 
that dissolution takes longer than the transit time past its absorptive sites which results 
in poor bioavailability. There are many physical and physiological parameters 






C s - (Eq.l)
This equation shows that dissolution rate, DR, is a function of: the surface area of the 
exposed drug (A), the diffusion coefficient of the drug (D), the effective thickness of 
the boundary layer (h), the saturation solubility of the drug under the local 
gastrointestinal conditions (C s), the amount of dissolved drug (Xd) and V the volume 
of dissolution fluid. Many of these physicochemical and physiological factors which 
can have a great effect on the dissolution rate have been reviewed by Horter et a l [41]. 
Nevertheless, the aqueous solubility of a drug (So) is a prime determinant of its 
dissolution rate and is usually less than lOOpg/ml[41] for ‘poorly soluble’ compounds 
which often present problematic dissolution to absorption.
The medium into which the drug must dissolve has a great influence on its solubility 
hence; suitable media which satisfactorily simulate the physiological conditions are 
needed. In the GI tract, solubility of drug is a function of aqueous solubility, 
crystallinity, drug lipophilicity, pK& in relation to the pH profile of GI tract, 




Four suitable media have been suggested to simulate the composition of proximal GI 
tract[42]: SGF plus surfactant for fasted state stomach; long-life milk (3.5% fat) for fed 
state stomach; FaSSIF and FeSSIF for fasted and fed state small intestine, 
respectively (see, table 2.4 and 2.5 in chapter 2).
Furthermore, the effective permeability (P efr) is one of the physiological parameters 
that is crucial to drug dissolution and hence bioavailability. The transfer of most drugs 
across membranes occurs by passive diffusion from a region of higher concentration 
to one with lower concentration. Applying Fick's First Law to a membrane [43], the 
absorption across the mucosal surface can be written as in Eq. (2)
Where J  w is the mass transport across the gut wall, P w can be assumed as the
the surface area. According to Eq (2) permeability and solubility are the important 
parameters to determine the mass transport through a membrane. If the P eff has a 
value of more than 2, complete absorption can be expected and hence the drug is 
classified as highly permeable. On the other hand, if the P  eff value of a drug is below 
2, the drug is considered to be low membrane permeable as its absorption will be 
incomplete [44]. Highly permeable drugs are quickly absorbed and consequently 
concentrations in solution will remain lower, thus maintaining a maximal thrust for 
dissolution. Therefore, intestinal permeability to the drug can indirectly influence the 
dissolution rate [40].
The Biopharmaceutics Classification System [44] which classifies drugs into four 
categories depending on inter-related functions of compound permeability and 
solubility (table 3.3.1), is useful for identifying candidate compounds for oral lipid- 
based formulations to improve bioavailability. According to this paradigm, drugs in 
class I have high permeability and high solubility hence, they are generally well 
absorbed (> 90%). Class II drugs are those with too low aqueous solubility, and high 
membrane permeability. Class III drugs have good solubility with membrane 
permeability too low for absorption to be complete. Class IV compounds have neither 
sufficient solubility nor permeability for complete absorption to occur.
dM  1
  X —
dt A (Eq. 2)
effective permeability, C w is the concentration of the drug at the membrane and A is
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Table 3.1: Selecting Candidate drugs for oral delivery of lipid systems based on 
The Biopharmaceutics Classification System (BCS) (Modified from Ref. 40)
BCS
Physical and
Physiological P a r a m e t e r s ^ \ _
Class I Class II Class III Class IV
Aqueous Solubility High Low High Low
Membrane permeability High High Low Low
Potential Lipid-Based Emulsion 
System
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Figure 3.3.1
Scheme showing the possible improvement in absorption for candidate compounds 
based on the biopharmaceutics classification system (BCS) by the use of lipid-based 
formulations [adapted from Ref. 45]. According to the BCS, Class I drugs have high 
permeability (HP) and high solubility (HS), Class II drugs; low solubility (LS) and 
high permeability (HP), Class III drugs; high solubility (HS) and low permeability 
(LP) and Class IV drugs; low solubility (LS) and low permeability (LP).
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Oral bioavailability for selected compounds in every BCS category can possibly be 
enhanced via reformulation in oil vehicle. Yet, promoting apparent shifts in drug class 
from Class ID and Class IV to class I by enhancement in intestinal permeability are 
not well characterised in terms of toxicity and are generally avoided [45], dashed 
arrows in figure 3.3.1. In contrast, BCS Category II compounds which have low 
solubility (LS) and high permeability (LP), tend to demonstrate the most substantial 
enhancements in bioavailability when formulated in a solubilizing lipid excipient. 
Therefore, by the use of proper formulation strategies, it is possible to promote an 
apparent shift in drug properties from Class II to Class I (Figure 3.3.1).
In designing formulation strategies for enhancing the absorption and thus the 
bioavailability of ‘poorly soluble’ dugs, probing the solubility behaviour of these 
compounds in relation to the GI tract pH profile is crucial. As many drugs are weak 
electrolytes (acids or bases), the solubility is dependent on their ionization constant, 
Ka and the pH of the dissolution media. The pH of the gastrointestinal fluids widely 
varies with location in the GI tract; in the fasted stomach typical pH values are in the 
range of 1-2 while in the upper small intestine pH values lie between 5 and 6.5.
Poorly soluble weak acids with pKa values less than 7.5 such as furosemide and 
indomethacin [46] (pKa = 3.9 and 4.5, respectively) are predominantly un-ionised 
(insoluble) in the pre-prandial gastric fluids at pH 1 while are essentially ionised in 
the upper small intestine whereby dissolution occurs first. However, very weak acids 
with pKa values more than 8 such as phenytoin, theophylline, or glutethemide are 
essentially un-ionised over the physiological pH range of the GI tract thus, they are 
very much equivalent in the gut to non-electrolytes. By contrast, weak bases with pKa 
less than 5 like dapson, diazepam or chlorodiazepoxide will be predominantly ionised 
in the stomach and will not be highly soluble in the small intestine. Hence, after 
gastric emptying delivers these compounds to the small intestine, precipitation is 
likely to occur. Their absorption is likely to be dissolution rate-limited, analogous to 
biopharmaceutical properties of non-electrolytes [27J.
Therefore, crystalline hydrophobic weak electrolytes are often absorbed to an 
adequate extent because their pKa (s) allow them to exist predominantly as ionised 
species in the lumen of the gut. Hence, the drug is absorbed as the lipid-soluble un-
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ionised species but the ionised species represents a reservoir of drug from which the 
un-ionised species is immediately available [47]. When the drug is a non-electrolyte or 
an electrolyte with pKa (s) which are unfavourable for dissolution in the gut i.e.
for weak acids and less than 5 in the case of basic compounds), assuming 
sufficient solvent capacity to allow for a unit dose formulation is achievable, 
reformulation using different types of oil systems (Type. I, II or IE) can improve 
absorption. These systems can provide a reservoir of drug dissolved in either lipid or 
micellar solution and hence slow dissolution of the unionised species is avoided.
Another key issue in the formulation design of lipid systems is to maintain solubility 
of the drug throughout its passage through the GI tract. Crystallization of the drug due 
to loss of solvent capacity of oil formulation on dilution in the lumen of the gut 
depends on the hydrophilicity of oil system; log P of the drug and the solubilization 
capacity of native surfactants (bile salt-lecithin mixed micelles) to maintain the drug 
in solution during digestion. Many reports [40,41 and 431 have dealt with the influence of 
drug physical features and many physiological parameters on the solubilization 
behaviour of poorly soluble drugs in the GI tract. Yet, the implementation of these 
studies in the formulation design of lipid systems, as an important approach to 
improve absorption, needs further focus in order for this technology to see wide­
spread application within the pharmaceutical industry.
We are, however, investigating how the physicochemical properties of emulsions 
formed by various types of lipid systems can influence drug solubilization in an 
attempt to investigate the fate of dissolved drug after dispersion. Parameters in the oil 
pre-concentrate which can affect the solvent capacity of the resultant dispersion and 
thus lead to precipitation of the drug such as, oil-cosurfactant ratio, type of surfactant 
used in the system and the inclusion of water soluble co-solvents were studied. 
Furthermore, physicochemical properties such as droplet size of the resultant 
emulsions, ionic strength of the emulsification media and the solubilization capacity 
of bile salt-lecithin mixed micelles in relation to keeping the drug in solution and 
avoid crystallization were also investigated. Dimethyl Yellow (DMY) was used as a 
model ‘poorly soluble’ weak base (log P of 4.52, pKa of 3.226 and aqueous solubility 
(So), = 1.33pg/ml). Different types of self-emulsifying systems (type II, IIIA and IEB) 
were used to probe the influence of the various physicochemical properties of the 
resultant dispersions on the fate of dissolved drug.
172
Chapter 3
3.3.1.1. Solubility of Dimethyl Yellow (DMY) in the Lipid Matrix
One commonly used approach to improve absorption is to solubilise the drug in a 
water-soluble cosolvent, such as polyethylene glycol which may have sufficient 
solvent capacity for drug administration as a unit dose. Yet, it is likely that the drug 
will crystallize on dilution of the cosolvent in the lumen of the gut. Unlike water- 
miscible cosolvent systems, lipids due to their immiscibility with water, can maintain 
poorly soluble drugs in solution. However, when oil systems can not provide 
sufficient solvent capacity for the drug in the unit dosage form, water-miscible 
cosolvents can be included in the pre-concentrate formulation. Therefore, verification 
of drug solubilization in the excipient matrix with a suitable assay for the drug is a 
crucial pre-formulation step that should be undertaken to assess the viability of any 
lipid system.
The solubility of DMY in various water-miscible cosolvents and also in different 
types of lipid-based formulations is depicted in figures 3.3.2 and 3.3.3, respectively. 
Maximum solubilization of DMY was obtained in Glycofurol system followed by 
Transcutol, see figure 3.3.2. An approximately 2.5 fold decrease in the DMY 
solubility was observed in Polyethylene glycol 400 system vis-a-vis Glycofurol. The 
solubility of DMY, on the other hand, was the lowest in the case of Propylene glycol 
system.
Considering the cosolvent solubilization power (a) concept in the log-linear model 
proposed by Yalkowsky and coworkers [48, 49,50], we can retrospectively work out o 
for DMY in the various cosolvent systems which were used in this study. The log- 
linear model describes an exponential increase in the solubility of non-polar drugs 
with a linear increase in cosolvent concentration. This is presented in the following 
equation:
Log S tot = log S w + cr X f  c ( Eq. 3)
where S tot is the total solubility of drug in the. cosolvent-water mixture, S w is its water 
solubility, o is the cosolvent solubilization power for the particular cosolvent-solute 
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Figure 3.3.2
Apparent solubility of DMY in various cosolvent systems, the drug was added in 
excess to these systems and left to equilibrate at 25°C for 24h.
174
Chapter 3
For this study a  was obtained from the log (S tot / S w) considering f  c = 1 as no water 
was included in the cosolvent system. Table 3.3.2 lists the cosolvent solubilization 
power (a) obtained from Eq 3 and the partition coefficient (log P) of the considered 
cosolvent systems. The log P values were obtained by means of the ClogP software 
package.
The log P denotes the polarity of the cosolvent system. As table 3.3.2 illustrates, the 
higher the log P of the cosolvent, the lower the polarity and hence the higher the 
solubilization power. The following order is observed: log PGiycofuroi > log Piranscutoi > 
log P p e g  40 0  > log p g - The least polar cosolvent, Glycofurol, has the maximum 
solubilization power for DMY (a = 4.8), and the highest polar cosolvent, PG, has the 
lowest value (a = 3.19). This is expected since less polar cosolvents can reduce self­
association than polar cosolvents as they have better affinity for the non-polar 
compounds. It is worth noting here that, Polyethylene glycol 400 has higher a  value 
than Propylene glycol albeit they both have close log P values. This might be due to 
the large area of interaction with the DMY in the case of PEG 400 due to the 
relatively high number of polyoxyethylene residues (an average of 9 residues per 
molecule).
Table 3.3.2: The effect of cosolvent polarity on the cosolvent solubilization power 
(gj for DMY in PG, PEG 400, Transcutol and Glycofurol (sorted by increasing 
log Pi.
Cosolvent System Cosolvent Solubilisation Solubility of DMY
log P power (a) mg/g
Propylene glycol -0.92 3.19 2.06±0.002
Polyethylene glycol 400 -0.88 4.36 30.46±0.42
Transcutol -0.15 4.66 60.99±1.54
Glycofurol -0.04 4.80 83.53±1.69
Figure 3.3.3 displays the solubility of DMY in the different types of lipid systems 
(Type I, II, IIIA and IIIB). DMY solubility of ~ 40mg/g was obtained in almost all 
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Figure 3.3.3
Apparent solubility of DMY in various Lipid systems; Formula 1 is composed of 
Miglyol 812/Tagat TO at ratio of (70/30); Formula 2 = Miglyol 812/Imwitor 988- 
Tagat TO 70(50/50)30; Formula 3 = Miglyol 812/Imwitor 988-Cremophor RH40 
70(60/40)30; Formula 4 = Miglyol 812/Imwitor 988-Cremophor EL 70(70/30)30; 
Formula 5 = Miglyol 812/Imwitor 988-Crillet 4 70(70/30)30; Formula 6  = Imwitor 
988/Cremophor RH40-PEG 400 30/30/40. According to Pouton's [5] classification; 
Formula 1 and 2 represent Type II class systems, Formula 3, 4 and 5 Type IIIA, and 
Formula 6  Type IIIB lipid system. The drug was added in excess to these systems and 
left to equilibrate at 25°C for 24h.
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Furthermore, identical solubilization power of 4.5 was found for these lipid systems, 
yet, with lower value in the case of Imwitor 988 (a = 4.2) as it is a more polar oil due 
to the monoglyceride content. On the other hand, the inclusion of PEG 400 in the oil 
mixture to formulate Type IHB system (Figure 3.3.3, formula 6) did not, however,
enhance the solubility of DMY as PEG 400 has a relatively low solubilization power.
*»
If a high DMY solubility is required, cosolvents, with high solubilization power such 
as, Glycofurol and Transcutol can be used.
3.3.I.2. Physicochemical Parameters Influencing the Solvency of Dispersions 
Formed by Various Lipid-Based Formulations
Hydrophilicity o f  the lipid-Vehicle: Oil Formulations Vs Cosolvent Systems
Studies generally, in the field of lipid-based formulations, focus on investigating the 
effect of drug on the physicochemical characteristics of the resultant dispersions in 
particular, emulsion droplet size as it is crucial for the enhanced bioavailability. Also, 
equilibrium phase behaviour is being studied in the presence of drug, especially if  the 
drug has surface activity, in order to establish an empirical link between these effects 
incurred by the inclusion of a particular drug and emulsification. Nonetheless, there 
have not been many reports which outline how the physicochemical properties of 
emulsions formed by SEDDS can influence the fate of dissolved drug after dispersion. 
We are investigating the effect of solvent capacity of these dispersions on the 
solubilization behaviour of the drug and how factors such as, oil-cosurfactant ratio, 
type of surfactant and the inclusion of various cosolvents can influence this behaviour 
in an attempt to circumvent the precipitation of drug.
Photos presented in figures 3.3.4 and 3.3.5 outline the effect of various types of either 
lipid-based formulations or cosolvent systems on the precipitation of drug after 
dispersion of the formulation. Figure 3.3.4 shows the aqueous dispersions of oil 
formulations in the presence of approximately 40mg/g DMY representing Type II 
lipid-class system (bottles A & B), and Type IIIA (bottles C, D & E). In Type II lipid 
systems, the pre-concentrate mixture, which is composed of water in-soluble 
materials, was selected to from either a self-emulsified dispersion of particle size 




Photograph of the effect of various lipid systems (Type II and Type HIA) on the 
solubilization of DMY after dispersion of the formulation. Bottles A to E represent 
dispersions of formulations from 1 to 5 denoted in figure 3.3.3. lg of each 
formulation containing approximately 40mg DMY was allowed to emulsify in 100ml 
water at 37°C for 15 minutes. Dispersions were assessed visually and analytically for 








Photograph of the effect of either Type IIIB lipid class formulation (Imwitor 
988/Cremophor RH40-PEG 400) or water-miscible cosolvent based systems 
(Glycofurol and Transcutol) on the solubilization of DMY after dispersion of the 
formulation, lg  of each formulation was emulsified in the presence of DMY in 100ml 
water at 37°C for 15 minutes.
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hand, various types of hydrophilic surfactants Cremophor RH40, EL or Crillet 4 were 
included in Type HLA. systems, bottles, C, D or E, respectively. Visual assessment of 
dispersions depicted in figure 3.3.4 did not reveal any crystallization of DMY in the 
first 24 hours. Nonetheless, dispersions which formed fine emulsions (bottles B & C) 
were subjected to further analytical assessment for several days in order to study the 
solubilization behaviour of DMY with time in these systems.
Furthermore, an instant crystallization of DMY occurred from the emulsification of 
either Imwitor 988/RH40-PEG 400 (30/30/40) system, an archetypal example of Type 
mB lipid formulations, or cosolvent-based systems (Glycofurol and Transcutol), see 
photo in figure 3.3.5). Type IHB formulations generally produce the finest dispersions 
because of their high content of water-soluble solubilizing agents, viz. they contain 
more than 60% hydrophilic surfactant and/or water-miscible cosolvents [5]. Hence, the 
water soluble components tend to diffuse away from the oil during dispersion, and 
become dissolved in the aqueous phase. The result of this separation, which may be 
the driving force for emulsification by ‘diffusion and stranding’, is likely to be loss of 
solvent capacity [5]. As a consequence, the drug is partially precipitated when the 
formulation disperses. This was also evident from the water-miscible cosolvent 
systems Glycofurol and Transcutol whereby, spontaneous crystallization of DMY 
occurred after dilution in the aqueous phase (figure 3.3.5).
The extent of precipitation will depend on hydrophilicity of the lipid system, the 
particle size of the resultant dispersion, the contribution of the hydrophilic material 
(hydrophilic surfactant and/or cosolvent) to the solubilization of the drug within the 
formulation and the log P of the drug.
Figure 3.3.6 displays the effect of hydrophilicity of the lipid matrix, as controlled by 
type of excipients included in the system, on the solubilization behaviour of DMY. 
The {Miglyol 812/Imwitor 988}-Tagat TO at ratio of (70(70/30)30) is a pre­
microemulsion Type II lipid mixture. This type of formulation is composed of water 
insoluble materials i.e. a hydrophobic system. Hence, it is expected to retain its 
solvent capacity for the drug after dispersion. It is evident from the emulsification of 
this system in the presence of DMY that the solvency of the resultant dispersion was 
able to keep the drug in super-saturated state for up to 3 days after the emulsification 
event. However, at equilibrium which can take up to five days, only 6mg of DMY out
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Figure 3.3.6
Effect of hydrophilicity of the oil vehicle on the solubilization profiles with time for 
DMY. Lipid formulations representing Type II, III A and IIIB and containing around 
40mg/g DMY were allowed to emulsify (lg) in 100ml of water at 37°C for 15 




of an initial dose of approximately 40mg came out of solution. This might be due to 
the fact that this system forms fine dispersion on emulsification so oil droplets which 
contain the dissolved drug will be highly exposed to the aqueous phase due to large 
surface area of contact. Therefore, the system can not reduce water's ability to 
“squeeze out” the drug from the fine oil droplets and consequently drug crystallization 
might occur. This process, however, might take long time to reach equilibrium as it 
was demonstrated. On the other hand, the self-emulsified type II class lipid-system 
which forms dispersion with particle size of > 250 nm such as Miglyol 812/Tagat TO 
(bottle A, figure 3.3.4) had shown no indication for DMY crystallization. This might 
be attributable to the relatively large droplet size whereby, DMY will be sequestered 
within the oil phase. Hence, there will be virtually minimal interaction between the 
non-polar compound and the water's hydrogen network which will reduce the ability 
of water to induce crystallization due to self-association.
On the other hand, for Type IIIA lipid system, {Miglyol 812/Imwitor 988}- 
Cremophor RH40 at ratio of 70(60/40)30, DMY was able to remain in a super­
saturated state up to 24 h after emulsification (figure 3.3.6). The crystallization of 
DMY from this system was also found to take up to 5 days to reach equilibrium. 
Unlike the limited crystallization which occurred at equilibrium from the self-micro­
emulsified type II lipid-system (figure 3.3.6), approximately 42% of the initial DMY 
dose (40mg) precipitated out from the Type IIIA system. This might by due to two 
factors, one of which is the amount of DMY which the hydrophilic surfactant 
(Cremophor RH40) was contributing to its solubilization within the formulation.
The amount of solubilized DMY within the pre-concentrate mixture which is 
contributed by the hydrophilic surfactant can be calculated using the following 
equation:
S total = Fa X SA + FB X SB + Fc X Sc (Eq. 4)
where S total is the total solubility of DMY in the lipid mixture, Fa, Fb and Fc; mole 
fraction of each lipid excipient in the oil system, and Sa, Sb and Sc; the respective 
DMY solubility in each constituent.
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In the case of {Miglyol 812/Imwitor 988}-Cremophor RH40 system at ratio of 
70(60/40)30, an amount of approximately 19mg of DMY is solubilized within lg of 
the oil mixture due to the contribution of Cremophor RH40. On emulsification of lg 
formulation containing around 40mg DMY in 100ml of water, Cremophor RH40 
which has a concentration of 30% w/w in the pre-concentrate, parts from the oil 
during, dispersion and becomes diluted in the aqueous phase making a final 
concentration of 0.3% w/v. By applying the linear regression equation for Cremophor 
RH40 system presented in figure 3.3.7 which relates the increase of DMY solubility 
in Cremophor RH40-water system as a function of surfactant concentration, we can 
work out the amount of DMY that the surfactant can maintain in solution after the 
dispersion of the formulation. The dissolved surfactant in the aqueous phase after 
dispersion can maintain an amount of around 5mg of DMY in solution out of the 
19mg which Cremophor RH40 is responsible for in the initial pre-concentrate dose. 
Therefore, approximately 14mg of DMY (~ 35% of initial dose) will tend to come out 
of solution at equilibrium as a result of diffusion of the hydrophilic surfactant into the 
aqueous phase after dispersion. Another important factor which might further initiate 
crystallization of DMY from Type IDA lipid system is the large surface available for 
contact with water due to the formation of very fine oil particles after dispersion.
In the case of the very hydrophilic Type DIB lipid system, the risk of precipitation is 
greater as the formulation contains a higher proportion of hydrophilic components 
(hydrophilic surfactants and/or water-soluble cosolvents). This is demonstrated by the 
instant crystallization of DMY from the Imwitor 988/Cremophor RH40-PEG 400 
Type IHB lipid system depicted in figure 3.3.6. Almost 70% of an initial DMY dose 
of ~ 40mg came out of solution in the first hour after the dispersion of the 
formulation. The amount of DMY that is dissolved within the lipid mixture due to the 
contribution of Cremophor RH40 or PEG 400 is around 23 or 12mg, respectively. 
This means that the hydrophilic components in the Imwitor 988/Cremophor RH40- 
PEG 400 system are responsible for solubilizing approximately 35mg of DMY in the 
lipid matrix. Cremophor RH40 and PEG 400 can keep up to only 5mg of DMY in 
solution after the dispersion of the formulation as they tend to lose their solvent 
capacity on dilution with water. Therefore, 30mg of DMY, which is almost equivalent 
to 75% of DMY initial dose, is expected to come out of solution after the
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emulsification. This is, however, in full agreement with the solubilization profile of 
DMY from this system which is depicted in figure 3.3.6.
The partition coefficient (log P) of the drug is an important physicochemical factor 
which influences the formulation design for lipid systems. Generally, drugs with log P 
values < 2 are the most difficult drugs as they have limited solubility in both water 
and lipid. Therefore, it is unlikely that lipid formulation will be of value for such 
compounds [5].
On the other hand, more hydrophobic drugs may have good permeability to lipid 
membranes but dissolve very slowly in the lumen of the gut. Hydrophobic drugs with 
intermediate log P [2-4] may benefit the most from the formulation design of lipid- 
based systems. Hydrophilic surfactants and/or water-soluble cosolvents can be 
blended with the lipid systems to increase the solvent capacity of the formulation for 
molecules with intermediate log P. Yet, the choice between the different types of 
lipid-based formulations (Type I, II or IE) has to be made considering the risk of drug 
precipitation and also the desirability of rapid absorption. Furthermore, drugs with log 
P > 2 are likely to be solubilized by bile salt micelles during digestion which in effect 
might prevent the drug from precipitation in the gut.
Drugs with log P > 5 can also benefit from the reformulation with lipid systems yet 
digestion by lipolysis will be crucial for the absorption of these drugs. The natural 
process of digestion offers the possibility that highly lipophilic drugs with log P 
values greater than 5 and triglyceride solubility of at least 50mg/ml are preferentially 
transported via lymphatic route [51,52]. Lymphatic transport may be enhanced by lipid- 
based formulations yet the enhancement depends on the nature of the vehicle. 
According to a study by Porter et a l [45], the rate and extent of lymphatic transport of a 
highly lipophilic drug was of the following rank order; micellar > emulsion > lipid 
solution.
Effect o f Oil-Cosurfactant Ratio on the Solvency o f  Dispersions
As was demonstrated in section 3.2, oil-cosurfactant ratio in the pre-concentrate 
mixture is an important parameter which determines the droplet size of the resultant 
emulsion. Nevertheless, in the case of hydrophilic surfactants with high solubilization 
capacity such as Cremophor RH 40 or EL, oil-cosurfactant ratio becomes also a
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crucial factor in affecting the kinetics of drug crystallization after the dispersion of the 
oil-system. This becomes more evident in the case of high hydrophilic lipid 
formulations and in particular, when water-miscible cosolvent is included in the 
system. By increasing the oil fraction in oil-cosurfactant blend, we increase the non­
polar hydrocarbon regions which interfere with water's hydrogen bonding network. 
As a result, water's ability to “squeeze out” non-polar compounds is reduced and 
hence the rate of crystallization is retarded.
Figures 3.3.8 to 3.3.11 display the effect of oil-cosurfactant ratio in Miglyol 
812/Imwitor 988-Cremophor RH40 system containing increasing concentration of 
PEG 400 on the solubilization behaviour of DMY after aqueous dispersion. For 
Miglyol 812-Imwitor 988 at ratios of 1:9 and 3:7 without PEG 400, gradual loss of 
DMY solubility was observed (Figures 3.3.8 and 9, respectively). Yet, in the case of 
5:5 system (without PEG 400), DMY was maintained in supersaturated state for up to 
24h from the initial event of emulsification (Figure 3.3.10). However, the inclusion of 
PEG 400 at only 10-20% (w/w) in these systems accelerated DMY precipitation. 
There had been progressive drop in the solubility of DMY due to drug crystallization 
as the concentration of PEG 400 in the formulation was increased. The dissolved 
amount of DMY within the pre-concentrate mixture is enhanced as more cosolvent is 
used in the system. On dispersion of the formulation and due to loss of solvent 
capacity as hydrophilic components diffuse into the aqueous phase, crystallization of 
DMY occurs depending on the extent the cosolvent was contributing to its 
solubilization within the oil mixture, see table 3.3.3.
For Miglyol 812-Imwitor 988 (1:9) system at 10% or 20% PEG 400 in the case of 
(3:9), more than half of the drug precipitated within the first 6h (Table 3.3.3), which 
suggests that precipitation from SEDDS containing a cosolvent is likely to occur 
within the lumen of the gut. In contrast, when the Miglyol 812 content was further 
increased in the oil blend as in (5:5) system, only 10 and 30% of the DMY dose came 
out of solution in the case of inclusion either 10 or 20% PEG, respectively (Table 
3.3.3). Therefore, by increasing the weight fraction of Miglyol 812 in the oil- 
cosurfactant blend, the solvency of the lipid system to maintain the drug in solution 
after the dispersion of the formulation is enhanced and consequently, precipitation is 
retarded, see figure 3.3.11.
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Figure 3.3.8
Effect of inclusion increasing concentration of PEG 400 in the Miglyol 812/Imwitor 
988-Cremophor RH40 {70(10/90)30} system on the solubilization behaviour of DMY 
after Aqueous dispersion, lg of each formulation containing approximately 40mg 
DMY was allowed to emulsify in 100ml water at 37°C for 15 minutes. Concentration 
of DMY in solution as function of time was quantified analytically by UV method.
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Figure 3.3.9
Effect of inclusion increasing concentration of PEG 400 in the Miglyol 812/Imwitor 
988-Cremophor RH40 {70(30/70)30} system on the solubilization behaviour of DMY 
after dispersion in water.
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Figure 3.3.10
Effect of inclusion increasing concentration of PEG 400 in the Miglyol 812/lmwitor 
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Figure 3.3.11
The effect of oil-cosurfactant ratio in the pre-microemulsion concentrate of Miglyol 
812/Imwitor 988-Cremophor RH40 at increasing concentration of PEG 400 on the 
solubilization of DMY after 6h from the emulsification event. 1 g of each formulation 
containing approximately 40mg DMY was allowed to emulsify in 100ml water at 




Figure 3.3.12 displays the effect of inclusion various cosolvents in the Miglyol 
812/Imwitor 988 (5:5)-Cremophor RH40 system on the solubilization behaviour of 
DMY after the dispersion of the formulation. The solubilization profiles of DMY 
were comparable for oil systems containing either PEG 400 or Ethanol. On the other 
hand, in the case of using Transcutol or Glycofurol, almost equivalent profiles were 
also obtained yet with relatively high crystallization rate vis-a-vis formulations 
containing PEG 400 or Ethanol. This is attributed to the high solubilization power of 
these cosolvents as they are able to dissolve more DMY within the lipid formulation 
which tend to crystallize on dispersion.
Table 3.3.3: The effect of oil-Cosurfactant ratio on the crystallization of DMY 
from the Miglvol 812/Imwitor 988-Cremophor system containing various 
percentages of PEG 400. (Miglyol 812 is used as oil, Imwitor 988 as a cosurfactant 
and Cremophor RH 40 is the hydrophilic surfactant).
■—■—Qd^Cosurfactmit^ 1:9 3:9 5:5
PEG 400 % (w/w) Amount of precipitated DMY after 6h from dispersion
(mg)
0 6.88±0.54 3.72±0.61 ~ 0
10 21.95±2.4 13.94±3.44 4.32±0.17
20 28.58±0.91 24.54±0.53 12.88±3.14
Furthermore, the effect of including water-miscible cosolvent in Type II self-micro- 
emulsified lipid system, which is composed of water insoluble materials, on the 
crystallization of DMY after emulsification was also investigated and presented in 
figure 3.3.13. The solubilization profiles of DMY observed from Miglyol 
812/Imwitor 988 (7:3)-Tagat TO system with and without any cosolvent have shown 
similar trend to the Miglyol 812/Imwitor 988 (5:5)-Cremophor RH40 system (Figures 
3.3.13 and 3.3.10, respectively). The inclusion of 10% PEG in the system did not 
influence the solubilization behaviour of DMY yet, around 25% of the drug 
precipitated after 6h from dispersion when 20% PEG was included in the pre- 
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Figure 3.3.13
Effect of inclusion increasing concentration of PEG 400 in Type II self-micro- 
emulsified lipid system (Miglyol 812/Imwitor 988-Tagat TO) on the solubilization 
behaviour of DMY after dispersion in water.
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and large surface area of contact with water due to the formation of fine dispersion are 
the two main factors which affect the crystallization of DMY in this system.
Effect o f the ionic strength o f Emulsification media
In order to establish better in vitro-in vivo correlations for the oral administration of 
poorly water-soluble drugs, the composition, volume and hydrodynamics of the 
contents in the gastrointestinal lumen following the administration of the dosage form 
need to be accurately simulated [40]. Four media have been developed to simulate 
composition of the gastric and intestinal contents before and after ingested meal. 
Simulated Gastric Fluid (SGF) is used to simulate fasted gastric conditions, 
homogenized long-life milk (3.5% fat, pH 6.5) has been suggested to simulate fed 
state stomach, FaSSIF and FeSSIF to model fasted and fed state conditions in the 
small intestine, respectively.
In this study the effect of FaSSIF and FeSSIF media on the solubilization behaviour 
of DMY from Type II and Type m  lipid class systems were investigated. In order to 
establish the importance of the bile salt-lecithin mixed micelles in the kinetics of drug 
crystallization from these systems, FaSSIF medium was prepared without bile salt and 
lecithin, see table 3 in chapter 2. This will give us an insight into the solubilization 
capacity of the endogenous surfactants and moreover will address the effect of 
electrolytes on the solvency of these lipid systems after dispersion.
Figure 3.3.14 depicts the crystallization of DMY from Miglyol 812/Imwitor 988 
(7:3)-Tagat TO system after the emulsification in water or FaSSIF medium without 
bile slats-lecithin mixed micelles. As this figure shows, the emulsification of this 
system in FaSSIF accelerated the crystallization o f DMY. At equilibrium which took 
up to 5 days to reach, around 15% of drug precipitated when the system was 
emulsified in water in comparison with 35% in the case of FaSSIF. The effect of 
electrolytes on the emulsification behaviour of this system without drug was 
thoroughly studied in section 3.1. Generally, electrolytes reduce the hydrophilicity of 
the non-ionic surfactants and hence they become more soluble in the oil phase. This 
will cause depression in the phase inversion temperature (PIT) of the system and 
eventually and phase separation.
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Figure 3.3.14
Effect of ionic strength of the emulsification media on the crystallization of DMY as 
function of time from Type II self-micro-emulsified lipid system which contains 
water insoluble materials (Miglyol 812/Imwitor 988-Tagat TO 70(70:30)30). FaSSIF 




This effect will depend on the inclusion of high polar oil in the formulation like 
Imwitor 988 and moreover, the use of non-ionic surfactant with relatively low HLB 
such as Tagat TO. In this case, the reduction in the HLB of the surfactant incurred by 
the presence of electrolytes in the emulsification media will be sufficient to cause shift 
in its solubility from the aqueous to the oil phase which results in phase separation 
and eventually crystallization of the dissolved drug. However, for Miglyol 
812/Imwitor 988 (7:3)-Tagat TO phase separation was not seen yet, there had been 
substantial increase in the droplet size due to the shift in Tagat To solubility. 
Nonetheless, by including more Imwitor 988 in the oil blend as in the case of Miglyol 
812/Imwitor 988 (6:4)-Tagat TO total phase separation was observed after the 
dispersion in FaSSIF, which will be further elaborated in next section.
It is expected that the use of surfactant systems with high HLB value such as, 
Cremophor RH40 or EL will not be affected by the ionic strength of the 
emulsification media as the reduction in the surfactant HLB is not sufficient to induce 
phase separation. This was evident from the crystallization profiles of DMY from 
Miglyol 812/Imwitor 988 (5:5)-Cremophor system depicted in figure 3.3.15. Almost 
comparable trends were observed from the emulsification in water or FaSSIF. In both 
media more than 40% of DMY came out of solution at equilibrium, vis-a-vis 15% in 
the case of Miglyol 812/Imwitor 988 (7:3)-Tagat TO when emulsified in water 
(Figure 3.3.14). This is attributed to the fact that the former system contains a 
hydrophilic surfactant that tends to lose its solvent capacity after the dispersion.
As depicted in these figures (3.3.14 and 15) both formulations can take up to 5 days to 
reach equilibrium and that the drug can remain in a supersaturated state for up to 24h 
after the initial emulsification event. It could be argued that such products are unlikelyt
to cause precipitation of the drug before the drug is absorbed and moreover, super­
saturation might enhance absorption by increasing the thermodynamic activity of the 
drug f5].
The Effect o f  Bile Salt-Lecithin Mixed Micelles
In the small intestine, drug solubility can be enhanced by the secretion of bile salts 
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Figure 3.3.15
Effect of ionic strength of the emulsification media on the crystallization of DMY as 
function of time from Type III self-micro-emulsified lipid system which contains a 




cholesterol. At concentrations higher than critical micelle concentration (CMC) these 
substances form mixed micelles which can enhance the solubilization capacity of the 
GI tract. Solubilization enhancement into simple bile salt micelles has been reported 
for many lipophilic compounds [53,54, “ d 55]. Up to 100-fold increase in solubility has 
been observed upon addition of bile salts at physiological concentrations to aqueous 
media. Moreover, Dissolution rate for many lipophilic compounds was substantially 
improved in the presence of bile salts. Improve the wetting was the predominant 
mechanism for substances at log P values in the range of 1-2 [41]. However, in the case 
of highly lipophilic compounds such as danazol (log P 4.53), the increase in powder 
dissolution rate was attributed to the solubilization enhancement 5^6\
On the other hand, bile salt-lecithin mixed micelles was found to further enhance the 
solubility of lipophilic compounds t57’58 md 59]. Addition of lecithin causes an increase 
in the molecular weight of micelles from 6000to 150,000 Dalton [60^ and hence more 
molar volume could be included into the palisade layer of the micelle. The extent of 
solubilization was shown to be influenced by the ratio of bile salts to lecithin t61]. 
Nonetheless, at high mixed micelles concentration enormous increase of the micellar 
diameter occurs. Therefore, a consequence of drug solubilization within micelles is a 
decrease in the apparent diffusion coefficient [62\  since the effective diffusivity will be 
that of the micelle rather than of the drug monomer.
Mithani et al [58] studied the solubilization of a range of drugs by taurocholate 
solutions, and based on the drug log P and aqueous solubility developed good 
predictive estimates of the solubilization enhancement by bile salts. A linear 
correlation (Eq. 5) was observed between the logarithm of the solubilization ratio 
(SR), and log P.
[SR] = 0.64 X log [P] + 2.09 (Eq. 5)
Solubilization ratio (SR) can be defined as the ratio between the solubilizing capacity 
of bile salt micelles (SCbs) measured as moles drug /mole taurocholate and the 
solubilization capacity in water (SCaq). According to this model, the process of 
solubilization is entirely driven by the hydrophobicity of the drug. Yet, in addition to
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partitioning behaviour other factors such as, the drug molecular weight or shape, and 
the affinity for bile salt micelles can also play a role.
Data obtained by Solomon et al [591 for a range of steroids confirmed that shape is a 
factor which clearly can influence the extent of solubilization as the spatial orientation 
into the micelles available to the drug is limited. Long-chain esters of hydrocortisone 
such as hydrocortisone caprylate whilst being hydrophobic with log P 7.82 could not 
be incorporated into the micelles as efficiently as progesterone which is less 
hydrophobic (log P 4.22) and therefore, solubilization enhancement was found to be 
far more less in the former. Furthermore, the higher affinity of bile salt micelles for 
indomethacin as compared to phenylbutazone could not be explained on the basis of 
lipid solubility and molal volume. The lower interaction of phenylbutazone with bile 
salts was attributed to repulsion forces due to its carbon acid t63l
Figures 3.3.16, 17 and 18 depict the effect of various emulsification media on the 
solubilization behaviour of DMY from Type II and IE lipid-class systems. For this 
study, FaSSIF medium was used without bile salt-lecithin mixture while FeSSIF 
contained mixed micelles of 15mM sodium taurocholate (NaTC)/3.75mM lecithin. 
For Miglyol 812/Imwitor 988 (7:3)-Tagat TO system, there was no significant 
difference in the solubilization profiles of DMY in FaSSIF vis-a-vis FeSSIF media for 
the first 6h from the emulsification event, see Figure 3.3.16. This is because loss of 
solvent capacity of the resultant dispersion in FaSSIF medium started to occur 
significantly 24h aftermath emulsification (Figure 3.3.14). Therefore, the effect of 
NaTC/lecithin mixed micelles in the solubilization enhancement of DMY could not 
be discerned.
Nevertheless, the solubilization behaviour of DMY from Miglyol 812/Imwitor 988 
(6:4)-Tagat TO system was substantially influenced by emulsification in FaSSIF 
media, see figure 3.3.17. As was previously elaborated, gradual phase separation was 
observed after the dispersion of the former system in FaSSIF. Formation of an oil 
layer that is rich with hydrophobic surfactant and increasing amounts of dissolved 
DMY continued to develop on the top of the aqueous phase which contained few 
dispersed oil droplets. As a result, there had been drop in DMY solubility 
progressively with time after emulsification in FaSSIF (Figure 3.3.17). After 24h from 
the emulsification event and due to oil separation, almost 75% drop of the initial 
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Figure 3.3.16
Effect of bile salt-lecithin mixed micelles on the solubilization capacity of Miglyol 
812/Imwitor 988-Tagat TO {70(70/30)30} system after dispersion, lg of each 
formulation containing approximately 40mg DMY was allowed to emulsify in 100ml 
FaSSIF (without bile salt mixed micelles) or FeSSIF medium which contained 15mM 
NaTC/3.75mM lecithin mixed micelles.
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Figure 3.3.17
Effect of bile salt-lecithin mixed micelles on the solubilization capacity of Miglyol 
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Figure 3.3.18
Effect of bile salt-lecithin mixed micelles on the solvency of class IIIA lipid system 
containing a water-soluble cosolvent (Miglyol 812/Imwitor 988-Cremophor RH40- 





bile salt-lecithin mixed micelles to stimulate the intestine at fed state as in FeSSIF, the 
resulting dispersion was able to keep DMY in solution almost up to 24h after 
dispersion, see figure 3.3.17. This increase in DMY solubility is attributed to the 
enhancement of oil solubilization within the bile salt micellar system.
Similarly, as depicted in figure 3.3.18, in contrast to the loss of solvent capacity of 
Miglyol 812/Imwitor 988-Cremophor RH40 system containing 20% w/w Ethanol 
after dispersion in water, the emulsification in FeSSIF maintained the solubility of 
drug in solution. This indicates the capacity of NaTC/lecithin mixed micelles to 
prevent the drug from precipitation in the lumen of the gut during digestion of lipid 
formulation.
Despite the claim that the absorption of Cyclosporin A ‘Sandimmune Neoral’ is less 
affected by bile flow and pancreatin [64], it is anticipated that the role of mixed 
micelles must become evident in the pharmacokinetics of Neoral whereby, at least a 
single oral dose of 200mg might be needed. Therefore, there is an immense need for 
practical methods to predict the fate of drugs after the dispersion of lipid systems in 
the GI tract.
It is worth noting here that loss of solvent capacity for all dispersions in FeSSIF was 
only observed 24h aftermath emulsification which might reflect the in-stability of 
mixed micelles with time. Yet, it is evident that the efficiency of dissolution and 
absorption for lipophilic compounds with log P > 2 are probably better in the fed state 
than fasted. In a study by Charman et a l [651 in healthy human volunteers showed that 
both peak concentration and area under the curve were about three times higher when 
danazol was administered in fed than fasted conditions.
3.3.2. Concluding Remarks
The bioavailability enhancement of most oral lipid-based formulations depends on the 
ability of the oil vehicle to maintain the drug in solution after dispersion. Solvency of 
emulsions formed by self-emulsifying drug delivery system is an important parameter 
influencing the fate of dissolved drug after dispersion of the formulation. 
Physicochemical factors which determine the solvent capacity of these emulsions 
such as, hydrophilicity of lipid system, droplet size of the resultant dispersion, log P
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of drug, ionic strength of the emulsification media and the bile salt-lecithin mixed 
micelles were sought for investigating the tendency of drug to precipitate after 
administration of an oily vehicle. In vitro methods, however, were used in this study 
in order to investigate the solubilization behaviour of the drug from dispersions 
formed by Type II and Type IE lipid class systems in an attempt to predict the 
dynamic changes, which are expected to occur in the gut. Nonetheless, there is a clear 
need for developing methods for tracking the solubilization state of the drug in vivo.
Self-micro-emulsified lipid systems formulated with Miglyol 812, Imwitor 988 and 
Cremophor RH40 or Tagat TO lost solvent capacity on dispersion and were not able 
to keep the drug in solution at equilibrium. For several hours after dispersion 
crystalline drug could not be detected, and precipitation continued for several days 
until equilibrium was reached. In this case the drug is likely to be maintained in a 
supersaturated state for the period required for the absorption from the GI tract. 
Nonetheless, for pre-microemulsion systems containing Tagat TO, dispersions were 
found to hold more drug in solution at equilibrium than in the case of Cremophor 
REMO. Moreover, the Miglyol 812/Imwitor ratio in the pre-concentrate mixture 
appeared to influence the kinetics of drug crystallization. The inclusion of as little as 
10-20% PEG in the lipid mixture accelerated drug precipitation. Up to half of the drug 
came out of solution within the first 6h, which suggests that precipitation from a 
SEDDS containing a cosolvent is likely to occur within the gut lumen. Yet, bile salt- 
lecithin mixed micelles appears to enhance to some extent the solubilization capacity 
of these systems after dispersion, though it is not clear whether the capacity of the 
mixed micelles would be sufficient to prevent drug precipitation in the gut during 
digestion of the lipid formulation.
Therefore, in order to maximize the solubilization capacity of lipid systems after 
dispersion and hence circumvent drug crystallization, pre-formulation studies are 
required to assess the viability of any lipid system.; This includes; determination of 
drug solubility in the lipid matrix, optimization of factors which can influence the 
solubilization behaviour of the drug after dispersion such as oil-cosurfactant ratio, 
type of surfactant and the inclusion of water-miscible cosolvents, and more 
importantly the use of suitable emulsification media to stimulate the physiological 




Preparation of Solid Self-Micro-emulsified Lipid Systems 
(SMELS) for the Delivery of Hydrophobic Drugs
4.1. Introduction
Sekiguchi et al. [1,2] in the early 1960s reported that formulation of eutectic mixtures 
could lead to an improvement in the release rate and hence the bioavailability of 
poorly soluble drugs. Solid eutectic mixtures are usually prepared by rapid cooling of 
a comelt of two compounds to obtain a physical mixture of very fine crystals of the 
two compounds. Eutectic combinations such as sulphathiazole/urea and 
chloramphenicol/ urea exhibited examples for the preparation of poorly soluble 
drug in a highly water-soluble carrier.
The preparation of solid solution was then developed by Levy ^  and Kanig [4]. In 
contrast to a eutectic mixture, the dispersed component in a solid solution is 
molecularly dispersed. The term ‘solid dispersion’ refers to the dispersion of one or 
more active ingredients in an inert carrier or matrix at a solid state They are 
commonly used in the field of pharmaceutical technology in order to solve problems 
related to poor water solubility and poor bioavailability of active molecules, 
instability and dosing problems [6’ n\  The increase in aqueous solubility and 
dissolution of drugs can be attributed to the following factors [8, 91: increase of the 
surface area available for dissolution by reducing the drug particle size, improvement 
of the apparent solubility of the solid compound under physiologically relevant 
conditions, and enhancement of the wettability and dispersability of the drug by the 
carrier which ensures sink conditions for dissolution. Moreover, the possible 
formation of a metastable dispersion that has a greater solubility resulting in faster 
dissolution rate.
The selection of the carrier and the method of preparation influence the properties of 
the resulting solid dispersion Among the popular carriers used in the formulation 
of solid dispersions are polyethylene glycols (PEG) [5,10, u ’ n,\  polyvinylpyrrolidone
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(PVP) [13, 14, 15], Cellulose derivatives (such as, hydroxypropylmethylcellulose 
(HPMC)) [16], sugars [17’ 18], polyacrylates [19] and urea [2]. However, PEG based 
polymers have been extensively used due to their favourable solution properties, low 
toxicity and low cost. The general formula of these compounds is shown below:
HO—CH2—CH2— [O—CH2—CH2]W— OH
where n represents the average number of oxyethylene groups (OCH2CH2), i.e. the 
degree of polymerization.
Solid dispersion systems are usually manufactured by the hot melt method whereby, a 
physical mixture of the drug and the polymer is heated until the fluid state is reached 
and then the melt is cooled, or by the solvent method. Tachibani and Nakumara f20] 
were the first to dissolve both the drug and the carrier in a common solvent and then 
evaporate the solvent under vacuum to produce a solid solution.
In recent years there has been a growing interest in the lipid based formulations as a 
method to improve the bioavailability of poorly water-soluble hydrophobic drugs. The 
development of Cyclosporin Neoral™ demonstrated an excellent example of such 
successful approach. Self-emulsifying lipid systems are described as mixtures of oil 
and surfactant which emulsify in water under condition of gentle agitation, and can 
only be delivered in soft or hard gelatin capsules. Pouton [21] has recently classified 
these systems into type I, II and IE with reference to the hydrophilicity of oil mixture, 
oil droplet size after aqueous dispersion and digestion by bile salts
In the present investigation solid self-micro-emulsified lipid systems (SMELS) were 
developed based on solid dispersion technology in an attempt to make a solid dosage 
form in order to replace costly and inconvenient soft gelatin capsule forms. Several 
solid formulations were developed using the hot melt method by the inclusion of 
either PEG 1000 or camauba wax respectively in self-micro-emulsified lipid class 
systems representing type III or type II with and without a model drug. The physical 
stability and characteristics of these solid systems were investigated using differential 
scanning calorimetry and X-ray powder diffraction.
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4.2. Characterization of Solid Dispersions
Various methods which have been used to characterize solid dispersions are listed in 
table 4.1. The most important methods among these are; thermoanalytical, X-ray 
diffraction, infrared spectroscopy and measurement of the release rate of the drug. 
These methods can be used to differentiate between solid solutions whereby drug is 
molecularly dispersed, solid dispersions in which drug is only partly molecularly 
dispersed and physical mixtures of drug and carrier. In the case of dispersions in 
which no crystallinity can be detected are considered to be molecularly dispersed. 
Therefore, the absence of ciystallinity is used as a criterion to differentiate between 
solid solutions and solid dispersions [22].
Table 4.1: Methods for characterization of solid dispersions
Dissolution testing
Thermoanalytical methods: hot stage microscopy and differential analysis 
Microscopic methods including polarization microscopy and scanning electron 
microscopy
Calorimetric analysis of the solution or melting enthalpy for calculation o f entropy 
change
Spectroscopy methods, e.g. IR spectroscopy 
X-Ray diffraction
4.2.1. Differential Scanning Calorimetry (DSC)
Thermoanalytical methods include all that examine a characteristic of the system as a 
function of temperature. Of these, differential scanning calorimetry (DSC) and a 
related technique, differential thermal analysis (DTA), are the most highly effective 
thermal methods for studying the physical nature'of a pure compound as well as its 
solid dispersion systems. These thermal techniques have been used in pharmaceutical 
industry for the detection and estimation of impurities [23,24], for the identification of 
polymorphic forms and solvates [25, 26\  for the assessment of molecular interactions
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occurring between solid components of pharmaceuticals, [27, 281 and the rapid 
evaluation of the compatibility of drug substances with excipients [29,30].
The techniques of DTA and DSC are linked together viz. both are concerned with the 
measurement of energy changes in a substance. The word differential emphasises that 
measurements involve both a test sample and a reference material; in DTA it is 
proportional to the temperature difference (AT = Ts - Tt) while both are subjected to 
the same heating program, and in DSC to the differential thermal energy dq/dt.
DSC is usually regarded as quantitative technique in which endothermic or 
exothermic phase transformations (energy required and produced) are detected for all 
processes. The usual method of measurement is to heat the reference and test samples 
while keeping the temperature of the two identical throughout the controlled 
temperature program (AT = Ts - Tt = 0). If an energy-requiring phase transition occurs 
in the test sample (endothermic process), extra heat is applied to this sample so that its 
temperature increases at the same rate as in the reference. The additional heat required 
is recorded and used to quantitate the energy of the phase transition. In DSC, 
endothermic responses are usually represented as being positive (+AH), i.e. above the 
baseline, corresponding to an increased transfer of heat to the sample compared to the 
reference. Exothermic transitions (AH negative) such as, oxidation or conversion of 
one polymorph to a more stable polymorph can also be detected however, the 
response will be in the opposite direction.
Lack of a melting peak in the DSC of a solid dispersion indicates that the drug exists
in an amorphous rather than a crystalline state. The degree of crystallinity can be
calculated for systems in which the drug is partly amorphous and partly crystalline.
Nonetheless, crystallinities of less than 2% cannot generally be detected using DSC 
[31]
4.2.2. X-Ray Diffraction
A crystal consisting of atoms arranged in a pattern which is repeated regularly in a 
three dimensions, acts as a three dimensional diffraction grating for X-rays with 
wavelengths from about 0.5-2.5 A [32]. The X-rays interact with the atoms (more
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precisely, with their electrons) present in the crystal and the waves of scattered X-rays 
reinforce one another in certain orientations. Bragg has shown that reinforcement will 
occur when the rays diffracted from parallel planes are in phase with one another, i.e. 
when the path difference is an integral number of wavelengths. As depicted in figure 
4.1 this can be represented by :
rik = 2 d sm 6  (4.1)
where X is the wavelength, d is the distance between successive planes, 6 is the angle 
of incidence and reflection of the X-rays, and n is an integer.
B
Figure 4.1
Bragg Law: Reinforcement of the diffracted rays from successive planes of a crystal 
occurs when the path difference is equal to an integral number of wavelengths (nk), 
i.e. AB + BC = rik, where n is an integer. Since AB = BC = d sin#, nk = 2d sin 6.
The principel behind X-ray diffraction is that when an X-ray beam is applied to the 
sample, interference bands can be detected. The angle at which the interference bands 
can be detected depends on the wavelength applied and the geometry of the sample
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with respect to periodicities in the structure. The X-ray diffraction pattern of the 
single crystal or powder type can be recorded and interpreted using powder cameras 
or most efficiently by a counter diffractometer. In the powder camera the intensity of 
the diffracted X-radiation is measured by the degree of blackening the radiation 
produced on a photographic film. On the other hand, the intensity in the case of a 
counter diffractometer is measured directly in terms of the rate at which the diffracted 
photons trigger the counting device.
Crystallinity in the sample is reflected by a characteristic fingerprint region in the 
diffraction pattern. Due to the specificity of the fingerprint, crystallinity in the drug 
can be separately identified from crystallinity in the carrier. Hence, it is possible with 
X-ray diffraction to differentiate between solid solutions, in which the drug is 
amorphous, and solid dispersions, in which it is at least partly present in the 
crystalline form, irrespective whether the carrier is amorphous or crystalline. 
However, crystallinities of under 5-10% cannot generally be detected with X-ray 
diffraction [22\
4.3. Materials and Methods
4.3.1. Materials
Miglyol 812® (Medium chain triglycerides) and Imwitor 988® (Glycerol mono-/di- 
caprylate) were obtained from Condea Chemie GmbH, Hiils. Tagat® TO 
(polyoxyethylene-(25)-glyceryl trioleate, HLB 11.3) (Goldschmidt Chemical, 
Germany) and Cremophor RH 40 (polyoxyethylene-(40)-hydrogenated caster oil, 
HLB 14-16 ) (BASF Corporation) were used as nonionic surfactants to prepare with 
Miglyol 812 and Imwitor 988 formulations representing type II and IE lipid class 
systems, respectively. Polyethylene glycol (PEG 10000) purchased from Sigma and 
Camauba wax from Aldrich, were used as carriers for solid dispersions. n-Butyl p- 
hydroxy benzoic acid (BPHBA) also known as butyl parabens was used as a model 
lipophilic weak acid (log P= 3.24 and pKa 9.03), and was obtained from Sigma. 
Ethanol 96% w/w GPR, was purchased from BDH Chemicals and water was obtained 




4.3.2.1. Formulation of Self-micro-emulsified systems
Self-emulsifying systems representing type II and IE lipid class formulations were 
prepared by mixing blends of Miglyol 812 and Imwitor 988 at ratios of 1:9, 3:7, 5:5, 
or 7:3 (w/w) with 30% (w/w) of either Tagat TO or Cremophor RH40, respectively. 
Stock mixtures of oil and surfactants to make formulations of 50g were accurately 
weighed into screw-capped glass bottles with tight closures followed by vortexing. 
Because of the waxy nature of Cremophor RH40, it was first melted in a water bath at 
40C° before it was added to the oil mixture. The glass bottles were held at 50 °C in a 
thermostated water bath for 2 minutes before lipid mixtures were thoroughly 
vortexed. Lipid formulations were then left to equilibrate over night in an oven set up 
at 25 °C.
4.3.2.2. Phase behaviour of Self-emulsified Oil mixture-Carrier System
Oil mixtures containing various blends of Miglyol 812/Imwitor 988 at 30% w/w of 
Cremophor RH40 (type III systems) were added to increasing concentration of PEG 
10000 (5-50% w/w). Increasing concentrations of camauba wax (solid carrier) were 
used in the case of oil formulations containing blends of Miglyol 812/Imwitor 988 at 
Tagat TO concentration of 30% w/w (type II systems). The oil-carrier mixtures were 
then heated at 80°C in a water bath. When the carrier was completely molten and the 
obtained mixture was found to be homogenous, the molten mixture was left to cool 
down at 4°C in a refrigerator for solidification. Phase behviour study was conducted 
by visual observation of the appearance of final products. Three types of mixtures 
were formed; pasty (semi-solid); solid glossy formulations; and immiscible two-phase 
mixtures, they were denoted P, S and II, respectively.
4.3.2.3. Preparation of Solid Self-Micro-emulsified Lipid Systems (SMELS)
Self-micro-emulsified lipid systems, which form on aqueous dilution dispersions of 
<50nm, composed of blends of Miglyol 812/Imwitor 988 at ratios of 1:9 or 3:7 and
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Cremophor RH40 at concentration of 30% w/w were added to varying amounts of 
PEG 10000 32.5 or 22.5% w/w, respectively. For systems composed of Miglyol 
812/Imwitor 988 (7:3) and Tagat TO at concentration of 30% w/w, camauba wax was 
used and was included at percentage of 30% w/w. Mixtures were then heated in a 
water bath at 80°C. After the carrier was completely molten, the drug (BPABA) was 
added at concentrations of (0-20% w/w) at the same temperature to allow the fusion 
of drug into the mixture. When the molten mixture was found to be homogenous, it 
was placed in a refrigerator at 4°C for rapid solidification.
4.3.2.4. Solubility of BPHBA in the Lipid Formulations
The model drug (BPHBA) was added in excess to the lipid formulations. Lipid 
suspensions were then vortexed for 3 minutes and then stored in a controlled 
temperature oven at 25°C for 24 hours to reach saturation, samples were vortexed in 
between. Oil suspensions were then transferred into 2ml eppendorphs and centrifuged 
at maximum speed (13000g) for 10 minutes. The clear saturated oil solution was then 
removed and assayed analytically by UV spectrophotometry (Perkin-Elmer Lamboda 
7, UV/VIS Spectrophotometer) at A,max of 252nm.
4.3.2.5. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) measurements for various solid dispersions 
(see table 4.2) were carried out using a DSC-2910 differential scanning calorimeter 
(TA Instruments, Inc. UK) equipped with a liquid nitrogen sub-ambient accessory. 
Samples (6-8mg) were accurately weighed into 50 pi aluminum pans and hermetically 
sealed. The samples were heated from 20 to 80°C at rate of 10°C/min under a dry 
nitrogen gas purge.
4.3.2.6. X-Ray Powder Diffraction (XRD) Analysis
The physical state of BPABA in PEG 10000, Camauba wax and various SMELS 
formulations (see table 4.2) were evaluated with X-ray powder diffraction. Diffraction 
patterns were obtained on a Philips PW 1710 powder X-ray diffractometer using with
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a radius of 173mm, using nickel-filtered Cu-Ka radiation, a voltage of 40kV and a 
current of 25mA. Cross-sections of the solid dispersions were taken and held on a 
quartz plate for exposure to Cu-Ka radiation. The samples were analysed at room 
temperature over an angle ranged from 2 to 60° of 26 with sampling intervals of 0.01° 
of 26 and a scanning rate of 17min.
4.3.2.7. Physical Stability Study
Dispersions of varying drug concentrations in PEG 10000, Camauba wax or SMELS 
(see table 4.2) were prepared as mentioned above. These dispersions were stored at 
25°C for two years for physical stability investigation to detect any presence of 
crystalline BPHBA. Visual observations and XRD analysis were conducted over a 
period of 2 years. On the other hand, SMELS formulations without any drug (blank 
carriers) were monitored for chemical and physical stability periodically for 4 weeks.
Table 4.2: Various Solid systems used in this investigation with the method of 







Wt % of 
carrier








- PEG 10000 100-80 0-20 DSC, XRD 2-years
1 PEG 10000 22.50 0-20 DSC, XRD 4-weeks
1 PEG 10000 32.5 0-20 DSC, XRD 4-weeks
2 PEG 10000 32.5 0 DSC 4-weeks &
2-years
3 PEG 10000 22.5 0-20 DSC, XRF 2-years
- Camauba 100-80 0-20 XRD -
4 Camauba 30% 0-20 XRD 2-years
O il mixture 1 = Miglyol/Imwitor/Cremophor RH40 70(10/90)30 
O il mixture 2 = Miglyol/Imwitor/Cremophor RH40 70(20/80)30 
O il mixture 3 = Miglyol/Imwitor/Cremophor RH40 70(30/70)30 
O il mixture 4 = Miglyol/lmwitor/Tagat TO 70(70/30)/30
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4.4. Results and Discussion
4.4.1. Phase Behaviour of Solid Self-micro-emulsified Lipid Systems (SMELS)
Various approaches have been attempted to improve the bioavailability of poorly 
water-soluble drugs. Such approaches are based on micronization of powders to 
increase the available area for dissolution, inclusion complexes such as cyclodextrines 
and derivatives, molecular dispersions in water-soluble polymers (PEG, PVP, HPMC, 
Poloxamer) and in non-electrolytes (urea, mannitol, sugars), micellar solubilization in 
surfactant systems (Tweens, Cremophors, Gellucires), liposomes, emulsions, 
microemulsions and self-emulsifying oil mixtures.
In this study, however, in order to develop a self-micro-emulsified system as a solid 
dosage form (tablet) in an attempt to circumvent costly and inconvenient soft gelatin 
capsule forms, the inclusion of water soluble polymer (PEG 10000) or camauba wax 
in self-emulsified oil mixtures was investigated. PEG 10000 was included using the 
hot melt method in a hydrophilic type HI lipid class system composed of various 
ratios of Miglyol 812/Imwitor 988-Cremophor RH40 to produce hydrophilic solid 
self-micro-emulsified lipid systems (/z-SMELS). On the other hand, Camauba wax 
due . its lipophilic nature was incorporated in a hydrophobic type II oil class system 
composed of Miglyol 812/Imwitor 988-Tagat TO in order to obtain lipophilic solid 
carrier systems (/-SMELS).
Figures 4.2 and 4.3 depict the phase behaviour of inclusion PEG 10000 or Camauba 
wax in oil mixtures representing type III and type II, respectively. Type IE lipid class 
system which forms very fine dispersions on dilution with water consists of various 
oil blends of Miglyol 812/Imwitor 988 at a fixed concentration of Cremophor RH40 
(30% w/w). Due to the fact that Imwitor 988 is polar oil as it is composed of equa- 
molar of mono and di-glycerides, Miglyol 812/Imwitor 988 ratio in the oil system is 
the only factor which influences the hydrophilicity of the oil droplets. Therefore, as 
figure 4.2 shows the more Imwitor 988 in the oil mixture the more PEG 10000 could 
be incorporated in the system to form solid preparations (/z-SMELS) before the 
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Figure 4.2:
The effect of various oil blends (Miglyol 812/Imwitor 988) and increasing amounts of 
PEG 10000 on the phase behaviour of /i-SMELS. Formulations of /2-SMELS are 
composed of eutectic mixtures of the type III self-micro-emulsified oil mixture 
(Miglyol 812/Imwitor 988-Cremophor RH40) and the polymeric carrier PEG 10000. 
According to the nature of the final preparations, systems were classified into paste, 




It is clear from figure 4.2 that the oil mixture in the system, depending on its degree of 
hydrophilicity, has a limited capacity for solubilizing certain concentrations of the 
water soluble polymer (PEG) above which the system tends to phase separate. 
Formulations containing <30% w/w of Imwitor 988 in the oil blend induced phase 
separation at all PEG concentrations.
For oil blends containing >50% Imwitor 988 a region of semi-solid systems was 
obtained at PEG concentrations of <15% w/w. As the percentage of PEG 10000 
included in the system increases solidification occurs which suggests the formation of 
eutectic mixtures whereby, an intimate mixture of the self-emulsified oil is contained 
in the crystalline matrix of the polymeric carrier (PEG). As our interest in this 
investigation focuses on solid systems (SMELS) which might have the potential for 
tablet formulation, four preparations were selected for further characterization; 
{(Miglyol 812/Imwitor 988)-Cremophor RH40}ou mixture at ratios of 70(10/90)30 with 
PEG 10000 at concentrations of 22.5 or 32.5% w/w; oil mixture of 70(20/80)30 with 
PEG at concentration of 32.5% w/w; and 70(30/70)30 at PEG of 22.5% w/w.
It is worth noting here that similar phase behaviour was observed when PEG of higher 
molecular weight (20000) was used to formulate /z-SMELS. However, a relatively 
slight shift in the phase boundary has occurred towards lower PEG concentrations in 
the case of PEG 20000 retrospective to PEG 10 000 as the former is considered to be 
more hydrophilic.
The phase behaviour of Miglyol 812/Imwitor 988/Tagat TO-Camauba wax system is 
depicted in figure 4.3. This system has formed eutectic mixtures which are completely 
miscible in the liquid state at all Miglyol 812/Imwitor 988 ratios. This reflects the 
congruity of the degree of hydrophobicity of both the solid carrier and the self­
emulsified oil mixture. As figure 4.3 shows semi-solid (paste) preparations are formed 
at camauba wax concentration of <25% w/w. On the other hand, solid carrier systems 
can be obtained at camauba wax concentration of >25% w/w.
The self-emulsified oil mixture {Miglyol 812/Imwitor 988-Tagat TO} is classified as 
type II lipid system according to the classification described by Pouton [2]\  and is 
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Figure 4.3:
The effect of various oil blends (Miglyol 812/Imwitor 988) and increasing amounts of 
Camauba wax on the phase behaviour of Miglyol 812/Imwitor 988-Tagat T0- 
Camauba wax carrier sytem. Formulations of /-SMELS are composed of eutectic 
mixtures of the type II self-emulsified oil mixture (Miglyol 812/Imwitor 988)-Tagat 




of 70(70/30)/30 can be arbitrary called a self-micro-emulsified oil system as it 
produces on aqueous dilution very fine dispersions of oil droplet size >50nm (see 
chapter 3, section 3.1). Therefore, this system was selected to produce with camauba 
wax lipophilic solid self-micro-emulsified lipid systems (/-SMELS).
Gelatin is added to w/o microemulsions to prepare microemulsion-based organogels 
(MBGs) which are rigid, optically transparent and thermoreversible. Organogels have 
been suggested as novel delivery vehicles for drugs and antigens [33]. MBGs have 
been prepared using various systems of surfactants and oils such as, Sodium bis(2- 
ethylhexyl)-sulfocucinate (AOT)/Isooctane [34] and more recently Tween 80/IPM 
(isopropyly myristate) [35]. Formed microemulsions are incubated at 50°C and added 
to a solution of gelatin in water incubated at the same temperature; the resultant 
mixture is shaken and then allowed to cool to room temperature.
In this investigation, however, MBGs could not be prepared from the self-micro- 
emulsified systems of Miglyol 812/Imwitor 988-Cremophor RH40 or Miglyol 
812/Imwitor 988 (7:3)/Tagat TO. Gelatin added to the parent microemulsions formed 
from these systems agglomerated and precipitated. This may be due to either chemical 
interaction or polarity difference between the o/w microemulsion and the gelatin 
solution.
4.4.2. Physico-chemical Properties of SMELS
4.4.2.I. /i-SMELS
As mentioned earlier, solid carrier systems (SMELS) developed in this investigation 
were classified into hydrophilic (h) and lipophilic (/) depending on the solid carrier 
used and the type of self-micro-emulsified oil mixture. PEG 10000 with type HI self- 
micro-emulsified oil system constitute /z-SMELS while, Camauba wax with type II 
self-micro-emulsified lipid system form /-SMELS.
The physical characterization of SMELS was carried out using differential scanning 
calorimetry (DSC) and X-ray diffraction (XRD). Figure 4.4 shows DSC thermograms 
for the pure polymeric carrier (PEG 10000) and four selected formulations of h- 
SMELS composed of different ratios of Miglyol 812/Imwitor 988 in the oil blend 
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Figure 4.4: DSC thermograms of PEG 10000 and four selected formulations of h- 
SMELS; (A) ratios of oil 70(10/90)30 and PEG at 32.5% w/w, (B) oil ratios at 
70(10/90)30 and PEG 22.5%, (C) oil ratios at 70(20/80)30 and PEG 32.5% and (D) 




Each thermogram of /z-SMELS (A, B, C, and D, figure 4.4) has displayed a single 
melting endothermic peak similar to the blank carrier PEG yet, with shifts towards 
relatively lower melting temperatures and lower endothermic energies. The polymeric 
carrier PEG has a peak melting temperature of 63 °C with an endothermic energy of 
181 J/g whereas, formulations of/z-SMELS have peak temperatures ranging from 49- 
54°C with enthalpies between 40 and 60 J/g, see table 4.3
There are two main elements in the composition of these solid carrier systems which 
can influence these thermal shifts; the percentage of included PEG and the ratio of 
Miglyol 812 (source of triglycerides) in the oil blend. At constant ratio of Miglyol 
812/Imwitor 988, the more PEG used in these solid vehicles the higher the peak 
temperatures and endothermic energies these systems would have (compare peak A 
and B, see also table 4.3). This agrees fully with the phase behaviour depicted in 
figure 4.2 for /z-SMELS whereby, the progressive increase of included PEG shifts the 
region of semi-solid preparations into region of solid systems due to corresponding 
increases in the melting point. On the other hand, at fixed concentration of PEG, a 
slight decrease in enthalpy is observed in systems containing relatively higher 
proportions of Miglyol 812 in the oil blend (compare peak A with C, and B with D). 
This emphasizes the point we have mentioned earlier about the physical nature of 
these solid carrier systems whereby eutectic mixtures have formed. The constituents 
are completely miscible at elevated temperature and form one-phase liquid system, 
which on cooling, the polymeric carrier (PEG) crystallizes while solubilzing within its 
matrix the self-emulsified oil mixture.
In order to shed more light on these carrier systems (/z-SMELS), XRD analysis was 
carried out. Figure 4.5 shows the X-ray diffraction patterns of pure PEG 10000 and 
four selected formulations of /z-SMELS. Two characteristic peaks appeared in the X- 
ray diffractogram of PEG at a diffraction angle of 20 19.16 and 23.25. Regardless 
their composition, all formulations of /z-SMELS have produced diffractograms with 
characteristic peaks similar to that of the polymeric carrier (PEG) suggesting the 
formation of intimate mixtures whereby the self-emulsified oil is contained within the 
crystalline matrix of the PEG. The intensity of the peaks produced by /z-SMELS 
corresponds to the percentage of PEG included in the system. Formulation B depicted 
in figure 4.5 contains more PEG and hence has produced peaks with relatively higher 
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Figure 4.5:
X-ray powder diffractograms of pure polymeric carrier PEG 10000 and four selected 
formulations of /t-SMELS; (A) ratio of oil 70(10/90)30 and PEG at 22.5% w/w, (B) 
oil ratios at 70(10/90)30 and PEG at 32.5% w/w, (C) oil ratios of 70(20/80)30 and 
PEG at 22.5% and (D) oil ratios at 70(30/70)30 at PEG concentration of 22.5%. All 
oil mixtures are composed of (Miglyol 812/Imwitor 988)-Cremophor RH40.
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Thermal analysis using DSC on the stability of these blank carrier systems was 
carried out over a period of 4 weeks and the results are listed in table 4.3. Results 
suggest that these solid carrier systems are thermodynamically stable, rigid enough to 
stabilize the drug, are not susceptible to the aging processes and can maintain the drug 
molecularly dispersed in the amorphous state due their high content of oil. Therefore, 
these new carrier systems can form the bases of promising and genuine approach to 
formulate self-micro-emulsifying systems as a solid dosage form in order to deliver 
hydrophobic molecules. Furthermore, these solid carriers have produced in water fine 
dispersions of oil droplet size <50 nm which adds to the advantages of these systems 
in enhancing the bioavailability of poorly water-soluble drugs.
Table 4.3: Thermal stability of four blank vehicles of A-SMELS over a period of 
4 weeks. Systems are composed of the self-micro-emulsified oil mixture (Miglyol 
812/Imwitor 988-Cremophor RH40) and varying amounts of PEG 10000.
Formulation Onset temperature (°C) Peak temperature (°C) Enthalpy (J/g)
of/z-SMELS Week 1 Week 4 Week 1 Week 4 Week 1 Week 4
A 45.7 47.8 49.3 50.7 40.58 40.22
B 48.6 48 53.5 53.4 58.9 59.46
C 49.7 49.7 53.2. 53 55.4 59
D 49.4 49.2 51.1 52.9 37.8 40.7
Formulation A  = o il ratios o f 70(10/90)30 at PEG 22.5% w/w 
Formulation B =  o il ratios o f 70(10/90)30 at PEG 32.5% w/w  
Formulation C = o il ratios o f 70(20/80)30 at PEG 32.5% w/w 
Formulation D = o il ratios o f 70(30/70)30 at PEG 22.5% w/w
A potential advantage of solid dispersion systems is their capacity to present drugs to 
the gastrointestinal tract (GIT) in their high energy (metastable) amorphous state [34], 
which is considered to be more highly .soluble than that of most stable form 
(crystalline). The energy required to break up .the . crystalline structure of the drug 
before it can dissolve is therefore, not a limitation to the release of the drug from these 
systems. However, solid dispersions generally have limited loading capacity of active 
materials in the amorphous state, not more than 10% in best cases, after which 
contaminating crystalline material can be detected. Another limitation of the solid
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dispersion systems is the tendency of the thermodynamically metastable amorphous 
dmg to revert to the more stable crystalline form on aging. In a study on a 
griseofulvin-PEG 6000 solid dispersion system Chiou [35] reported that the amorphous 
material crystallized out on aging except when the dmg concentration in the 
dispersion was < 5%. Furthermore, Khoo et ah [34J showed that low percentages of 
Halofantrine (Hf) (< 10%) in Hf-PEG 6000 dispersions were more stable than those 
containing a higher percentage of Hf
This was evident in our investigation on Butyl-para hydroxy benzoic acid (BPHBA)- 
PEG 10000 solid dispersion systems. BP ABA was used here as a model dmg for 
lipophilic weak base compounds with log p = 3.24 and pKa = 9.03. Figure 4.6 shows 
the X-ray diffraction patterns for pure BPHBA, PEG 10000 and solid dispersions of 
PEG with increasing percentages of crystalline BPHBA. The diffractogram of 
BPHBA showed a number of characteristic peaks at a diffraction angle of 20 17.84, 
18.87 and 24.5 (the peak occurring at 24.5 20 had the highest intensity), suggesting 
that the dmg is present as a crystalline material. The BPHBA crystalline peak 
occurring at 24.5 20 was observed in all BPHBA-PEG solid dispersion systems 
containing amounts of dmg at 10% or more, as indicated by the arrows in figure 4.6. 
This suggests that at BPHBA concentrations of > 10% these formulations become 
contaminated with crystalline material. Absence of the characteristic peaks of 
crystalline BPHBA in the formulations containing < 7.5% of dmg indicates that the 
BPHBA was present in these dispersions in the amorphous state.
X-ray diffractograms of pure crystalline BPHBA, blank carriers of /z-SMELS and h- 
SMELS with increasing amounts of BPHAB are shown in figures 4.7 and 4.8. 
Formulations of /z-SMELS are composed of the self-micro-emulsified oil mixture 
(Miglyol 812/Imwitor 988-Cremophor RH40) at ratios of either 70(10/90)30 or 
70(30/70)30 and PEG 10000 at concentrations of 32.5 or 22.5% w/w, respectively. 
Diffractograms of BPHBA-(Zz-SMELS) dispersions (figures 4.7 & 4.8) were similar to 
those of the corresponding blank carriers with no evidence of the presence of 
contaminating crystalline material. Regardless their composition, these new carrier 
systems (/z-SMELS) appear to have high loading capacity of the dmg in the 
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Figure 4.6:
X-ray diffractograms of crystalline BPHBA, pure polymeric PEG 10000 and solid 
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Figure 4.7:
X-ray powder diffractograms of pure BPHBA, blank carrier of h-SMELS and h- 
SMELS with increasing amounts of BPHBA. Carriers of /z-SMELS are composed of 
the oil mixture Miglyol 812/Imwitor 988-Cremophor RH40 at ratios of 70(10/90)30 
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Figure 4.8:
X-ray powder diffractograms of pure BPHBA, blank carrier of /z-SMELS and h- 
SMELS with increasing amounts of BPHBA. Carriers of /z-SMELS are composed of 
the oil mixture (Miglyol 812/Imwitor 988)-Cremophor RH40 at ratios of 70(30/70)30 
and the polymeric carrier PEG 10000 at concentration of 22.5% w/w.
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polymeric carrier PEG 10000. This is attributed to the fact that these carrier systems 
have high oil content in which the compound is highly soluble, the solubility of 
BPHBA in the oil mixture averages between 16 to 17% w/w.
DSC analysis was also carried out for further physical characterization of these 
systems in order to confirm results from the XRD. DSC thermograms of pure 
BPHBA, blank carriers of /z-SMELS (composed of various oil mixtures with varying 
concentrations of PEG 10000), and /z-SMELS with increasing percentages of BPHBA 
are shown in figures 4.9 and 4.10. Each thermogram of /z-SMELS based formulations 
displayed single melting endothermic peak similar to that of the corresponding blank 
carrier. The endothermic peak attributable to the melting of BPHBA (occurring at ~ 
65-70°C) was not observed in the spectra of /z-SMELS based formulation at all 
amounts of BPHBA used (Figures 4.9 & 4.10). In agreement with the XRD results, 
the absence of a second endothermic peak at ~ 65-70°C which corresponds to 
crystalline BPHBA suggests that the dmg was dispersed in the amorphous state in 
these carrier systems regardless their composition. However, in the case of /z-SMELS 
based formulations composed of the oil mixture Miglyol 812/Imwitor 988-Cremophor 
RH40 at ratios of 70(30/70)30 and 22.5% w/w of PEG (figure 4.10), at high 
percentages of BPHBA, for example 15% w/w, DSC thermograms produced 
relatively sharp peaks comparable to the carriers containing oil ratios of 70(10/90)30 
and 32.5% PEG at same concentrations of dmg (Figure 4.9). As the former carrier 
system contains relatively higher Miglyol 812 (source of triglycerides), it is 
anticipated that Miglyol 812 increases the fluidity of these systems and hence enables 
to solubilise more BPHBA within the formulation. On the other hand, it was observed 
that the progressive increase of BPHBA in these carrier systems resulted in 
corresponding decreases in the endothermic energy. This effect is may be due to the 
increased fluid viscosity when high dmg content is introduced into the formulations of 
/z-SMELS.
4.4.2.2. /-SMELS
These carrier systems are composed of the hydrophobic self-micro-emulsified oil 
mixture {Miglyol 812/Imwitor 988-Tagat TO} at ratios of 70(70/30)30 and camauba 
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Figure 4.9:
DSC thermograms of pure crystalline BPHBA, blank carrier of /z-SMELS and h- 
SMELS with increasing amounts of BPHBA. Formulations o f /z-SMELS are 
composed of the oil mixture Miglyol 812/Imwitor 988-Cremophor RH40 at ratios of 
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Figure 4.10:
DSC thermograms of pure BPHBA, blank carrier of /z-SMELS and /z-SMELS with 
increasing amounts of BPHBA. Formulations of /z-SMELS are composed of the oil 
mixture Miglyol 812/Imwitor 988-Cremophor RH40 at ratios of 70(30/70)30 and the 










physical nature of these solid vehicles, XRD analysis was carried out. Figure 4.11 
shows the X-ray diffraction patterns of pure camauba wax and the formulation of /- 
SMELS. The X-ray diffractogram of pure camauba wax reveals two distinctive 
characteristic peaks at diffraction angels of 20 21.43 and 23.75. On the hand, the XRD 
for the /-SMELS based formulation showed patterns similar to that of the pure 
camauba wax with same characteristic peaks at 21.43 and 23.75 20. This suggests that 
these new vehicles are thought to be composed of eutectic mixtures whereby, the self­
emulsified oil mixture is contained within the crystalline matrix of the camauba wax. 
Furthermore, on dilution with water, the oil mixture in situ tends to move out from the 
carrier system forming in the aqueous phase fine emulsions, while the camauba wax 
is left to disperse as large particles. The presence of camauba wax may, therefore, 
influence the release and the dissolution of the self-emulsified oil mixture which 
contains the active molecule forming what is thought to be a sustained release system. 
However, bioequivalent study needs to be carried out for further characterization of 
these carrier systems.
The /-SMELS based formulation was mixed with increasing amounts of crystalline 
BPHBA to investigate the physical state in which the active molecule exists in these 
carrier systems. The X-ray diffractograms of pure crystalline BPHBA, blank 
formulation of /-SMELS and /-SMELS with increasing percentages of BPHBA (5- 
15% w/w) are shown in figure 4.12. As mentioned earlier the crystalline BPHBA had 
shown various characteristic peaks of which the highest intensity occurred at 24.5 20. 
Yet, the X-ray diffractograms of /-SMELS based formulations containing increasing 
amounts BPHBA have shown similar diffraction patterns similar to that of the blank 
carrier with absence of the characteristic peaks of crystalline BPHBA. This suggests 
that the dmg is present in these carrier systems in the amorphous state without any 
contaminating crystalline material.
4.4.3. Physical Stability of SMELS
One of the major limitations of the solid dispersion approach is the orientation of the 
dispersed amorphous dmg for crystal nucleation and growth upon aging. Such 
changes may slow the dissolution rate of the dmg in the dispersion and hence result in 
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Figure 4.11:
X-ray powder diffractograms of pure camauba wax (solid carrier) and a blank 
formulation of /-SMELS. Formulations of /-SMELS are composed of eutectic 
mixtures of the self-micro-emulsified oil mixture of (Miglyol 812/Imwitor 988)-Tagat 
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Figure 4.12:
X-ray powder diffractograms of pure BPHBA, blank carrier of /-SMELS and /- 
SMELS with increasing amounts of BPHBA.
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seen with a solid dispersion, is a change in the physical state of the dmg to a higher 
energy faster dissolving form i.e. metastable amorphous form, then the conversion of 
dmg into a more thermodynamically stable form will ensue in losing the driving force 
for the increased dissolution rate [36l
The carrier system in which the amorphous dmg is dispersed is probably the most 
crucial element in preventing aging processes. If the carrier is insufficiently viscous or 
rigid enough to stabilize the dmg, or if the carrier is susceptible to aging, the 
dispersed dmg tends to revert to the more stable crystalline form [34]. Pemg et al. [36] 
reported that following storage at 25°C/60% relative humidity for 1 year, solid 
dispersions of SB-210661 (lipoxygenase inhibitor)-PEG 8000 showed a slowing in 
their dissolution rate, whereas no significant change was observed in the dissolution 
profile for PVP dispersion. X-ray powder diffraction results indicated that SB-210661 
was still amorphous in the PVP dispersion in contrast to the PEG 8000 dispersions 
whereby, the dmg initially existed in a partially crystalline form. In another study by 
Khoo et al. f34J on a solubilizing solid dispersion of Halofantrine (Hf):Gelucire 
44/14:Vitamin E TPGS, formulation revealed the presence of crystalline Hf free base 
after three weeks storage at room temperature.
In this study the physical state of BPHBA in dispersions of PEG 10000 or two 
selected formulations of SMELS was investigated after storage at room temperature 
(25°C) for two years using X-ray powder diffraction. The X-ray diffractograms of 
solid dispersions of BPHBA-PEG 10000 upon storing for two years are shown figure 
4.13. The presence of crystalline BPHBA could be detected in the formulation when 
the dmg concentration was 10% or more (as the arrow indicates), which is similar to 
the patterns observed when samples were initially characterized at day zero (figure 
4.5). The reason why contaminating crystalline material could not be detected at low 
amounts of dmg (< 10%) upon aging might be attributed to the low sensitivity of the 
apparatus.
Furthermore, the X-ray powder diffraction patterns of dispersions of BPHBA in 
vehicles representing /z-SMELS or /-SMELS after storage for two years are shown in 
figures 4.14 and 4.15, respectively. Those figures showed no evidence of the presence 
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Figure 4.13:
X-ray diffractograms of solid dispersions of BPHBA-PEG 10000 after storage for 2 
years at room temperature (25 °C), arrow corresponds to crystalline BPHBA of peak 
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Figure 4.14:
X-ray diffractograms of BPHBA-(/?-SMELS) dispersions after storage for 2 years at 
room temperature (25°C), absence of BPHBA crystalline peak at 24.5 20 in these 
dispersions suggests that the drug is still dispersed in the amorphous state.
Formulations of /z-SMELS are composed of the self-micro-emulsified oil mixture of
(Miglyol 812/Imwitor 988)-Cremophor RH40 at ratios of 70(30/70)30 and PEG 
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Figure 4.15:
X-ray diffractograms of BPHBA-(Z-SMELS) dispersions after storage for 2 years at 
room temperature (25°C), absence of BPHBA crystalline peak at 24.5 20 in these 
dispersions suggests that the drug is still dispersed in the amorphous state. 
Formulations of /-SMELS are composed of the self-micro-emulsified oil mixture of 
(Miglyol 812/Imwitor 988)-Tagat TO at ratios of 70(70/30)30 and Camauba wax at 
percentage of 30% w/w.
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The absence of crystalline BPHBA in these systems indicates that the drug is still 
dispersed in the amorphous state after storing for two years.
These new carrier systems appear to have the potential advantages over the traditional 
dispersion systems in first; the high loading capacity of drugs to be presented to the 
GIT in their high energy (metastable) amorphous form and secondly; in their ability to 
maintain the drug in this highly soluble form and hence prevents the crystal 
nucleation and growth upon aging.
4.5. Concluding Remarks
Various methods have been used to improve the bioavailability of poorly water- 
soluble molecules, amongst these approaches are; micronization, solubilization in 
surfactant systems, complexation by cyclodextrines, solid dispersions and the use self­
emulsified lipid technology. Solid dispersion systems have the potential advantage of 
presenting the drug to the GIT in the metastable amorphous form yet, they have low 
loading capacity of drugs in the amorphous state and also formulations are susceptible 
to the aging processes. The most significant improvement in bioavailability of 
hydrophobic drugs was achieved with self-emulsifying formulations; the development 
of Neoral™ demonstrates such successful approach.
In this investigation solid dispersion technology with the use of self-emulsifying lipid 
systems were employed to prepare new solid carrier systems which were identified as 
solid self-micro-emulsified lipid systems (SMELS) in an attempt to replace the costly 
and inconvenient soft gelatin capsule forms. Depending on the composition of these 
carrier systems, they are classified into hydrophilic and lipophilic type vehicles (h- 
SMELS and /-SMELS, respectively). Formulations of /z-SMELS are composed of 
eutectic mixtures of type El self-micro-emulsified oil formulations (Miglyol 
812/Imwitor 988-Cremophor RH40) and varying percentages of PEG 10000, whereas 
/-SMELS are composed of the type II self-emulsified system Miglyol 812/Imwitor 
988-Tagtat TO at ratios of 30(70/30)30 and , Camauba wax (solid carrier) at 
concentration of 30% w/w. The results of this study showed that it is possible with 
this new type of carrier systems to include relatively high quantities of drug in the 
amorphous state without the tendency for crystal nucleation and growth upon aging.
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Direction of Future Work
Self-emulsified drug delivery systems (SEDDS) have proved to be one of the most 
successful approaches in enhancing the bioavailability of hydrophobic molecules. The 
development of Neoral™ exhibits an excellent example of the advances in this lipid 
technology. Various elements in the composition of the self-emulsified oil mixture are 
crucial for the design of a successful lipid system. Type of oil (source of 
triglycerides), the use of mixed mono-/di-glycerides (co-surfactants), type of 
surfactant and the use of cosolvents are the key factors which can influence the drug 
solubility in the system, the physicochemical properties of the dispersions after the 
emulsification of the formulation and the propensity towards the effect of electrolytes 
present in the emulsification media. The preliminary criteria, however, in deciding on 
a potential successful oil formulation is the ability of the oil mixture to form fine 
dispersions on dilution with water. This is done through a tedious work of large 
screening of various oils and surfactants to obtain self-emulsifiable mixtures. We have 
found, as other researches, that medium chain triglycerides (MCT) and the use of 
mixed mono-/di-glycerides (such as, Imwitors and Capmuls) can facilitate the 
emulsification process. In order to help researchers and formulations scientists in 
quick selection for reliable oil systems, I intend to screen various oil blends 
(especially medium chain mixed glycerides) and surfactants in order to correlate 
physicochemical factors (such as, the polarity of oil blend, surfactant HLB and the 
chemical structure of the surfactant) with the emulsification process.
In this study we have identified some formulations representing type II lipid class 
systems which can produce very fine dispersions (50-100nm) with materials which 
are substantially water insoluble. This type of formulation is valuable as there is no 
loss of solvent capacity on dilution. This system is composed Miglyol 812 (source of 
triglycerides), Imwitor 988 (equal amounts of mono and di-glycerides) and Tagat TO 
(polyoxyethylene-(25)-glyceryl trioleate). Oil blends of Miglyol 812 and Imwitor 988 
(i.e. oil-cosurfactant ratio) constitute a crucial factor in the resultant dispersions after 
the emulsification of the formulation. Miglyol 812/Imwitor 988 at ratios of 70/30 with 
Tagat TO (surfactant) at concentration of 30% w/w produced optimum dispersions of
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particle size <50nm. The mechanistics of emulsification of this system appeared to 
lack regions of liquid crystalline mesophases but showed high capacity for water 
solubilization. This suggests that the ‘Diffusion and Stranding’ is the putative 
mechanism for emulsification of these systems. Imwitor 988 as polar oil due to high 
content of monoglyceride acts as a cosurfactant in aiding the emulsification process. 
Therefore, its inclusion has to be optimized to obtain oil droplets with an overall 
polarity that matches the HLB value of the surfactant in order to produce good 
dispersions. Our findings have shown that the inclusion of Imwitor 988 in the Miglyol 
812/Tagat TO system has influenced the sensitivity of the oil mixture towards the 
effects of electrolytes present in the emulsification media. Corresponding to its 
concentration in the system, Imwitor 988 as polar oil was found to cause depression in 
the phase inversion temperature (PIT) by shifting the surfactant aqueous solubility 
towards the oil phase and hence inducing phase separation. The electrolytes present in 
the emulsification media results in further depression in the PIT which could 
accelerate phase separation at temperatures far below 37° (emulsification 
temperature). Furthermore, the inclusion of a cosurfactant with high monoglyceride 
content such as Imwitor 308 (90% of Glycerol mono- caprylate) instead of Imwitor 
988 induced relatively more depression in the PIT as it is considered to be more polar 
oil. In order to counteract the deteriorating effect of the ionic strength of the 
emulsification media on these systems, it was suggested to use surfactant systems 
with relatively high HLB value. In this case, the reduction of the surfactant HLB 
incurred by the inclusion of polar oil or the presence of electrolytes in the 
emulsification media will not be substantial to induce phase separation. In 
collaboration with Goldscmidt we intend to synthesise surfactants which have the 
basic chemical structure as Tagat TO (polyoxyethylene-(25)-glyceryl trioleate with 
wide range of HLB values by increasing the number of ethoxy residues. This will 
produce a surfactant system with a proper and relatively high HLB value which when 
optimized with Miglyol 812/Imwitor 988 oil blends will produce a formulation that is 
not sensitive to the ionic strength of the emulsification media.
Last but not least, based on solid dispersion technology and self-emulsified lipid 
formulations, new solid carrier systems were developed which were identified as solid 
self-micro-emulsified lipid systems (SMELS). According to the type of solid carrier 
included and the class of lipid system, those new vehicles were classified into
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hydrophilic (h) and lipophilic (/) SMELS. The polymeric carrier PEG 10000 was 
included in a hydrophilic type HI lipid class system to form /z-SMELS, whereas 
camauba wax was included in a lipophilic type II lipid class system to produce 
formulations of /-SMELS. Results obtained from XRD and DSC have shown that 
these new carrier systems have potential advantage of high loading capacity of drugs 
in the high energy amorphous state and are not susceptible to the aging processes. 
They can maintain the drug in the amorphous form without the orientation for crystal 
nucleation and growth after storing for a long period. I intend to use a drug which has 
a pharmacological activity in these vehicles and to carry out dissolution rate analysis 
study to substantiate results obtained from the XRD and DSC.
Spray congealing is a technique of making microparticles by atomizing a solution or a 
suspension of drug in a melted carrier; atomization process leads to the formation of 
melted droplets which then solidify upon contact with air 1371. I would like to use the 
spray congealing technique in preparing microparticles of dispersions of SMELS and 
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